Isolated mammalian antibody or antigen-binding fragment thereof, isolated nucleic acid, expression vector, host cell, pharmaceutical composition and use thereof.
Canine anti-IL-4Ra antibodies block IL-4 and IL-13 signaling, addressing the underlying immune response in atopic dermatitis, providing a more effective treatment than current palliative therapies.
Patent Information
- Application Number
- BR122024026201
- Authority / Receiving Office
- BR · BR
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2016-03-18
- Filing Date
- 2016-04-01
- Publication Date
- 2026-11-10
- Estimated Expiration
- 2036-04-01
AI Technical Summary
Current treatments for atopic dermatitis in dogs and cats are limited and often ineffective, relying on palliative therapies that do not address the underlying immune response mechanisms, leading to safety and efficacy issues.
Development of canine anti-interleukin-4 receptor alpha (IL-4Ra) antibodies with high binding affinity that block the binding of IL-4 and IL-13 to type I and type II IL-4 receptors, inhibiting their signaling and addressing the underlying immune response in atopic dermatitis.
The antibodies effectively target the IL-4Ra pathway, providing a potential therapeutic option for atopic dermatitis by blocking IL-4 and IL-13 signaling, offering a safer and more effective treatment than existing palliative therapies.
Description
1 / 138 Isolated mammalian antibody or antigen-binding fragment thereof, isolated nucleic acid, expression vector, HOST CELL, PHARMACEUTICAL COMPOSITION AND ITS USE Divided from BR 11 2017 020915 2, deposited on 01.04.2016 CROSS-REFERENCE TO RELATED REQUESTS
[001] This application claims priority under 35 U.S.C. § 119(e) of provisional applications serial numbers U.S. 62 / 142,108, filed April 2, 2015; 62 / 269,486, filed December 18, 2015; and 62 / 310,250, filed March 18, 2016, the contents of which are incorporated herein by reference in their entirety. FIELD OF THE INVENTION
[002] The present invention relates to antibodies to canine IL-4 alpha receptor having specific sequences, a high binding affinity for canine IL-4 alpha receptor, including some that can block the binding of canine IL-4 to canine IL-4 alpha receptor. The present invention also relates to specific epitopes that bind to antibodies to canine IL-4 alpha receptor. The present invention also relates to the use of the antibodies and epitopes of the present invention in the treatment of atopic dermatitis in dogs. FUNDAMENTALS OF THE INVENTION
[003] The immune system comprises a network of specialized resident and recirculating cells that work collaboratively to protect the host against infectious diseases and cancer. The immune system's ability to perform this function depends, to a large extent, on the biological activities of a group of proteins secreted by leukocytes and collectively referred to as interleukins. Among the well-studied interleukins are two important molecules identified as interleukin-4 (IL-4) and interleukin-13 (IL-13). IL-4 and IL-13 are two closely related proteins. Petition 870250121500, dated 12 / 30 / 2025, page 17 / 160 2 / 138 related cytokines that can be secreted by many cell types, including CD4+ Th2 cells, natural killer (NKT) T cells, macrophages, stem cells, and basophils. IL-4 and IL-13 exhibit many overlapping functions and are critical for the development of T cell-dependent humoral immune responses. Despite their similarities in general structure, cellular sources, and biological functions, each of these cytokines mediates certain specialized functions, which has spurred considerable research aimed at identifying the receptors and downstream signaling pathways through which these interleukins mediate both their common and specific biological activities.
[004] It is now known that IL-4 binds with high affinity to two receptors, namely type-I and type-II IL-4 receptors. The type-I IL-4 receptor consists of the α chain of the IL-4 receptor and the common γC chain, which is also part of the receptor for several other interleukins including IL-2, IL-7, IL-9 and IL-15. The type-II IL-4 receptor consists of the α chain of the IL-4 receptor and the α1 chain of the IL-13 receptor. On the other hand, IL-13 binds to the type-II IL-4 receptor and to the singular receptor designated IL-13 α2 receptor. The binding of IL-13 to the IL-13 α2 receptor does not transduce a signal and this receptor is also secreted in a soluble form. Consequently, the IL-13 α2 receptor has often been referred to as a decoy receptor.
[005] The genes encoding the IL-4 protein from several species have been cloned and expressed in bacterial and mammalian cells. For example, the cDNA encoding human IL-4 shows that mature human IL-4 is a secreted polypeptide of 129 amino acids with a predicted molecular weight of 15 kDa [Yokota et al., Proc Natl Acad Sci US A. 83(16): 5894-5898 (1986)]. The cDNA encoding the canine IL-4 protein has also been identified and shown to encode a 132-amino acid polypeptide that shares 40% identity with human IL-4 [van der Kaaij et al., Immunogenetics 49:142]. Petition 870250121500, dated 12 / 30 / 2025, page 18 / 160 3 / 138 [143(1999)]. The gene encoding human IL-13 has been cloned and expressed in several host systems [Minty et al., Nature 362:248-50 (1993)]. A cDNA encoding human IL-13 shows that mature IL-13 is a secreted polypeptide with an apparent molecular weight of 12.4 kDa. A cDNA encoding canine IL-13 has also been identified [Yang et al., J. Interferon and Cytokine Research 20:779785 (2000)]. The predicted mature canine IL-13 polypeptide consists of 111 amino acids and shares 61.8% identity with human IL-13.
[006] The genes encoding the α chains of the human IL-4 receptor and mouse IL-4 receptor have been cloned and expressed in several host systems. For example, the cDNA encoding the α chain of the human IL-4 receptor was described by Galizzi et al., [International Immunology 2(7):669-675 (1990)] and the cDNA encoding the α chain of the murine IL-4 receptor was described by Mosley et al., [Cell, 59(2):335-348 (1989)]. The cDNA for the α chain of the human IL-4 receptor encodes for 825 amino acid residues including the 24 amino acid residue signal sequence. Although the murine protein is 15 amino acid residues shorter than the human receptor, both proteins are closely related with an overall sequence identity of 50% at the amino acid level.
[007] Genes encoding equine, canine, and feline IL-4 receptor α chains have also been described [see, US 7,208,579 B2]. In addition, a cDNA predicted to correspond with a canine IL-4 receptor α isoform can be found in the Genbank database (SEQ ID NO: 1). The present invention has thus expended efforts to determine the IL-4 receptor α chain cDNA and to definitively determine its encoded polypeptide sequence.
[008] Although IL-4 and IL-13 are critical cytokines for the development of Th2 immune responses, which are necessary for Petition 870250121500, dated 12 / 30 / 2025, p. 19 / 160 4 / 138 protection against extracellular pathogens (e.g., parasites remaining in the tissue or lumen), both cytokines have been implicated in the pathogenesis of a variety of allergic diseases in humans and animals, including asthma and atopic dermatitis. Asthma is a common respiratory disease in humans. The disease is distinguished by pulmonary inflammation, hyperresponsiveness of the bronchial airways to external stimuli, and structural modifications of the bronchial wall tissues. The pathophysiology of allergic asthma was reviewed by Vatrella et al., [Journal of Asthma and Allergy 7:123-130 (2014)]. Asthma is sustained by CD4+ Th2 cells that produce large amounts of IL-4 and IL-13 and orchestrate the inflammatory immune response in the allergic airways. Recent progress in understanding the asthmatic response highlights the important roles played by both IL-4 and IL-13 in the pathogenesis of the disease.For example, both cytokines stimulate immunoglobulin isotype switching in B cells from IgM to IgE, and these allergen-specific IgE contribute to mast cell degranulation and the release of inflammatory mediators in the airways. Furthermore, both IL-4 and IL-13 increase bronchial smooth muscle contraction and stimulate the recruitment of eosinophils into the airways, which can also degranulate in response to the cross-linking of allergen-bound IgE to its receptor on eosinophils. Additionally, IL-13 also stimulates mucus secretion and promotes airway remodeling by stimulating goblet cell hyperplasia, collagen deposition, and airway smooth muscle cell proliferation. Thus, it is now clear that IL-4 and IL-13 are intimately involved in the pathological changes that lead to the expression of asthmatic episodes, including bronchial constriction and increased airway hyperactivity.
[009] Atopic dermatitis (AD) is a relapsing, itchy, inflammatory skin disease that is distinguished by dysregulation of the immune system and Petition 870250121500, dated 12 / 30 / 2025, page 20 / 160 5 / 138 Epidermal barrier abnormalities. The pathological and immunological attributes of AD have been the subject of extensive investigations [reviewed in Rahman et al. Inflammation & Allergy-drug target 10:486-496 (2011) and Harskamp et al., Seminar in Cutaneous Medicine and Surgery 32:132-139 (2013)]. AD is the most common skin disease in humans, affecting 2-10% of the adult population in the United States and approximately 25% of children worldwide. In humans, AD-type skin lesions are distinguished by infiltrations with Th2 cells, eosinophils, mast cells, and dendritic cells. In the acute phase of AD, these lesions exhibit a predominant expression of Th2-type cytokines, including IL-4 and IL-13. AD is also distinguished by elevated circulating levels of IgE and is positively correlated with the expression of IL-4 and IL-13 in CD4+ Th2 cells in the skin.Although AD has been classified as a Th2-type disease, other T-cell subsets, such as Th1, Th22, and Th17, may also contribute to the pathogenesis of the disease. Despite the increasing incidence of AD worldwide, treatment options available for patients whose symptoms are not adequately controlled by topical agents are limited to oral corticosteroids, oral cyclosporine, and narrowband UVB phototherapy. These therapies are not always effective, and their use is associated with a variety of safety effects. Recently, monoclonal antibodies specific for human IL-4 Ra and some of these antibodies have been extensively tested for their therapeutic uses in humans for the treatment of atopic dermatitis [see, for example, US20150017176 A1].
[0010] AD is also a common disease in companion animals, especially dogs, where its prevalence has been estimated to be approximately 10 to 15% of the canine population. The pathogenesis of AD in dogs and cats [reviewed in Nuttall et al., Veterinary Records 172(8):201-207 (2013)] shows significant similarities to that of AD in humans, including Petition 870250121500, dated 12 / 30 / 2025, page 21 / 160 6 / 138 Skin infiltration by a variety of immune cells and a medium of CD4+ Th2 polarized cytokines, including a preponderance of IL-4 and IL-13 cytokines. As in humans, current therapies for atopic dermatitis in dogs and cats rely on palliative therapy, such as shampoos and moisturizers, or symptomatic therapy through the use of oral or systemic corticosteroids and oral cyclosporine. As with human AD, these therapies do not address the underlying mechanism of the disease and present significant safety and efficacy problems. Thus, there is an unmet medical need for a safe and effective treatment option for AD in companion animals. This treatment should preferably interfere with the underlying mechanism of the disease.
[0011] The citation of any reference herein shall not be construed as an admission that such reference is available as a “prior technique” for the present application. SUMMARY OF THE INVENTION
[0012] The present invention relates to canine anti-interleukin-4 receptor alpha (IL-4Ra) antibodies that have a high binding affinity for canine IL-4Ra. In more particular embodiments, the canine anti-interleukin-4 receptor alpha (IL-4Ra) antibodies also have the ability to block the binding of canine IL-4 and IL-13 to type I or type II IL-4 receptors and subsequently inhibit the signaling of both canine IL-4 and IL-13. In particular embodiments, such canine IL-4Ra antibodies are murine anti-canine IL-4Ra antibodies. In more particular embodiments, the canine IL-4Ra antibodies have a high binding affinity for canine IL-4Ra, as well as the ability to block the binding of canine IL-4 and IL-13 to type I and type II IL-4 receptors.
[0013] Furthermore, the present invention relates to complementarity-determining regions (CDRs) constituted by these Petition 870250121500, dated 12 / 30 / 2025, p. 22 / 160 7 / 138 antibodies and the combination of these CDRs (e.g., obtained from murine anti-canine IL-4Ra antibodies) in canine structures to form caninized anti-canine IL-4Ra antibodies. The present invention also relates to the use of such antibodies in the treatment of conditions such as atopic dermatitis and / or other adverse conditions due to the downstream effects of signaling from the binding of canine IL-4 and / or canine IL-13 to type I and / or type II IL-4 receptors.
[0014] Consequently, the present invention provides unique sets of CDRs from fourteen (14) exemplified murine anti-canine IL-4Ra antibodies. The 14 exemplified murine anti-canine IL-4Ra antibodies have unique sets of CDRs, namely, three light chain CDRs: light CDR 1 (CDRL1), light CDR 2 (CDRL2) and light CDR 3 (CDRL3) and three heavy chain CDRs: heavy CDR 1 (CDRH1), heavy CDR 2 (CDRH2) and heavy CDR 3 (CDRH3). As detailed below, there is substantial sequence homology within each group of CDRs and even some redundancy, for example, see the set of CDRL1s below.Thus, the present invention not only provides amino acid sequences of the six CDRs from the 14 exemplified murine anti-canine IL-4Ra antibodies, but also provides conservatively modified variants of these CDRs, as well as variants that comprise (e.g., share) the same canonical structure and / or bind to one or more (e.g., 1 to 4, or more) amino acid residues of canine IL-4Ra that are constituted by a canine IL-4Ra epitope.
[0015] Thus, the present invention provides an antibody or antigen-binding fragment thereof that binds to IL-4Ra with specificity comprising a complementarity-determining region of light chain 1 (CDR1 of VL) comprising the amino acid sequence of SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49, Petition 870250121500, dated 12 / 30 / 2025, p. 23 / 160 8 / 138 SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 129, SEQ ID NO: 130, or SEQ ID NO: 131, and / or a light chain complementarity-determining region 2 (CDR2 of VL) comprising the amino acid sequence of SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 132, SEQ ID NO: 133, or SEQ ID NO: 134, and / or a light chain complementarity-determining region 3 (CDR3 of VL) comprising the amino acid sequence SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 135, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, or SEQ ID NO: 139, and / or a heavy chain complementarity-determining region 1 (VH CDR1) wherein CDRH1 comprises the amino acid sequence SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77,SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 80, SEQ ID NO: 81, SEQ ID NO: 82, SEQ ID NO: 140, SEQ ID NO: 141, SEQ ID NO: 142, or SEQ ID NO: 143, and / or a heavy chain complementarity-determining region 2 (VH CDR2) comprising the amino acid sequence of SEQ ID NO: 83, SEQ ID NO: 84, SEQ ID NO: 85, SEQ ID NO: 86, SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90, SEQ ID NO: 91, SEQ ID NO: 144, SEQ ID NO: 145, SEQ ID NO: 146, SEQ ID NO: 147, or SEQ ID NO: 148 and / or a heavy chain 3 complementarity-determining region (CDR3 of VH) comprising the amino acid sequence SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94, SEQ ID NO: 95, SEQ ID NO: 96, SEQ ID NO: 97, SEQ ID NO: 98, SEQ ID NO: 99, SEQ ID NO: 100, SEQ ID NO: 149, SEQ ID NO: 150, SEQ ID NO: 151, SEQ ID NO: 152, or SEQ ID NO: 153. In particular embodiments, the antibody is a mammalian antibody. In more particular embodiments, the antibody is a caninized antibody. Petition 870250121500, dated 12 / 30 / 2025, p. 24 / 160 9 / 138
[0016] Consequently, a caninized antibody of the present invention or antigen-binding fragment thereof comprises one or more of the heavy chain complementarity-determining region 1 (HV CDR1) with an amino acid sequence of SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 80, SEQ ID NO: 81, SEQ ID NO: 82, SEQ ID NO: 140, SEQ ID NO: 141, SEQ ID NO: 142, or SEQ ID NO: 143. In another embodiment, the heavy chain complementarity-determining region 2 (HV CDR2) comprises an amino acid sequence of SEQ ID NO: 83, SEQ ID NO: 84, SEQ ID NO: 85, SEQ ID NO: 86, SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90, SEQ ID NO: 91, SEQ ID NO: 144, SEQ ID NO: 145, SEQ ID NO: 146, SEQ ID NO: 147, or SEQ ID NO: 148.In yet another embodiment, the heavy chain complementarity-determining region 3 (CDR3 of VH) comprises an amino acid sequence with SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94, SEQ ID NO: 95, SEQ ID NO: 96, SEQ ID NO: 97, SEQ ID NO: 98, SEQ ID NO: 99, SEQ ID NO: 100, SEQ ID NO: 149, SEQ ID NO: 150, SEQ ID NO: 151, SEQ ID NO: 152, or SEQ ID NO: 153.In a particular embodiment of this type, the caninized antibody or antigen-binding fragment comprises either an HV CDR1 comprising an amino acid sequence of SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 80, SEQ ID NO: 81, SEQ ID NO: 82, SEQ ID NO: 140, SEQ ID NO: 141, SEQ ID NO: 142, or SEQ ID NO: 143 as well as an HV CDR2 comprising an amino acid sequence of SEQ ID NO: 83, SEQ ID NO: 84, SEQ ID NO: 85, SEQ ID NO: 86, SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90, SEQ ID NO: 91, SEQ ID NO: 144, SEQ ID NO: 145, SEQ ID NO: 146, SEQ ID NO: 147, or SEQ ID NO: 148. In another such embodiment, the caninized antibody or antigen-binding fragment comprises either a CDR1 of HV comprising a sequence. Petition 870250121500, dated 12 / 30 / 2025, p. 25 / 160 10 / 138 amino acid sequence of SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 80, SEQ ID NO: 81, SEQ ID NO: 82, SEQ ID NO: 140, SEQ ID NO: 141, SEQ ID NO: 142, or SEQ ID NO: 143, as a VH CDR3 comprising an amino acid sequence of SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94, SEQ ID NO: 95, SEQ ID NO: 96, SEQ ID NO: 97, SEQ ID NO: 98, SEQ ID NO: 99, or SEQ ID NO: 100, SEQ ID NO: 149, SEQ ID NO: 150, SEQ ID NO: 151, SEQ ID NO: 152, or SEQ ID NO: 153.In yet another such embodiment, the caninized antibody or antigen-binding fragment comprises either an HV CDR2 comprising an amino acid sequence of SEQ ID NO: 83, SEQ ID NO: 84, SEQ ID NO: 85, SEQ ID NO: 86, SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90, SEQ ID NO: 91, SEQ ID NO: 144, SEQ ID NO: 145, SEQ ID NO: 146, SEQ ID NO: 147, or SEQ ID NO: 148 as well as an HV CDR3 comprising an amino acid sequence of SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94, SEQ ID NO: 95, SEQ ID NO: 96, SEQ ID NO: 97, SEQ ID NO: 98, SEQ ID NO: 99, or SEQ ID NO: 100, SEQ ID NO: 149, SEQ ID NO: 150, SEQ ID NO: 151, SEQ ID NO: 152, or SEQ ID NO: 153.In yet another such embodiment, the caninized antibody or antigen-binding fragment comprises an HV CDR1 comprising an amino acid sequence of SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 80, SEQ ID NO: 81, SEQ ID NO: 82, SEQ ID NO: 140, SEQ ID NO: 141, SEQ ID NO: 142, or SEQ ID NO: 143, an HV CDR2 comprising an amino acid sequence of SEQ ID NO: 83, SEQ ID NO: 84, SEQ ID NO: 85, SEQ ID NO: 86, SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90, SEQ ID NO: 91, SEQ ID NO: 144, SEQ ID NO: 145, SEQ ID NO: 146, SEQ ID NO: 147, or SEQ ID NO: 148 and a VH CDR3 comprising an amino acid sequence of SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94, SEQ ID NO: 95, SEQ ID NO: 96, SEQ ID NO: 97, SEQ ID NO: 98, SEQ ID NO: 99, or SEQ. Petition 870250121500, dated 12 / 30 / 2025, page 26 / 160 11 / 138 ID NO: 100, SEQ ID NO: 149, SEQ ID NO: 150, SEQ ID NO: 151, SEQ ID NO: 152, or SEQ ID NO: 153.
[0017] In particular embodiments, the caninized antibody or antigen-binding fragment also comprises a complementarity-determining region of light chain 1 (VL CDR1) comprising an amino acid sequence of SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 129, SEQ ID NO: 130, or SEQ ID NO: 131. In related embodiments, the light chain complementarity-determining region 2 (VL CDR2) comprises an amino acid sequence with SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 132, SEQ ID NO: 133, or SEQ ID NO: 134. In yet another embodiment, the light chain complementarity-determining region 3 (VL CDR3) comprises an amino acid sequence with SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 135, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, or SEQ ID NO: 139.In a particular embodiment of this type, the caninized antibody or antigen-binding fragment comprises either a VL CDR1 comprising an amino acid sequence of SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 129, SEQ ID NO: 130, or SEQ ID NO: 131 as well as a VL CDR2 comprising an amino acid sequence of SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 132, SEQ ID NO: 133, or SEQ ID NO: 134.
[0018] In other such modalities, caninized antibody or Petition 870250121500, dated 12 / 30 / 2025, p. 27 / 160 The antigen-binding fragment 12 / 138 comprises either a VL CDR1 comprising an amino acid sequence of SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 129, SEQ ID NO: 130, or SEQ ID NO: 131 or a VL CDR3 comprising an amino acid sequence of SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 135, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, or SEQ ID NO: 139.In yet another embodiment, the caninized antibody or antigen-binding fragment comprises either a VL CDR2 comprising an amino acid sequence of SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 132, SEQ ID NO: 133, or SEQ ID NO: 134 as well as a VL CDR3 comprising an amino acid sequence of SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 135, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, or SEQ ID NO: 139.
[0019] In still other such embodiments, the caninized antibody or antigen-binding fragment comprises a VL CDR1 comprising an amino acid sequence of SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 129, SEQ ID NO: 130, or SEQ ID NO: 131, a VL CDR2 comprising an amino acid sequence of SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 132, SEQ ID NO: 133, or SEQ ID NO: 134 and a VL CDR3 comprising an amino acid sequence of SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ Petition 870250121500, dated 12 / 30 / 2025, page 28 / 160 13 / 138 ID NO: 68, SEQ ID NO: 69, SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 135, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, or SEQ ID NO: 139.
[0020] In particular embodiments, the caninized anticanine IL-4Ra antibody comprises complementarity-determining regions (CDRs) wherein the CDRs have canonical structures of: H1-1, H2-3A and H3-12, respectively for CDR1, CDR2 and CDR3 of the heavy chain, that is, CDR1 of the heavy chain has the canonical structure class 1, CDR2 of the heavy chain has the canonical structure class 3A and CDR3 of the heavy chain has the canonical structure class 12. In even more particular embodiments, the CDRs for the corresponding light chains have canonical structures of: L1-1, L2-1 and L3-1, respectively for CDR1, CDR2 and CDR3 of the light chain. In other embodiments, the caninized anti-canine IL-4Ra antibody comprises complementarity-determining regions (CDRs) in which the CDRs have canonical structures of: H1-1, H2-2A and H3-7, respectively for CDR1, CDR2 and CDR3 of the heavy chain.In even more particular embodiments of this type, the CDRs for the corresponding light chains have canonical structures of: L1-2A, L2-1, and L3-1, respectively for CDR1, CDR2, and CDR3 of the light chain. In still other embodiments, the caninized anti-canine IL-4Ra antibody also comprises complementarity-determining regions (CDRs) in which the CDRs have canonical structures of: H1-1, H2-2B, and H3-15, respectively for CDR1, CDR2, and CDR3 of the heavy chain. In even more particular embodiments of this type, the CDRs for the corresponding light chains have canonical structures of: L1-4, L2-1, and L3-1, respectively for CDR1, CDR2, and CDR3 of the light chain. In still other embodiments, the caninized anti-canine IL-4Ra antibody also comprises complementarity-determining regions (CDRs) in which the CDRs have canonical structures of: H1-1, H2-1 and H3-15, respectively for. Petition 870250121500, dated 12 / 30 / 2025, p. 29 / 160 14 / 138 CDR1, CDR2, and CDR3 of the heavy chain. In even more particular embodiments of this type, the CDRs for the corresponding light chains have canonical structures of: L1-3, L2-1, and L3-1, respectively for CDR1, CDR2, and CDR3 of the light chain. In still other embodiments, the caninized anti-canine IL-4Ra antibody also comprises complementarity-determining regions (CDRs) where the CDRs have canonical structures of: H1-1, H2-2B, and H3-6, respectively for CDR1, CDR2, and CDR3 of the heavy chain. In even more particular embodiments of this type, the CDRs for the corresponding light chains have canonical structures of: L1-2A, L2-1, and L3-1, respectively for CDR1, CDR2, and CDR3 of the light chain.
[0021] In still other embodiments, the caninized anti-canine IL-4Ra antibody further comprises complementarity-determining regions (CDRs) in which the CDRs have canonical structures of: H11, H2-2B and H3-4, respectively for CDR1, CDR2 and CDR3 of the heavy chain. In even more particular embodiments of this type, the CDRs for the corresponding light chains have canonical structures of: L1-6, L2-1 and L3-1, respectively for CDR1, CDR2 and CDR3 of the light chain. In still other embodiments the caninized anti-canine IL-4Ra antibody further comprises complementarity-determining regions (CDRs) in which the CDRs have canonical structures of: H1-1, H2-1 and H3-13, respectively for CDR1, CDR2 and CDR3 of the heavy chain. In even more specific embodiments of this type, the CDRs for the corresponding light chains have canonical structures of: L1-1, L2-1 and L3-1, respectively for CDR1, CDR2 and CDR3 of the light chain.In still other embodiments, the caninized anti-canine IL-4Ra antibody also comprises complementarity-determining regions (CDRs) in which the CDRs have canonical structures of: H1-1, H2-2A, and H3-6, respectively for CDR1, CDR2, and CDR3 of the heavy chain. In even more particular embodiments. Petition 870250121500, dated 12 / 30 / 2025, p. 30 / 160 15 / 138 of this type, the CDRs for the corresponding light chains have canonical structures of: L1-2A, L2-1 and L3-1, respectively for CDR1, CDR2 and CDR3 of the light chain.
[0022] In still other embodiments, the caninized anti-canine IL-4Ra antibody further comprises complementarity-determining regions (CDRs) in which the CDRs have canonical structures of: H11, H2-3A and H3-15 or alternatively H3-13, respectively for CDR1, CDR2 and CDR3 of the heavy chain. In even more particular embodiments of this type, the CDRs for the corresponding light chains have canonical structures of: L1-6, L2-1 and L3-1, respectively for CDR1, CDR2 and CDR3 of the light chain. In still other embodiments, the caninized anti-canine IL-4Ra antibody further comprises complementarity-determining regions (CDRs) in which the CDRs have canonical structures of: H1-1, H2-2A and H3-10, respectively for CDR1, CDR2 and CDR3 of the heavy chain. In even more specific embodiments of this type, the CDRs for the corresponding light chains have canonical structures of: L1-6, L2-1 and L3-1, respectively for CDR1, CDR2 and CDR3 of the light chain.In still other embodiments, the caninized anti-canine IL-4Ra antibody also comprises complementarity-determining regions (CDRs) where the CDRs have canonical structures of: H1-1, H2-3A, and H3-9, respectively for CDR1, CDR2, and CDR3 of the heavy chain. In even more particular embodiments of this type, the CDRs for the corresponding light chains have canonical structures of: L1-3, L2-1, and L3-3, respectively for CDR1, CDR2, and CDR3 of the light chain.
[0023] The present invention also provides an isolated caninized antibody or antigen-binding fragment thereof that specifically binds to IL-4Ra comprising a canine IgG heavy chain and a canine kappa or lambda light chain. In particular embodiments Petition 870250121500, dated 12 / 30 / 2025, p. 31 / 160 16 / 138 of this type, the canine kappa or lambda light chain comprising three light chain complementarity-determining regions (CDRs): CDR light 1 (CDRL1), CDR light 2 (CDRL2) and CDR light 3 (CDRL3); and the canine IgG heavy chain comprising three heavy chain CDRs: CDR heavy 1 (CDRH1), CDR heavy 2 (CDRH2) and CDR heavy 3 (CDRH3) is obtained from murine anti-canine IL4Ra antibodies. Particular embodiments of the caninized antibodies and antigen-binding fragments thereof of the present invention bind to canine IL-4Ra and / or block the binding of canine IL-4Ra to canine IL-4.
[0024] In specific embodiments, the present invention provides an isolated mammalian antibody or antigen-binding fragment thereof that binds to canine interleukin-4 alpha receptor (IL-4Ra) with specificity comprising three light chain complementarity-determining regions (CDRs): CDR light 1 (CDRL1), CDR light 2 (CDRL2) and CDR light 3 (CDRL3); and three heavy chain CDRs: CDR heavy 1 (CDRH1), CDR heavy 2 (CDRH2) and CDR heavy 3 (CDRH3).In some embodiments, CDRL1 comprises the amino acid sequence of SEQ ID NO: 47, a variant of SEQ ID NO: 47, a conservatively modified variant of SEQ ID NO: 47, a variant of SEQ ID NO: 47 comprising the canonical structure class of 1, SEQ ID NO: 48, a variant of SEQ ID NO: 48, a conservatively modified variant of SEQ ID NO: 48, a variant of SEQ ID NO: 48 comprising the canonical structure class of 2A, SEQ ID NO: 49, a variant of SEQ ID NO: 49, a conservatively modified variant of SEQ ID NO: 49, a variant of SEQ ID NO: 49 comprising the canonical structure class of 4, SEQ ID NO: 50, a variant of SEQ ID NO: 50, a conservatively modified variant of SEQ ID NO: 50, a variant of SEQ ID NO: 50 comprising the class of canonical structure of 3, SEQ ID NO: 51, a variant of SEQ ID NO: 51, a conservatively modified variant of SEQ ID NO: 51, a variant of SEQ ID NO: 51. Petition 870250121500, dated 12 / 30 / 2025, p. 32 / 160 17 / 138 comprising canonical structure class 3, SEQ ID NO: 52, a variant of SEQ ID NO: 52, a conservatively modified variant of SEQ ID NO: 52, a variant of SEQ ID NO: 52 comprising canonical structure class 2A, SEQ ID NO: 53, a variant of SEQ ID NO: 53, a conservatively modified variant of SEQ ID NO: 53, a variant of SEQ ID NO: 53 comprising canonical structure class 6, SEQ ID NO: 54, a variant of SEQ ID NO: 54, a conservatively modified variant of SEQ ID NO: 54, a variant of SEQ ID NO: 54 comprising canonical structure class 1, SEQ ID NO: 55, a variant of SEQ ID NO: 55, a conservatively modified variant of SEQ ID NO: 55, a variant of SEQ ID NO: 55 comprising the canonical structure class 2A, SEQ ID NO: 129, a variant of SEQ ID NO: 129, a conservatively modified variant of SEQ ID NO: 129,a variant of SEQ ID NO: 129 comprising canonical structure class 6, SEQ ID NO: 130, a variant of SEQ ID NO: 130, a conservatively modified variant of SEQ ID NO: 130, a variant of SEQ ID NO: 130 comprising canonical structure class 6, SEQ ID NO: 131, a variant of SEQ ID NO: 131, a conservatively modified variant of SEQ ID NO: 131, or a variant of SEQ ID NO: 131 comprising canonical structure class 3.
[0025] The corresponding CDRL2 comprises the amino acid sequence of SEQ ID NO: 56, a variant of SEQ ID NO: 56, a conservatively modified variant of SEQ ID NO: 56, a variant of SEQ ID NO: 56 comprising the canonical structure class of 1, SEQ ID NO: 57, a variant of SEQ ID NO: 57, a conservatively modified variant of SEQ ID NO: 57, a variant of SEQ ID NO: 57 comprising the canonical structure class of 1, SEQ ID NO: 58, a variant of SEQ ID NO: 58, a conservatively modified variant of SEQ ID NO: 58, a variant of SEQ ID NO: 58 Petition 870250121500, dated 12 / 30 / 2025, page 33 / 160 18 / 138 comprising the canonical structure class of 1, SEQ ID NO: 59, a variant of SEQ ID NO: 59, a conservatively modified variant of SEQ ID NO: 59, a variant of SEQ ID NO: 59 comprising the canonical structure class of 1, SEQ ID NO: 60, a variant of SEQ ID NO: 60, a conservatively modified variant of SEQ ID NO: 60, a variant of SEQ ID NO: 60 comprising the canonical structure class of 1, SEQ ID NO: 61, a variant of SEQ ID NO: 61, a conservatively modified variant of SEQ ID NO: 61, a variant of SEQ ID NO: 61 comprising the canonical structure class of 1, SEQ ID NO: 62, a variant of SEQ ID NO: 62, a conservatively modified variant of SEQ ID NO: 62, a variant of SEQ ID NO: 62 comprising the canonical structure class of 1, SEQ ID NO: 63, a variant of SEQ ID NO: 63, a conservatively modified variant of SEQ ID NO: 63, a variant of SEQ ID NO: 63 comprising canonical structure class of 1,SEQ ID NO: 64, a variant of SEQ ID NO: 64, a conservatively modified variant of SEQ ID NO: 64, or a variant of SEQ ID NO: 64 comprising the canonical structure class of 1, SEQ ID NO: 132, a variant of SEQ ID NO: 132, a conservatively modified variant of SEQ ID NO: 132, a variant of SEQ ID NO: 132 comprising the canonical structure class of 1, SEQ ID NO: 133, a variant of SEQ ID NO: 133, a conservatively modified variant of SEQ ID NO: 133, a variant of SEQ ID NO: 133 comprising the canonical structure class of 1, SEQ ID NO: 134, a variant of SEQ ID NO: 134, a conservatively modified variant of SEQ ID NO: 134, or a variant of SEQ ID NO: 134 comprising the canonical structure class of 1.,
[0026] The corresponding CDRL3 comprises the amino acid sequence of SEQ ID NO: 65, a variant of SEQ ID NO: 65, a conservatively modified variant of SEQ ID NO: 65, a variant of SEQ ID NO: Petition 870250121500, dated 12 / 30 / 2025, p. 34 / 160 19 / 138 comprising the canonical structure class of 1, SEQ ID NO: 66, a variant of SEQ ID NO: 66, a conservatively modified variant of SEQ ID NO: 66, a variant of SEQ ID NO: 66 comprising the canonical structure class of 1, SEQ ID NO: 67, a variant of SEQ ID NO: 67, a conservatively modified variant of SEQ ID NO: 67, a variant of SEQ ID NO: 67 comprising the canonical structure class of 1, SEQ ID NO: 68, a variant of SEQ ID NO: 68, a conservatively modified variant of SEQ ID NO: 68, a variant of SEQ ID NO: 68 comprising the canonical structure class of 1, SEQ ID NO: 69, a variant of SEQ ID NO: 69, a conservatively modified variant of SEQ ID NO: 69, a variant of SEQ ID NO: 69 comprising the canonical structure class 1, SEQ ID NO: 70, a variant of SEQ ID NO: 70, a conservatively modified variant of SEQ ID NO: 70, a variant of SEQ ID NO: 70 comprising canonical structure class 1,SEQ ID NO: 71, a variant of SEQ ID NO: 71, a conservatively modified variant of SEQ ID NO: 71, a variant of SEQ ID NO: 71 comprising the canonical structure class of 1, SEQ ID NO: 72, a variant of SEQ ID NO: 72, a conservatively modified variant of SEQ ID NO: 72, a variant of SEQ ID NO: 72 comprising the canonical structure class of 1, SEQ ID NO: 73, a variant of SEQ ID NO: 73, a conservatively modified variant of SEQ ID NO: 73, a variant of SEQ ID NO: 73 comprising the canonical structure class of 1, SEQ ID NO: 135, a variant of SEQ ID NO: 135, a conservatively modified variant of SEQ ID NO: 135, a variant of SEQ ID NO: 135 comprising the canonical structure class of 1, SEQ ID NO: 136, a variant of SEQ ID NO: 136, a conservatively modified variant of SEQ ID NO: 136, a variant of SEQ ID NO: 136 comprising the canonical structure class of 1, SEQ ID NO: 137, a variant of SEQ ID NO: 137,a conservative variant, Petition 870250121500, dated 12 / 30 / 2025, page 35 / 160 20 / 138 modified from SEQ ID NO: 137, a variant of SEQ ID NO: 137 comprising canonical structure class 1, SEQ ID NO: 138, a variant of SEQ ID NO: 138, a conservatively modified variant of SEQ ID NO: 138, a variant of SEQ ID NO: 138 comprising canonical structure class 3, SEQ ID NO: 139, a variant of SEQ ID NO: 139, a conservatively modified variant of SEQ ID NO: 139, or a variant of SEQ ID NO: 139 comprising canonical structure class 1.
[0027] The corresponding CDRH1 comprises the amino acid sequence of SEQ ID NO: 74, a variant of SEQ ID NO: 74, a conservatively modified variant of SEQ ID NO: 74, a variant of SEQ ID NO: 74 comprising the canonical structure class of 1, SEQ ID NO: 75, a variant of SEQ ID NO: 75, a conservatively modified variant of SEQ ID NO: 75, a variant of SEQ ID NO: 75 comprising the canonical structure class of 1, SEQ ID NO: 76, a variant of SEQ ID NO: 76, a conservatively modified variant of SEQ ID NO: 76, or a variant of SEQ ID NO: 76 comprising the canonical structure class of 1, SEQ ID NO: 77, a variant of SEQ ID NO: 77, a conservatively modified variant of SEQ ID NO: 77, or a variant of SEQ ID NO: 77 that comprises the canonical structure class of 1, SEQ ID NO: 78, a variant of SEQ ID NO: 78, a conservatively modified variant of SEQ ID NO: 78,a variant of SEQ ID NO: 78 comprising canonical structure class 1, SEQ ID NO: 79, a variant of SEQ ID NO: 79, a conservatively modified variant of SEQ ID NO: 79, a variant of SEQ ID NO: 79 comprising canonical structure class 1, SEQ ID NO: 80, a variant of SEQ ID NO: 80, a conservatively modified variant of SEQ ID NO: 80, a variant of SEQ ID NO: 80 comprising canonical structure class 1, SEQ ID NO: 81, a variant of SEQ ID NO: 81, a conservatively modified variant of, Petition 870250121500, dated 12 / 30 / 2025, page 36 / 160 21 / 138 SEQ ID NO: 81, a variant of SEQ ID NO: 81 comprising the canonical structure class of 1, SEQ ID NO: 82, a variant of SEQ ID NO: 82, a conservatively modified variant of SEQ ID NO: 82, or a variant of SEQ ID NO: 82 comprising the canonical structure class of 1, SEQ ID NO: 140, a variant of SEQ ID NO: 140, a conservatively modified variant of SEQ ID NO: 140, a variant of SEQ ID NO: 140 comprising the canonical structure class of 1, SEQ ID NO: 141, a variant of SEQ ID NO: 141, a conservatively modified variant of SEQ ID NO: 141, a variant of SEQ ID NO: 141 comprising the canonical structure class of 1, SEQ ID NO: 142, a variant of SEQ ID NO: 142, a conservatively modified variant of SEQ ID NO: 142, a variant of SEQ ID NO: 142 comprising the canonical structure class of 1, SEQ ID NO: 143, a variant of SEQ ID NO: 143, a conservatively modified variant of SEQ ID NO: 143,or a variant of SEQ ID NO: 143 that comprises the canonical structure class of 1.,
[0028] The corresponding CDRH2 comprises the amino acid sequence of SEQ ID NO: 83, a variant of SEQ ID NO: 83, a conservatively modified variant of SEQ ID NO: 83, a variant of SEQ ID NO: 83 comprising the canonical structure class 3A, SEQ ID NO: 84, a variant of SEQ ID NO: 84, a conservatively modified variant of SEQ ID NO: 84, a variant of SEQ ID NO: 84 comprising the canonical structure class 2A, SEQ ID NO: 85, a variant of SEQ ID NO: 85, a conservatively modified variant of SEQ ID NO: 85, or a variant of SEQ ID NO: 85 comprising the canonical structure class 2B, SEQ ID NO: 86, a variant of SEQ ID NO: 86, a conservatively modified variant of SEQ ID NO: 86, SEQ ID NO: 87, a variant of SEQ ID NO: 87, a conservatively modified variant of SEQ ID NO: 87, a variant of SEQ ID NO: Petition 870250121500, dated 12 / 30 / 2025, p. 37 / 160 22 / 138 comprising canonical structure class 1, SEQ ID NO: 88, a variant of SEQ ID NO: 88, a conservatively modified variant of SEQ ID NO: 88, a variant of SEQ ID NO: 88 comprising canonical structure class 2B, SEQ ID NO: 89, a variant of SEQ ID NO: 89, a conservatively modified variant of SEQ ID NO: 89, a variant of SEQ ID NO: 89 comprising canonical structure class 2B, SEQ ID NO: 90, a variant of SEQ ID NO: 90, a conservatively modified variant of SEQ ID NO: 90, a variant of SEQ ID NO: 90 comprising canonical structure class 1, SEQ ID NO: 91, a variant of SEQ ID NO: 91, a conservatively modified variant of SEQ ID NO: 91, a variant of SEQ ID NO: 91 that comprises the canonical structure class 2A, SEQ ID NO: 144, a variant of SEQ ID NO: 144, a conservatively modified variant of SEQ ID NO: 144,a variant of SEQ ID NO: 144 comprising canonical structure class 3A, SEQ ID NO: 145, a variant of SEQ ID NO: 145, a conservatively modified variant of SEQ ID NO: 145, a variant of SEQ ID NO: 145 comprising canonical structure class 2A, SEQ ID NO: 146, a variant of SEQ ID NO: 146, a conservatively modified variant of SEQ ID NO: 146, a variant of SEQ ID NO: 146 comprising canonical structure class 3A, SEQ ID NO: 147, a variant of SEQ ID NO: 147, a conservatively modified variant of SEQ ID NO: 147, a variant of SEQ ID NO: 147 comprising canonical structure class 3A, SEQ ID NO: 148, a variant of SEQ ID NO: 148, a conservatively modified variant of SEQ ID NO: 148, or a variant of SEQ ID NO: 148 comprising the canonical structure class of 3A.
[0029] The corresponding CDRH3 comprises the amino acid sequence of SEQ ID NO: 92, a variant of SEQ ID NO: 92, a conservatively modified variant of SEQ ID NO: 92, a variant of SEQ ID NO: Petition 870250121500, dated 12 / 30 / 2025, p. 38 / 160 23 / 138 comprising canonical structure class 12, SEQ ID NO: 93, a variant of SEQ ID NO: 93, a conservatively modified variant of SEQ ID NO: 93, a variant of SEQ ID NO: 93 comprising canonical structure class 7, SEQ ID NO: 94, a variant of SEQ ID NO: 94, a conservatively modified variant of SEQ ID NO: 94, or a variant of SEQ ID NO: 94 comprising canonical structure class 15, SEQ ID NO: 95, a variant of SEQ ID NO: 95, a conservatively modified variant of SEQ ID NO: 95, or a variant of SEQ ID NO: 95 comprising canonical structure class 11, SEQ ID NO: 96, a variant of SEQ ID NO: 96, a conservatively modified variant of SEQ ID NO: 96, a variant of SEQ ID NO: 96 comprising the canonical structure class of 15, SEQ ID NO: 97, a variant of SEQ ID NO: 97, a conservatively modified variant of SEQ ID NO: 97,a variant of SEQ ID NO: 97 comprising canonical structure class 6, SEQ ID NO: 98, a variant of SEQ ID NO: 98, a conservatively modified variant of SEQ ID NO: 98, a variant of SEQ ID NO: 98 comprising canonical structure class 4, SEQ ID NO: 99, a variant of SEQ ID NO: 99, a conservatively modified variant of SEQ ID NO: 99, a variant of SEQ ID NO: 99 comprising canonical structure class 13, SEQ ID NO: 100, a variant of SEQ ID NO: 100, a conservatively modified variant of SEQ ID NO: 100, or a variant of SEQ ID NO: 100 comprising canonical structure class 6, SEQ ID NO: 149, a variant of SEQ ID NO: 149, a conservatively modified variant of SEQ ID NO: 149, a variant of SEQ ID NO: 149 comprising canonical structure class 15, SEQ ID NO: 150, a variant of SEQ ID NO: 150, a conservatively modified variant of SEQ ID NO: 150,a variant of SEQ ID NO: 150 comprising canonical structure class 10, SEQ ID NO: 151, a variant of SEQ ID NO: 151, a variant, Petition 870250121500, dated 12 / 30 / 2025, page 39 / 160 24 / 138 conservatively modified from SEQ ID NO: 151, a variant of SEQ ID NO: 151 comprising canonical structure class 15, SEQ ID NO: 152, a variant of SEQ ID NO: 152, a conservatively modified variant of SEQ ID NO: 152, a variant of SEQ ID NO: 152 comprising canonical structure class 9, SEQ ID NO: 153, a variant of SEQ ID NO: 153, a conservatively modified variant of SEQ ID NO: 153, or a variant of SEQ ID NO: 153 comprising canonical structure class 13.
[0030] In particular embodiments, mammalian antibodies (including chimeric mammalian antibodies) and / or antigen-binding fragments thereof of the present invention bind to canine interleukin-4 alpha receptor (IL-4Ra) and / or block the binding of canine IL-4Ra to canine IL-4 and / or canine IL-13. In related embodiments, mammalian antibodies and / or antigen-binding fragments thereof of the present invention block the binding of canine IL-4 and / or canine IL-13 to the IL-4 type I receptor and / or the IL-4 type II receptor. In particular embodiments, the mammalian antibodies (whether isolated or not) are caninized antibodies.
[0031] Consequently, in some mammalian antibody embodiments (including caninized antibodies), CDRL1 comprises the amino acid sequence of SEQ ID NO: 47, a variant of SEQ ID NO: 47, a conservatively modified variant of SEQ ID NO: 47, or a variant of SEQ ID NO: 47 comprising canonical structure class 1; CDRL2 comprises the amino acid sequence of SEQ ID NO: 56, a variant of SEQ ID NO: 56, a conservatively modified variant of SEQ ID NO: 56, or a variant of SEQ ID NO: 56 comprising canonical structure class 1; CDRL3 comprises the amino acid sequence of SEQ ID NO: 65, a variant of SEQ ID NO: 65, a variant Petition 870250121500, dated 12 / 30 / 2025, p. 40 / 160 25 / 138 conservatively modified of SEQ ID NO: 65, or a variant of SEQ ID NO: 65 comprising canonical structure class 1, CDRH1 comprising the amino acid sequence of SEQ ID NO: 74, a variant of SEQ ID NO: 74, a conservatively modified variant of SEQ ID NO: 74, or a variant of SEQ ID NO: 74 comprising canonical structure class 1; CDRH2 comprises the amino acid sequence SEQ ID NO: 83, a variant of SEQ ID NO: 83, a conservatively modified variant of SEQ ID NO: 83, and a variant of SEQ ID NO: 83 comprising canonical structure class 3A; CDRH3 comprises the amino acid sequence SEQ ID NO: 92, a variant of SEQ ID NO: 92, a conservatively modified variant of SEQ ID NO: 92, or a variant of SEQ ID NO: 92 comprising canonical structure class 12.
[0032] In still other embodiments of mammalian antibodies (including caninized antibodies) CDRL1 comprises the amino acid sequence of SEQ ID NO: 48, a variant of SEQ ID NO: 48, a conservatively modified variant of SEQ ID NO: 48, or a variant of SEQ ID NO: 48 comprising canonical structure class 2A; CDRL2 comprises the amino acid sequence of SEQ ID NO: 57, a variant of SEQ ID NO: 57, a conservatively modified variant of SEQ ID NO: 57, or a variant of SEQ ID NO: 57 comprising canonical structure class 1;CDRL3 comprises the amino acid sequence SEQ ID NO: 66, a variant of SEQ ID NO: 66, a conservatively modified variant of SEQ ID NO: 66, or a variant of SEQ ID NO: 66 comprising canonical structure class 1; CDRH1 comprises the amino acid sequence SEQ ID NO: 75, a variant of SEQ ID NO: 75, a conservatively modified variant of SEQ ID NO: 75, or a variant of SEQ ID NO: 75 comprising canonical structure class 1; CDRH2 comprises the amino acid sequence of; Petition 870250121500, dated 12 / 30 / 2025, page 41 / 160 26 / 138 SEQ ID NO: 84, a variant of SEQ ID NO: 84, a conservatively modified variant of SEQ ID NO: 84, and a variant of SEQ ID NO: 84 comprising the canonical structure class of 2A, CDRH3 comprising the amino acid sequence of SEQ ID NO: 93, a variant of SEQ ID NO: 93, a conservatively modified variant of SEQ ID NO: 93, or a variant of SEQ ID NO: 93 comprising the canonical structure class of 7.
[0033] In still other embodiments of mammalian antibodies (including caninized antibodies) CDRL1 comprises the amino acid sequence of SEQ ID NO: 49, a variant of SEQ ID NO: 49, a conservatively modified variant of SEQ ID NO: 49, or a variant of SEQ ID NO: 49 comprising the canonical structure class of 4; CDRL2 comprises the amino acid sequence of SEQ ID NO: 58, a variant of SEQ ID NO: 58, a conservatively modified variant of SEQ ID NO: 58, or a variant of SEQ ID NO: 58 comprising the canonical structure class of 4;CDRL3 comprises the amino acid sequence SEQ ID NO: 67, a variant of SEQ ID NO: 67, a conservatively modified variant of SEQ ID NO: 67, or a variant of SEQ ID NO: 67 comprising canonical structure class 1; CDRH1 comprises the amino acid sequence SEQ ID NO: 76, a variant of SEQ ID NO: 76, a conservatively modified variant of SEQ ID NO: 76, or a variant of SEQ ID NO: 76 comprising canonical structure class 1; CDRH2 comprises the amino acid sequence SEQ ID NO: 85, a variant of SEQ ID NO: 85, a conservatively modified variant of SEQ ID NO: 85, and a variant of SEQ ID NO: 85 comprising the canonical structure class 2B; CDRH3 comprises the amino acid sequence SEQ ID NO: 94, a variant of SEQ ID NO: 94, a conservatively modified variant of SEQ ID NO: 94, or a variant of SEQ ID NO: 94 comprising the canonical structure class 15. Petition 870250121500, dated 12 / 30 / 2025, p. 42 / 160 27 / 138
[0034] In still other embodiments of mammalian antibodies (including caninized antibodies) CDRL1 comprises the amino acid sequence of SEQ ID NO: 51, a variant of SEQ ID NO: 51, a conservatively modified variant of SEQ ID NO: 51, or a variant of SEQ ID NO: 51 comprising canonical structure class 3; CDRL2 comprises the amino acid sequence of SEQ ID NO: 60, a variant of SEQ ID NO: 60, a conservatively modified variant of SEQ ID NO: 60, or a variant of SEQ ID NO: 60 comprising canonical structure class 1;CDRL3 comprises the amino acid sequence SEQ ID NO: 69, a variant of SEQ ID NO: 69, a conservatively modified variant of SEQ ID NO: 69, or a variant of SEQ ID NO: 69 comprising canonical structure class 1; CDRH1 comprises the amino acid sequence SEQ ID NO: 78, a variant of SEQ ID NO: 78, a conservatively modified variant of SEQ ID NO: 78, or a variant of SEQ ID NO: 78 comprising canonical structure class 1; CDRH2 comprises the amino acid sequence SEQ ID NO: 87, a variant of SEQ ID NO: 87, a conservatively modified variant of SEQ ID NO: 87, and a variant of SEQ ID NO: 87 comprising canonical structure class 1; CDRH3 comprises the amino acid sequence SEQ ID NO: 96, a variant of SEQ ID NO: 96, a conservatively modified variant of SEQ ID NO: 96, or a variant of SEQ ID NO: 96 comprising canonical structure class 15.
[0035] In still other embodiments of mammalian antibodies (including caninized antibodies) CDRL1 comprises the amino acid sequence of SEQ ID NO: 52, a variant of SEQ ID NO: 52, a conservatively modified variant of SEQ ID NO: 52, or a variant of SEQ ID NO: 52 comprising the canonical structure class 2A; CDRL2 comprises Petition 870250121500, dated 12 / 30 / 2025, page 43 / 160 28 / 138 the amino acid sequence of SEQ ID NO: 61, a variant of SEQ ID NO: 61, a conservatively modified variant of SEQ ID NO: 61, or a variant of SEQ ID NO: 61 comprising canonical structure class 1; CDRL3 comprises the amino acid sequence of SEQ ID NO: 70, a variant of SEQ ID NO: 70, a conservatively modified variant of SEQ ID NO: 70, or a variant of SEQ ID NO: 70 comprising canonical structure class 1; CDRH1 comprises the amino acid sequence of SEQ ID NO: 79, a variant of SEQ ID NO: 79, a conservatively modified variant of SEQ ID NO: 79, or a variant of SEQ ID NO: 79 comprising canonical structure class 1;CDRH2 comprises the amino acid sequence SEQ ID NO: 88, a variant of SEQ ID NO: 88, a conservatively modified variant of SEQ ID NO: 88, and a variant of SEQ ID NO: 88 comprising the canonical structure class 2B; CDRH3 comprises the amino acid sequence SEQ ID NO: 97, a variant of SEQ ID NO: 97, a conservatively modified variant of SEQ ID NO: 97, or a variant of SEQ ID NO: 97 comprising the canonical structure class 6.
[0036] In still other embodiments of mammalian antibodies (including caninized antibodies), CDRL1 comprises the amino acid sequence of SEQ ID NO: 53, a variant of SEQ ID NO: 53, a conservatively modified variant of SEQ ID NO: 53, or a variant of SEQ ID NO: 53 comprising canonical structure class 6; CDRL2 comprises the amino acid sequence of SEQ ID NO: 62, a variant of SEQ ID NO: 62, a conservatively modified variant of SEQ ID NO: 62, or a variant of SEQ ID NO: 62 comprising canonical structure class 1; CDRL3 comprises the amino acid sequence of SEQ ID NO: 71, a variant of SEQ ID NO: 71, a conservatively modified variant of SEQ ID NO: 71, or a variant of SEQ ID NO: 71 comprising canonical structure class 1. Petition 870250121500, dated 12 / 30 / 2025, page 44 / 160 29 / 138 of 1, CDRH1 comprises the amino acid sequence of SEQ ID NO: 80, a variant of SEQ ID NO: 80, a conservatively modified variant of SEQ ID NO: 80, or a variant of SEQ ID NO: 80 comprising the canonical structure class of 1; CDRH2 comprises the amino acid sequence of SEQ ID NO: 89, a variant of SEQ ID NO: 89, a conservatively modified variant of SEQ ID NO: 89 and a variant of SEQ ID NO: 89 comprising the canonical structure class of 2B; CDRH3 comprises the amino acid sequence of SEQ ID NO: 98, a variant of SEQ ID NO: 98, a conservatively modified variant of SEQ ID NO: 98, or a variant of SEQ ID NO: 98 comprising the canonical structure class of 4.
[0037] In still other embodiments of mammalian antibodies (including caninized antibodies) CDRL1 comprises the amino acid sequence of SEQ ID NO: 54, a variant of SEQ ID NO: 54, a conservatively modified variant of SEQ ID NO: 54, or a variant of SEQ ID NO: 54 comprising canonical structure class 1; CDRL2 comprises the amino acid sequence of SEQ ID NO: 63, a variant of SEQ ID NO: 63, a conservatively modified variant of SEQ ID NO: 63, or a variant of SEQ ID NO: 63 comprising canonical structure class 1;CDRL3 comprises the amino acid sequence SEQ ID NO: 72, a variant of SEQ ID NO: 72, a conservatively modified variant of SEQ ID NO: 72, or a variant of SEQ ID NO: 72 comprising canonical structure class 1; CDRH1 comprises the amino acid sequence SEQ ID NO: 81, a variant of SEQ ID NO: 81, a conservatively modified variant of SEQ ID NO: 81, or a variant of SEQ ID NO: 81 comprising canonical structure class 1; CDRH2 comprises the amino acid sequence SEQ ID NO: 90, a variant of SEQ ID NO: 90, a conservatively modified variant of SEQ ID NO: 90, and a variant of SEQ ID NO: 90 comprising; Petition 870250121500, dated 12 / 30 / 2025, p. 45 / 160 30 / 138 canonical structure class 1, CDRH3 comprises the amino acid sequence of SEQ ID NO: 99, a variant of SEQ ID NO: 99, a conservatively modified variant of SEQ ID NO: 99, or a variant of SEQ ID NO: 99 comprising canonical structure class 13. In particular embodiments of this type, when the antibody (or antigen-binding fragment thereof) binds to canine interleukin-4 receptor α (IL-4Ra), the antibody binds to at least one amino acid residue, preferably two to five amino acid residues, and / or more preferably three to eight amino acid residues or more within the amino acid sequence of SEQ ID NO: 157, or SEQ ID NO: 158, or within both SEQ ID NO: 157 and SEQ ID NO: 158.
[0038] In still other embodiments of mammalian antibodies (including caninized antibodies) CDRL1 comprises the amino acid sequence of SEQ ID NO: 55, a variant of SEQ ID NO: 55, a conservatively modified variant of SEQ ID NO: 55, or a variant of SEQ ID NO: 55 comprising the canonical structure class 2A; CDRL2 comprises the amino acid sequence of SEQ ID NO: 64, a variant of SEQ ID NO: 64, a conservatively modified variant of SEQ ID NO: 64, or a variant of SEQ ID NO: 64 comprising the canonical structure class 1;CDRL3 comprises the amino acid sequence SEQ ID NO: 73, a variant of SEQ ID NO: 73, a conservatively modified variant of SEQ ID NO: 73, or a variant of SEQ ID NO: 73 comprising canonical structure class 1; CDRH1 comprises the amino acid sequence SEQ ID NO: 82, a variant of SEQ ID NO: 82, a conservatively modified variant of SEQ ID NO: 82, or a variant of SEQ ID NO: 82 comprising canonical structure class 1; CDRH2 comprises the amino acid sequence SEQ ID NO: 91, a variant of SEQ ID NO: 91, a conservatively modified variant of SEQ ID NO: 91, and a variant of SEQ ID NO: 91 comprising; Petition 870250121500, dated 12 / 30 / 2025, p. 46 / 160 31 / 138 the canonical structure class 2A, CDRH3 comprises the amino acid sequence of SEQ ID NO: 100, a variant of SEQ ID NO: 100, a conservatively modified variant of SEQ ID NO: 100, or a variant of SEQ ID NO: 100 comprising the canonical structure class 6.
[0039] In still other embodiments of mammalian antibodies (including caninized antibodies) CDRL1 comprises the amino acid sequence of SEQ ID NO: 129, a variant of SEQ ID NO: 129, a conservatively modified variant of SEQ ID NO: 129, or a variant of SEQ ID NO: 129 comprising canonical structure class 6; CDRL2 comprises the amino acid sequence of SEQ ID NO: 132, a variant of SEQ ID NO: 132, a conservatively modified variant of SEQ ID NO: 132, or a variant of SEQ ID NO: 132 comprising canonical structure class 1;CDRL3 comprises the amino acid sequence SEQ ID NO: 135, a variant of SEQ ID NO: 135, a conservatively modified variant of SEQ ID NO: 135, or a variant of SEQ ID NO: 135 comprising canonical structure class 1; CDRH1 comprises the amino acid sequence SEQ ID NO: 140, a variant of SEQ ID NO: 140, a conservatively modified variant of SEQ ID NO: 140, or a variant of SEQ ID NO: 140 comprising canonical structure class 1;CDRH2 comprises the amino acid sequence of SEQ ID NO: 144, a variant of SEQ ID NO: 144, a conservatively modified variant of SEQ ID NO: 144, and a variant of SEQ ID NO: 144 comprising the canonical structure class 3A. CDRH3 comprises the amino acid sequence of SEQ ID NO: 149, a variant of SEQ ID NO: 149, a conservatively modified variant of SEQ ID NO: 149, or a variant of SEQ ID NO: 149 comprising the canonical structure class 15. In particular embodiments of this type, when the antibody (or antigen-binding fragment thereof); Petition 870250121500, dated 12 / 30 / 2025, p. 47 / 160 32 / 138 binds to canine interleukin-4 receptor α (IL-4Ra) the antibody binds to at least one amino acid residue, preferably two to five amino acid residues, and / or more preferably three to eight amino acid residues or more within the amino acid sequence of SEQ ID NO: 127, or SEQ ID NO: 128, or within both SEQ ID NO: 127 and SEQ ID NO: 128.
[0040] In still other embodiments of mammalian antibodies (including caninized antibodies) CDRL1 comprises the amino acid sequence of SEQ ID NO: 130, a variant of SEQ ID NO: 130, a conservatively modified variant of SEQ ID NO: 130, or a variant of SEQ ID NO: 130 comprising canonical structure class 6; CDRL2 comprises the amino acid sequence of SEQ ID NO: 133, a variant of SEQ ID NO: 133, a conservatively modified variant of SEQ ID NO: 133, or a variant of SEQ ID NO: 133 comprising canonical structure class 1;CDRL3 comprises the amino acid sequence of SEQ ID NO: 136, a variant of SEQ ID NO: 136, a conservatively modified variant of SEQ ID NO: 136, or a variant of SEQ ID NO: 136 comprising canonical structure class 1; CDRH1 comprises the amino acid sequence of SEQ ID NO: 141, a variant of SEQ ID NO: 141, a conservatively modified variant of SEQ ID NO: 141, or a variant of SEQ ID NO: 141 comprising canonical structure class 1; CDRH2 comprises the amino acid sequence SEQ ID NO: 145, a variant of SEQ ID NO: 145, a conservatively modified variant of SEQ ID NO: 145, and a variant of SEQ ID NO: 145 comprising the canonical structure class 2A; CDRH3 comprises the amino acid sequence SEQ ID NO: 150, a variant of SEQ ID NO: 150, a conservatively modified variant of SEQ ID NO: 150, or a variant of SEQ ID NO: 150 comprising the canonical structure class 10. In particular embodiments; Petition 870250121500, dated 12 / 30 / 2025, p. 48 / 160 33 / 138 of this type, when the antibody (or antigen-binding fragment thereof) binds to canine interleukin-4 α receptor (IL-4Ra), the antibody binds to at least one amino acid residue, preferably two to five amino acid residues, and / or more preferably three to eight amino acid residues or more within the amino acid sequence of SEQ ID NO: 158, or SEQ ID NO: 162, or within both SEQ ID NO: 158 and SEQ ID NO: 162.
[0041] In still other embodiments of mammalian antibodies (including caninized antibodies) CDRL1 comprises the amino acid sequence of SEQ ID NO: 129, a variant of SEQ ID NO: 129, a conservatively modified variant of SEQ ID NO: 129, or a variant of SEQ ID NO: 129 comprising canonical structure class 6; CDRL2 comprises the amino acid sequence of SEQ ID NO: 134, a variant of SEQ ID NO: 134, a conservatively modified variant of SEQ ID NO: 134, or a variant of SEQ ID NO: 134 comprising canonical structure class 1;CDRL3 comprises the amino acid sequence SEQ ID NO: 137, a variant of SEQ ID NO: 137, a conservatively modified variant of SEQ ID NO: 137, or a variant of SEQ ID NO: 137 comprising canonical structure class 1; CDRH1 comprises the amino acid sequence SEQ ID NO: 140, a variant of SEQ ID NO: 140, a conservatively modified variant of SEQ ID NO: 140, or a variant of SEQ ID NO: 140 comprising canonical structure class 1; CDRH2 comprises the amino acid sequence SEQ ID NO: 146, a variant of SEQ ID NO: 146, a conservatively modified variant of SEQ ID NO: 146, and a variant of SEQ ID NO: 146 that comprises the canonical structure class 3A; CDRH3 comprises the amino acid sequence SEQ ID NO: 151, a variant of SEQ ID NO: 151, a conservatively modified variant of SEQ ID NO: 151, or a variant of SEQ ID NO: 151 that; Petition 870250121500, dated 12 / 30 / 2025, page 49 / 160 34 / 138 comprises the canonical structure class of 15. In particular embodiments of this type, when the antibody (or antigen-binding fragment thereof) binds to canine interleukin-4 receptor α (IL-4Ra), the antibody binds to at least one amino acid residue, preferably two to five amino acid residues, and / or more preferably three to eight amino acid residues or more within the amino acid sequence of SEQ ID NO: 125 or SEQ ID NO: 126, or within both SEQ ID NO: 125 and SEQ ID NO: 126.
[0042] In still other embodiments of mammalian antibodies (including caninized antibodies) CDRL1 comprises the amino acid sequence of SEQ ID NO: 131, a variant of SEQ ID NO: 131, a conservatively modified variant of SEQ ID NO: 131, or a variant of SEQ ID NO: 131 comprising canonical structure class 3; CDRL2 comprises the amino acid sequence of SEQ ID NO: 60, a variant of SEQ ID NO: 60, a conservatively modified variant of SEQ ID NO: 60, or a variant of SEQ ID NO: 60 comprising canonical structure class 1;CDRL3 comprises the amino acid sequence of SEQ ID NO: 138, a variant of SEQ ID NO: 138, a conservatively modified variant of SEQ ID NO: 1385, or a variant of SEQ ID NO: 138 comprising canonical structure class 3; CDRH1 comprises the amino acid sequence of SEQ ID NO: 142, a variant of SEQ ID NO: 142, a conservatively modified variant of SEQ ID NO: 142, or a variant of SEQ ID NO: 142 comprising canonical structure class 1; CDRH2 comprises the amino acid sequence SEQ ID NO: 147, a variant of SEQ ID NO: 147, a conservatively modified variant of SEQ ID NO: 147, and a variant of SEQ ID NO: 147 that comprises the canonical structure class 3A; CDRH3 comprises the amino acid sequence SEQ ID NO: 152, a variant of SEQ ID NO: 152, a conservatively modified variant; Petition 870250121500, dated 12 / 30 / 2025, page 50 / 160 35 / 138 modified from SEQ ID NO: 152, or a variant of SEQ ID NO: 152 comprising canonical structure class 9. In particular embodiments of this type, when the antibody (or antigen-binding fragment thereof) binds to canine interleukin-4 receptor α (IL-4Ra), the antibody binds to at least one amino acid residue, preferably two to five amino acid residues, and / or more preferably three to eight amino acid residues or more within the amino acid sequence of SEQ ID NO: 154, or SEQ ID NO: 155, or SEQ ID NO: 156, or any combination thereof.
[0043] In still other embodiments of mammalian antibodies (including caninized antibodies) CDRL1 comprises the amino acid sequence of SEQ ID NO: 129, a variant of SEQ ID NO: 129, a conservatively modified variant of SEQ ID NO: 129, or a variant of SEQ ID NO: 129 comprising canonical structure class 6; CDRL2 comprises the amino acid sequence of SEQ ID NO: 132, a variant of SEQ ID NO: 132, a conservatively modified variant of SEQ ID NO: 132, or a variant of SEQ ID NO: 132 comprising canonical structure class 1;CDRL3 comprises the amino acid sequence SEQ ID NO: 139, a variant of SEQ ID NO: 139, a conservatively modified variant of SEQ ID NO: 139, or a variant of SEQ ID NO: 139 comprising canonical structure class 1; CDRH1 comprises the amino acid sequence SEQ ID NO: 143, a variant of SEQ ID NO: 143, a conservatively modified variant of SEQ ID NO: 143, or a variant of SEQ ID NO: 143 comprising canonical structure class 1; CDRH2 comprises the amino acid sequence SEQ ID NO: 148, a variant of SEQ ID NO: 148, a conservatively modified variant of SEQ ID NO: 148, and a variant of SEQ ID NO: 148 comprising canonical structure class 3A; CDRH3 comprises the amino acid sequence SEQ ID NO:; Petition 870250121500, dated 12 / 30 / 2025, page 51 / 160 36 / 138 153, a variant of SEQ ID NO: 153, a conservatively modified variant of SEQ ID NO: 153, or a variant of SEQ ID NO: 153 comprising the canonical structure class of 13. In particular embodiments of this type, when the antibody (or antigen-binding fragment thereof) binds to canine interleukin-4 receptor α (IL-4Ra), the antibody binds to at least one amino acid residue, preferably two to five amino acid residues, and / or more preferably three to eight amino acid residues or more within the amino acid sequence of SEQ ID NO: 159, or SEQ ID NO: 160, or SEQ ID NO: 161, or any combination thereof.
[0044] The present invention includes antibodies and antigen-binding fragments thereof that bind to canine interleukin-4 alpha receptor (IL-4Ra) with specificity. In particular embodiments of this type, the antibodies and antigen-binding fragments thereof bind to canine IL-4Ra and block the binding of canine IL-4Ra to canine IL-4 and / or IL-13. As indicated above, isolated mammalian antibodies or antigen-binding fragments thereof may be caninized antibodies or caninized antigen-binding fragments thereof. In other embodiments, isolated mammalian antibodies or antigen-binding fragments thereof may be murine antibodies or murine antigen-binding fragments thereof.
[0045] The caninized antibodies or caninized antigen-binding fragments thereof of the present invention may comprise a hinge region. In a particular embodiment of this type, the hinge region comprises the amino acid sequence of SEQ ID NO: 101. In another embodiment, the hinge region comprises the amino acid sequence of SEQ ID NO: 102. In yet another embodiment, the hinge region comprises the amino acid sequence of SEQ ID NO: 103. In yet another embodiment, the Petition 870250121500, dated 12 / 30 / 2025, page 52 / 160 The 37 / 138 hinge region comprises the amino acid sequence SEQ ID NO: 104.
[0046] In some embodiments, the caninized antibody or antigen-binding fragment thereof comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 164. In particular embodiments of this type, the heavy chain is encoded by the nucleotide sequence of SEQ ID NO: 163. In other embodiments, the caninized antibody or antigen-binding fragment thereof comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 166. In particular embodiments of this type, the heavy chain is encoded by the nucleotide sequence of SEQ ID NO: 165. In still other embodiments, the caninized antibody or antigen-binding fragment thereof comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 168. In particular embodiments of this type, the heavy chain is encoded by the nucleotide sequence of SEQ ID NO: 167.In specific embodiments of such types, when the caninized antibody (or antigen-binding fragment thereof) binds to canine interleukin-4 receptor α (IL-4Ra), the antibody binds to at least one amino acid residue, preferably two to five amino acid residues, and / or more preferably three to eight amino acid residues or more within the amino acid sequence of SEQ ID NO: 154, or SEQ ID NO: 155, or SEQ ID NO: 156, or any combination thereof.
[0047] In related embodiments, the caninized antibody or antigen-binding fragment thereof comprises a light chain comprising the amino acid sequence of SEQ ID NO: 170. In particular embodiments of this type, the light chain is encoded by the nucleotide sequence of SEQ ID NO: 169. In other embodiments, the caninized antibody or antigen-binding fragment thereof comprises a light chain comprising the amino acid sequence of SEQ ID NO: 172. In particular embodiments Petition 870250121500, dated 12 / 30 / 2025, p. 53 / 160 In embodiments of this type, the light chain is encoded by the nucleotide sequence SEQ ID NO: 171. In still other embodiments, the caninized antibody or antigen-binding fragment thereof comprises a light chain comprising the amino acid sequence SEQ ID NO: 174. In particular embodiments of this type, the light chain is encoded by the nucleotide sequence SEQ ID NO: 173. In particular embodiments of such types, when the caninized antibody (or antigen-binding fragment thereof) binds to canine interleukin-4 receptor α (IL-4Ra), the antibody binds to at least one amino acid residue, preferably two to five amino acid residues, and / or more preferably three to eight amino acid residues or more within the amino acid sequence SEQ ID NO: 154, or SEQ ID NO: 155, or SEQ ID NO: 156, or any combination thereof.
[0048] The present invention further provides antibodies comprising a combination of such heavy chains and light chains. In particular embodiments, the heavy chain comprises the amino acid sequence of SEQ ID NO: 164 and the light chain comprises the amino acid sequence of SEQ ID NO: 170. In more particular embodiments of this type, the heavy chain is encoded by the nucleotide sequence of SEQ ID NO: 163 and the light chain is encoded by the nucleotide sequence of SEQ ID NO: 169. In other embodiments, the heavy chain comprises the amino acid sequence of SEQ ID NO: 166 and the light chain comprises the amino acid sequence of SEQ ID NO: 172. In more particular embodiments of this type, the heavy chain is encoded by the nucleotide sequence of SEQ ID NO: 165 and the light chain is encoded by the nucleotide sequence of SEQ ID NO: 171.In still other embodiments, the heavy chain comprises the amino acid sequence with SEQ ID NO: 168 and the light chain comprises the amino acid sequence with SEQ ID NO: 174. In more particular embodiments of this type, a. Petition 870250121500, dated 12 / 30 / 2025, p. 54 / 160 39 / 138 The heavy chain is encoded by the nucleotide sequence SEQ ID NO: 167 and the light chain is encoded by the nucleotide sequence SEQ ID NO: 173.
[0049] In related embodiments, the heavy chain comprises the amino acid sequence SEQ ID NO: 164 and the light chain comprises the amino acid sequence SEQ ID NO: 172. In other embodiments, the heavy chain comprises the amino acid sequence SEQ ID NO: 164 and the light chain comprises the amino acid sequence SEQ ID NO: 174. In still other embodiments, the heavy chain comprises the amino acid sequence SEQ ID NO: 166 and the light chain comprises the amino acid sequence SEQ ID NO: 170. In still other embodiments, the heavy chain comprises the amino acid sequence SEQ ID NO: 166 and the light chain comprises the amino acid sequence SEQ ID NO: 174.In still other embodiments, the heavy chain comprises the amino acid sequence with SEQ ID NO: 168 and the light chain comprises the amino acid sequence with SEQ ID NO: 170. In other embodiments, the heavy chain comprises the amino acid sequence with SEQ ID NO: 168 and the light chain comprises the amino acid sequence with SEQ ID NO: 172.
[0050] In particular embodiments of such types, when the caninized antibody (or antigen-binding fragment thereof) binds to canine interleukin-4 receptor α (IL-4Ra), the antibody binds to at least one amino acid residue, preferably two to five amino acid residues, and / or more preferably three to eight or more amino acid residues within the amino acid sequence of SEQ ID NO: 154, or SEQ ID NO: 155, or SEQ ID NO: 156, or any combination thereof.
[0051] Consequently, the present invention also provides isolated mammalian antibodies or antigen-binding fragments thereof (including caninized antibodies or antigen-binding fragments). Petition 870250121500, dated 12 / 30 / 2025, page 55 / 160 40 / 138 of the same) that bind to canine interleukin-4 receptor α (IL-4Ra) with specificity and, when bound to canine IL-4Ra, the antibody binds to at least one amino acid residue, preferably two to five amino acid residues, and / or more preferably three to eight amino acid residues or more within the amino acid sequence of SEQ ID NO: 125, or SEQ ID NO: 126, or SEQ ID NO: 127, or SEQ ID NO: 128, or SEQ ID NO: 154, or SEQ ID NO: 155, or SEQ ID NO: 156, or SEQ ID NO: 157, or SEQ ID NO: 158, or SEQ ID NO: 159, or SEQ ID NO: 160, or SEQ ID NO: 161, or SEQ ID NO: 162, or any combination thereof. In particular embodiments, the antibody or antigen-binding fragment thereof binds to canine IL-4Ra and blocks the binding of canine IL-4Ra to canine interleukin-4.
[0052] The present invention further provides mammalian antibodies or antigen-binding fragments thereof that bind to canine IL-4Ra with a dissociation constant (Kd) that is less than (e.g., 1 x 10¹³M, or less) than 1 x 10⁻¹²M. In particular embodiments, the mammalian antibodies or antigen-binding fragments thereof bind to canine IL-4Ra with a dissociation constant of 1 x 10⁻⁵M to 1 x 10⁻¹²M. In more particular embodiments, the mammalian antibodies or antigen-binding fragments thereof bind to canine IL-4Ra with a dissociation constant of 1 x 10⁻⁷M to 1 x 10⁻¹¹M. In even more particular embodiments, mammalian antibodies or antigen-binding fragments thereof bind to canine IL-4Ra with a dissociation constant of 1 X 10-8M to 1 X 10-11M.In even more particular embodiments, mammalian antibodies or antigen-binding fragments thereof bind to canine IL-4Ra with a dissociation constant of 1 X 10-8M to 1 X 10-10M.
[0053] The present invention also provides mammalian antibodies or antigen-binding fragments thereof that bind to ILPetion 870250121500, dated 12 / 30 / 2025, page 56 / 160 41 / 138 Canine IL-4Ra with a binding ratio (kon) greater than 1 x 10⁷ M-1s-1. In particular embodiments, mammalian antibodies or antigen-binding fragments thereof bind to canine IL-4Ra with a binding ratio of 1 x 10² M-1s-1 to 1 x 10⁷ M-1s-1. In more particular embodiments, mammalian antibodies or antigen-binding fragments thereof bind to canine IL-4Ra with a binding ratio of 1 x 10³ M-1s-1 to 1 x 10⁶ M-1s-1. In still more particular embodiments, mammalian antibodies or antigen-binding fragments thereof bind to canine IL-4Ra with a binding ratio of 1 x 10³ M-1s-1 to 1 x 10⁵ M-1s-1. In more specific embodiments, mammalian antibodies or antigen-binding fragments thereof bind to canine IL-4Ra at a binding rate of 1 x 10⁴M-1s-1a to 1 x 10⁵M-1s-1.
[0054] The present invention further provides mammalian antibodies or antigen-binding fragments thereof that bind to canine IL-4Ra with a switch-off ratio (koff) of less than 1 x 10⁻⁷s⁻¹. In particular embodiments, the mammalian antibodies or antigen-binding fragments thereof bind to canine IL-4Ra with a switch-off ratio of 1 x 10⁻³s⁻¹ to 1 x 10⁻⁸s⁻¹. In more particular embodiments, the mammalian antibodies or antigen-binding fragments thereof bind to canine IL-4Ra with a switch-off ratio of 1 x 10⁻⁴s⁻¹ to 1 x 10⁻⁷s⁻¹. In even more particular embodiments, the mammalian antibodies or antigen-binding fragments thereof bind to canine IL-4Ra with a switch-off ratio of 1 x 10⁻⁵s⁻¹ to 1 x 10⁻⁷s⁻¹.
[0055] In particular embodiments, a mammalian antibody of the present invention (including chimeric antibodies) blocks the binding of canine IL-4 to IL-4Ra. In more particular embodiments, the antibody blocks the binding of canine IL-4 to IL-4Ra with a minimum EC50 of 1 X10-8M to 1 X10-9M or at an even lower concentration. In even more particular embodiments, the Petition 870250121500, dated 12 / 30 / 2025, pp. 57 / 160 42 / 138 EC50 ranges from 5 x 10-9M to 5 x 10-13M. In even more specific configurations, EC50 ranges from 5 x 10-9M to 5 x 10-11M.
[0056] In related embodiments, mammalian antibodies or antigen-binding fragments thereof negatively attenuate, for example, inhibit, cell signaling pathway(s) mediated by IL-4 and / or IL-13 binding to type I and / or type II IL-4 receptors. In particular embodiments, mammalian antibodies or antigen-binding fragments thereof improve a pruritic inflammatory skin disease, for example, atopic dermatitis, in an animal subject. In more specific embodiments, the animal subject is a canine. In a related embodiment, the animal subject is a feline.
[0057] Consequently, any of the antibodies of the present invention may exhibit one, two, three, four, or all of these properties, that is, the aforementioned dissociation constants with canine IL-4Ra, the aforementioned binding rates for binding with canine IL-4Ra, the aforementioned unbinding rates for dissociation of the antibody-canine IL-4Ra binding complex, inhibiting the cell signaling pathway(s) mediated by IL-4 and / or IL-13 binding to type I and / or type II IL-4 receptors, or improving a pruritic inflammatory skin disease, for example, atopic dermatitis, in an animal subject.
[0058] As indicated above, the antibodies (and antigen-binding fragments thereof) of the present invention, including the aforementioned antibodies (and antigen-binding fragments thereof), may be monoclonal antibodies (and antigen-binding fragments thereof), mammalian antibodies (and antigen-binding fragments thereof), for example, murine (mouse) antibodies (and antigen-binding fragments thereof), caninized antibodies (and antigen-binding fragments thereof). Petition 870250121500, dated 12 / 30 / 2025, pp. 58 / 160 43 / 138 antigens thereof) including caninized murine antibodies (and antigen-binding fragments thereof) and, in some embodiments, the antibodies (and antigen-binding fragments thereof) are isolated.
[0059] The present invention further provides nucleic acids (including isolated nucleic acids) encoding any of the light chains of the caninized antibody of the present invention. Similarly, the present invention provides isolated nucleic acids encoding any of the heavy chains of the caninized antibody of the present invention.
[0060] The present invention further provides expression vectors comprising one or more of the nucleic acids (including isolated nucleic acids) of the present invention. The present invention further provides host cells comprising one or more expression vectors of the present invention.
[0061] In particular embodiments, the antibody is a recombinant antibody or an antigen-binding fragment thereof. In related embodiments, the variable heavy chain domain and variable light chain domain are connected by a flexible linker to form a single-chain antibody.
[0062] In particular embodiments, the antibody or antigen-binding fragment is a Fab fragment.
[0063] In other embodiments, the antibody or antigen-binding fragment is a Fab' fragment. In other embodiments, the antibody or antigen-binding fragment is a (Fab')2 fragment. In still other embodiments, the antibody or antigen-binding fragment is a diabody. In particular embodiments, the antibody or antigen-binding fragment is a domain antibody. In particular embodiments, the antibody or antigen-binding fragment is a single-domain antibody. Petition 870250121500, dated 12 / 30 / 2025, page 59 / 160 44 / 138
[0064] In particular embodiments, a caninized murine anti-canine IL-4Ra antibody or antigen-binding fragment negatively attenuates the cell signaling pathway(s) mediated by IL-4 and / or IL-13 binding to type I and / or type II IL-4 receptors in an animal subject (e.g., canine) being treated. In more particular embodiments, administration of a caninized murine anti-canine IL-4Ra antibody or antigen-binding fragment of the present invention serves to improve one or more symptoms of atopic dermatitis in the animal subject (e.g., canine) being treated.
[0065] The present invention further provides isolated nucleic acids encoding caninized murine anti-canine IL-4Ra antibodies or portions thereof. In related embodiments, such antibodies or antigen-binding fragments can be used for the preparation of a medicament to treat atopic dermatitis in a canine subject. Alternatively, or in combination, the present invention provides the use of any of the antibodies or antibody fragments of the present invention for diagnostic use. In still further embodiments, a kit is provided comprising any of the caninized antibodies or antigen-binding fragments described herein.
[0066] In further embodiments, an expression vector is provided comprising an isolated nucleic acid encoding any of the caninized murine anti-canine IL-4Ra antibodies or antigen-binding fragments of the invention. The invention also relates to a host cell comprising any of the expression vectors described herein. In particular embodiments, these nucleic acids, expression vectors or polypeptides of the invention are usable in methods for obtaining an antibody.
[0067] The present invention also provides peptides (including Petition 870250121500, dated 12 / 30 / 2025, pages 60 / 160 45 / 138 isolated antigenic peptides) consisting of 80 or fewer amino acid residues comprising an amino acid sequence of SEQ ID NO: 125, or SEQ ID NO: 126, or SEQ ID NO: 127, or SEQ ID NO: 128, or SEQ ID NO: 154, or SEQ ID NO: 155, or SEQ ID NO: 156, or SEQ ID NO: 157, or SEQ ID NO: 158, or SEQ ID NO: 159, or SEQ ID NO: 160, or SEQ ID NO: 161, or SEQ ID NO: 162. In related embodiments, the peptides (including isolated antigenic peptides) consist of 60 or fewer amino acid residues comprising the amino acid sequence of SEQ ID NO: 125, or SEQ ID NO: 126, or SEQ ID NO: 127, or SEQ ID NO: 128, or SEQ ID NO: 154, or SEQ ID NO: 155, or SEQ ID NO: 156, or SEQ ID NO: 157, or SEQ ID NO: 158, or SEQ ID NO: 159, or SEQ ID NO: 160, or SEQ ID NO: 161, or SEQ ID NO: 162.In related embodiments, the peptides (including isolated antigenic peptides) consist of 10 to 45 amino acid residues comprising the amino acid sequence SEQ ID NO: 125, or SEQ ID NO: 126, or SEQ ID NO: 127, or SEQ ID NO: 128, or SEQ ID NO: 154, or SEQ ID NO: 155, or SEQ ID NO: 156, or SEQ ID NO: 157, or SEQ ID NO: 158, or SEQ ID NO: 159, or SEQ ID NO: 160, or SEQ ID NO: 161, or SEQ ID NO: 162. In still other embodiments, the peptides (including isolated antigenic peptides) consist of 5 to 25 amino acid residues from, or comprising, the amino acid sequence SEQ ID NO: 125, or SEQ ID NO: 126, or SEQ ID NO: 127, or SEQ ID NO: 128, or SEQ ID NO: 154, or SEQ ID NO: 155, or SEQ ID NO: 156, or SEQ ID NO: 157, or SEQ ID NO: 158, or SEQ ID NO: 159, or SEQ ID NO: 160, or SEQ ID NO: 161, or SEQ ID NO: 162.
[0068] The present invention further provides antigenic peptides (including isolated peptides) consisting of 80 or fewer amino acid residues comprising an amino acid sequence that is 80%, 85%, 90%, 95% or 100% identical with the amino acid sequence of SEQ ID NO: 125, Petition 870250121500, dated 12 / 30 / 2025, pp. 61 / 160 46 / 138 or SEQ ID NO: 126, or SEQ ID NO: 127, or SEQ ID NO: 128, or SEQ ID NO: 154, or SEQ ID NO: 155, or SEQ ID NO: 156, or SEQ ID NO: 157, or SEQ ID NO: 158, or SEQ ID NO: 159, or SEQ ID NO: 160, or SEQ ID NO: 161, or SEQ ID NO: 162 and binds to an isolated mammalian antibody or antigen-binding fragment thereof of the present invention. In related embodiments, antigenic peptides (including isolated antigenic peptides) consist of 60 or fewer amino acid residues comprising an amino acid sequence that is 80%, 85%, 90%, 95%, or 100% identical with the amino acid sequence of SEQ ID NO: 125, or SEQ ID NO: 126, or SEQ ID NO: 127, or SEQ ID NO: 128, or SEQ ID NO: 154, or SEQ ID NO: 155, or SEQ ID NO: 156, or SEQ ID NO: 157, or SEQ ID NO: 158, or SEQ ID NO: 159, or SEQ ID NO: 160, or SEQ ID NO: 161, or SEQ ID NO: 162, and binds to an isolated mammalian antibody or antigen-binding fragment thereof. In other embodiments, the peptides consist of 5 to 25 amino acid residues from, or comprise an amino acid sequence that is 80%, 85%, 90%, 95%, or 100% identical with the amino acid sequence of SEQ ID NO: 125, or SEQ ID NO: 126, or SEQ ID NO: 127, or SEQ ID NO: 128, or SEQ ID NO: 154, or SEQ ID NO: 155, or SEQ ID NO: 156, or SEQ ID NO: 157, or SEQ ID NO: 158, or SEQ ID NO: 159, or SEQ ID NO: 160, or SEQ ID NO: 161, or SEQ ID NO: 162 and binds to an isolated mammalian antibody or antigen-binding fragment thereof. In particular embodiments, the mammalian antibody comprises the CDRs of 4D8. In other embodiments, the mammalian antibody comprises the CDRs of 11H2. In still other embodiments, the mammalian antibody comprises the CDRs of 4H3. In still other embodiments, the mammalian antibody comprises the CDRs of 11B6.In still other embodiments, the mammalian antibody comprises the CDRs of 2E2. In still other embodiments, the mammalian antibody comprises the CDRs of 6C12. Petition 870250121500, dated 12 / 30 / 2025, pp. 62 / 160 47 / 138
[0069] The present invention further provides fusion proteins comprising any of the aforementioned peptides. In a particular embodiment, the fusion protein comprises such antigenic peptide and an Fc region of a non-canine mammalian IgG antibody. In a more particular embodiment, the fusion protein comprises an Fc region of a non-canine mammalian IgG antibody. In some embodiments, the non-canine mammalian IgG antibody is a murine IgG. In alternative embodiments, the non-canine mammalian IgG antibody is a human IgG. In other embodiments, the non-canine mammalian IgG antibody is an equine IgG. In still other embodiments, the non-canine mammalian IgG antibody is a porcine IgG. In still other embodiments, the non-canine mammalian IgG antibody is a bovine IgG.
[0070] In particular embodiments, the non-canine mammalian IgG antibody is an IgG1. In other embodiments, the non-canine mammalian IgG antibody is an IgG2a. In still other embodiments, the non-canine mammalian IgG antibody is an IgG3. In still other embodiments, the non-canine mammalian IgG antibody is an IgG4. In other embodiments, the fusion protein comprises any of the aforementioned antigenic peptides and maltose-binding protein. In still other embodiments, the fusion protein comprises any of the aforementioned antigenic peptides and beta-galactosidase. In still other embodiments, the fusion protein comprises any of the aforementioned antigenic peptides and glutathione S-transferase. In still other embodiments, the fusion protein comprises any of the aforementioned antigenic peptides and thioredoxin.In still other embodiments, the fusion protein comprises any of the above-mentioned antigenic peptides and Gro EL. In still other embodiments, the fusion protein comprises any of the above. Petition 870250121500, dated 12 / 30 / 2025, pp. 63 / 160 48 / 138 mentioned antigenic peptides and NusA.
[0071] The present invention further provides nucleic acids (including isolated nucleic acids) encoding the antigenic peptides and corresponding fusion proteins of the present invention. The present invention also provides expression vectors comprising these nucleic acids and host cells comprising one or more expression vectors of the present invention.
[0072] In addition, the present invention includes pharmaceutical compositions comprising canine anti-IL-4Ra antibodies or antigen-binding fragments thereof of the present invention, antigenic peptides (including isolated antigenic peptides) from canine IL-4Ra, fusion proteins comprising the canine IL-4Ra antigenic peptides of the present invention, nucleic acids (including isolated nucleic acids) encoding the antigenic fragments and / or fusion proteins of the present invention, expression vectors comprising such nucleic acids, or any combination thereof and a pharmaceutically acceptable carrier or diluent.
[0073] Furthermore, the present invention provides methods for negatively attenuating the activity of IL-4 and / or IL-13 comprising administering to an animal subject in need thereof a therapeutically effective amount of such pharmaceutical compositions. In some embodiments, the method is used for the treatment of atopic dermatitis in a canine.
[0074] These and other aspects of the present invention will be better appreciated by reference to the following Brief Description of the Drawings and Detailed Description. BRIEF DESCRIPTION OF THE DRAWINGS Petition 870250121500, dated 12 / 30 / 2025, pp. 64 / 160 49 / 138
[0075] Figure 1 shows the reactivity of monoclonal antibodies to Mouse canine IL-4Ra anti-mAbs (mAbs) against the extracellular domain of canine IL-4Ra. Several mouse mAbs were tested for their binding to the extracellular domain of canine IL-4Ra by ELISA. The mAbs tested are designated as: 1A3(·), 1A9(0), 1B12 (·), 10C12( ▼), 10F2(^), 10E10(·), 10G8(0), 11B6(·), 11D3(^) and the control antibody (♦). The abscissa shows the Log concentration of the mAb (nM) being added, the ordinate shows the optical density obtained by ELISA.
[0076] Figure 2A shows the dose-response curve for canine IL-4 binding to canine IL-4Ra expressed on the surface of CHO cells, using a cell-based CHO-cIL-4Rα binding assay. The abscissa shows the Log concentration of IL-4 being added, the ordinate shows the mean fluorescence intensity (MFI) using FACS.
[0077] Figure 2B shows the dose-response curve for CHO-cIL4Rα by mouse anti-canine IL-4Ra monoclonal antibodies (mAbs): 11B6(·), 4D8(0), 4H3(·), 2E2(V), 11H2(4) and 6C12(o). The abscissa shows the Log concentration of mAb (nM) being added, the ordinate shows the mean fluorescence intensity (MFI) using FACS. The half-maximal effective concentrations (EC50) for each of the antibodies are given in Table 2 below.
[0078] Figures 3A and 3B show the results of successively diluted individual mouse anti-canine IL-4Ra monoclonal antibodies (mAbs) on cell-based IL-4 binding to CHO-cIL-4Rα. Figure 3A shows the concentration-dependent ability of the monoclonal antibodies 11B6(>), 4D8(0), 4H3(..&), 2E2(▼), and 11H2(4) to individually block cell-based IL-4 binding to CHO-cIL-4Rα. Figure 3B shows the concentration-dependent ability of the antibodies. Petition 870250121500, dated 12 / 30 / 2025, pp. 65 / 160 50 / 138 monoclonal antibodies 11H2(♦) and 6C12(0) to individually block IL-4 binding to CHO-cIL-4R. Cell-based. The abscissa shows the Log concentration of mAb (nM) being added, the ordinate shows the mean fluorescence intensity (MFI) using FACS.
[0079] Figure 4 shows the binding of chimeric and caninized monoclonal antibodies to canine IL-4Ra as assessed by ELISA. The dose-dependent reactivity of caninized monoclonal antibodies against the alpha chain of canine IL-4 receptor is as follows: 4H3 MC (·); 2G9 MC (◊); c4H3 H1-L1 (0); c4H3 H2-L2(.A); c4H3 H3-L3 (o). DETAILED DESCRIPTION
[0080] Several approaches to the treatment of human AD are now under investigation in many clinical trials [reviewed in Malajian et al., New pathogenic and therapeutic paradigms in atopic dermatitis Cytokine, (2014)]. Some of these approaches aim to interfere with one or more of the signaling molecules / events that lead to the development and activation of Th2 cells. One line of research in this area approaches blocking the actions of key interleukin drivers of the Th2 pathway.Based on observations that AD is largely a Th2-dominated disease and the accumulation of data supporting a key role for the combined actions of both IL-4 and IL-13 as major drivers of Th2 cell development, and based on data indicating that the α chain of the IL-4 receptor is a required receptor for signaling from both cytokines, the present invention describes the generation and characterization of monoclonal antibodies that block the binding of canine IL-4 and canine IL-13 to type I and type II IL-4 receptors and subsequently inhibit signaling from both canine IL-4 and IL-13. These antibodies have applications in the treatment of atopic dermatitis and other diseases in companion animals. Petition 870250121500, dated 12 / 30 / 2025, pp. 66 / 160 51 / 138 as described here. Abbreviations
[0081] Throughout the detailed description and examples of the invention The following abbreviations will be used: ADCC antibody-dependent cellular cytotoxicity CDC complement-dependent cytotoxicity CDR complementarity-determining region Immunoglobulin variables, defined using the Kabat numbering system. CHO Chinese hamster ovary EC50 concentration resulting in 50% efficacy or binding ELISA enzyme-linked immunosorbent test FR antibody framework region: variable regions of the immunoglobulin excluding the CDR regions HRP horseradish peroxidase, IFN-10 interferon, IC50 concentration resulting in 50% inhibition of IgG, Immunoglobulin G, Kabat, an immunoglobulin numbering and alignment system. started by Elvin A. Kabat [Sequences of Proteins of Immunological Interest, 5a. Ed. Public Health Service, National Institutes of Health, Bethesda, Md. (1991)] mAb monoclonal antibody (also Mab or MAb) MES 2-(N-morpholino)ethanesulfonic acid MOA mechanism of action NHS normal human serum PCR polymerase chain reaction PK pharmacokinetics SEB Staphylococcus enterotoxin B Petition 870250121500, dated 12 / 30 / 2025, pp. 67 / 160 52 / 138 TT tetanus toxoid Region Vo is a segment of IgG chains that varies in sequence between different antibodies. It extends to Kabat residue 109 in the light chain and 113 in the heavy chain. VH immunoglobulin heavy chain variable region VL (variable region of the immunoglobulin light chain) VK variable region of immunoglobulin kappa light chain DEFINITIONS
[0082] In order for the invention to be more easily understood, certain technical and scientific terms are specifically defined below. Unless specifically defined elsewhere in this document, all other technical and scientific terms used herein have the meaning commonly understood by one skilled in the art to which this invention pertains.
[0083] As used herein, including the attached claims, the singular forms of words such as a, an, and so on include their corresponding plural references, unless the context clearly dictates otherwise.
[0084] Activation, as applied to cells or receptors, refers to the activation or treatment of a cell or receptor with a ligand, unless otherwise indicated by the context or explicitly. Ligand includes natural and synthetic ligands, for example, cytokines, cytokine variants, analogues, muteins, and antibody-derived binding compounds. Ligand also includes small molecules, for example, cytokine peptide mimetics and antibody peptide mimetics. Activation may refer to cellular activation as regulated by internal mechanisms as well as by external or environmental factors.
[0085] The activity of a molecule can describe or do Petition 870250121500, dated 12 / 30 / 2025, pp. 68 / 160 53 / 138 refers to the binding of a molecule to a ligand or receptor, to catalytic activity; to the ability to stimulate gene expression or signaling, cell differentiation or maturation; to antigenic activity, to the modulation of the activities of other molecules and the like. The activity of a molecule may also refer to activity in modulating or maintaining cell-to-cell interactions, for example, adhesion, or activity in maintaining a cell structure, for example, cell membranes or cytoskeleton. Activity may also mean specific activity, for example, [catalytic activity] / [mg of protein], [immunological activity] / [mg of protein], concentration in a biological compartment or the like. Activity may refer to the modulation of components of the innate or adaptive immune system.
[0086] Administration and treatment, as applied to an animal, for example, a canine experimental subject, cell, tissue, organ or biological fluid, refers to the contact of a pharmaceutical, therapeutic, exogenous diagnostic agent or composition to the animal, for example, a canine subject, cell, tissue, organ or biological fluid. Treatment of a cell encompasses the contact of a reagent with the cell, as well as the contact of a reagent with a fluid, where the fluid is in contact with the cell. Administration and treatment also mean in vitro and ex vivo treatments, for example, of a cell, by a reagent, diagnostic, binding compound or by another cell. The term subject includes any organism, preferably an animal, more preferably a mammal (e.g., canine, feline or human) and most preferably a canine.
[0087] As used herein, a substitution of one amino acid residue with another amino acid residue in an antibody amino acid sequence, for example, is equivalent to exchanging a residue. Petition 870250121500, dated 12 / 30 / 2025, pp. 69 / 160 The term "54 / 138 amino acid" with another amino acid residue denotes that a particular amino acid residue at a specific position in an amino acid sequence has been exchanged for (or replaced by) a different amino acid residue. Such substitutions can be specifically engineered, i.e., purposefully exchanging an alanine for a serine at a specific position in an amino acid sequence by, for example, recombinant DNA technology. Alternatively, a particular amino acid residue or strands of amino acid residues of an antibody can be exchanged for one or more amino acid residues through more natural selection processes, for example, based on the ability of the antibody produced by a cell to bind to a given region on that antigen, for example, one containing an epitope or a portion thereof, and / or for the antibody to comprise a particular CDR that retains the same canonical structure as a CDR it is replacing.Such substitutions / exchanges can lead to "variant" CDRs and / or variant antibodies.
[0088] “Treating” or “treating” means administering a therapeutic agent, such as a composition containing any of the antibodies or antigen-binding fragments of the present invention, internally or externally to a canine subject or patient having one or more symptoms of disease, or being suspected of having a disease, for which the agent has therapeutic activity.
[0089] Typically, the agent is administered in an amount effective to relieve and / or improve one or more symptoms of the disease in the treated population or subject, either by inducing regression of or inhibiting the progression of such symptom(s) to any clinically measurable degree. The amount of therapeutic agent that is effective in relieving any particular disease symptom (also referred to as the “therapeutically effective amount”) may Petition 870250121500, dated 12 / 30 / 2025, pp. 70 / 160 55 / 138 vary according to factors such as the disease state, age and weight of the patient (e.g., canine) and the ability of the pharmaceutical composition to elicit a desired response in the subject. Whether a disease symptom has been relieved or improved can be assessed by any clinical measurement typically used by veterinarians or other qualified healthcare professionals to assess the severity or progression state of that symptom. Although an embodiment of the present invention (e.g., a treatment method or manufacturing article) may not be effective in relieving the target disease symptom(s) in every subject, it should relieve the target disease symptom(s) in a statistically significant number of subjects, as determined by any statistical test known in the art, such as the Student's t-test, the chi-square test, the Mann-Whitney U test, the Kruskal-Wallis test (H-test), the Jonckheere-Terpstra test, and the Wilcoxon test.
[0090] Treatment, as applied to a human, veterinary (e.g., canine) or research subject, refers to therapeutic treatment, as well as in research and diagnostic applications. Treatment as applied to a human, veterinary (e.g., canine) or research subject, or cell, tissue or organ, encompasses the contact of antibodies or antigen-binding fragments of the present invention to a canine or other animal subject, a cell, tissue, physiological compartment or physiological fluid.
[0091] As used herein, the term canine includes all domestic dogs, Canis lupus familiaris or Canis familiaris, unless otherwise indicated.
[0092] As used herein, the term feline refers to any member of the family Felidae. Members of this family include wild, zoological, and domestic members, such as any member of the subfamilies Felinae, for example, cats, lions, tigers, pumas, jaguars, leopards, cheetahs Petition 870250121500, dated 12 / 30 / 2025, pp. 71 / 160 56 / 138 snow cats, panthers, North American mountain lions, cheetahs, lynx, bobcats, caracals, or any crossbreed of them. Cats also include domestic cats, purebred and / or mixed-breed cats, show cats, laboratory cats, cloned cats, and wild or feral cats.
[0093] As used herein, the term “canine frame” refers to an amino acid sequence of the heavy and light chains of a canine antibody that differs from the hypervariable region residues defined herein as CDR residues. With respect to a caninized antibody, in most embodiments, the amino acid sequences of the native canine CDRs are exchanged with the corresponding foreign CDRs (e.g., those of a mouse antibody) in both chains. Optionally, the heavy and / or light chains of the canine antibody may contain some non-CDR foreign residues, for example, in order to conserve the conformation of the foreign CDRs within the canine antibody, and / or modify the Fc function, as exemplified below.
[0094] Canine IL-4Ra has been verified as comprising the amino acid sequence SEQ ID NO: 2 [SEQ ID NO: 4, without a signal sequence]. In a specific embodiment, canine IL-4Ra is encoded by a nucleic acid comprising the nucleotide sequence SEQ ID NO: 1 [SEQ ID NO: 3, without the signal sequence]. Canine IL-4Ra sequences may differ by having, for example, conserved variations in non-conserved regions, but canine IL-4Ra will have substantially the same biological function as canine IL-4Ra comprising the amino acid sequence SEQ ID NO: 2 [SEQ ID NO: 4, without the signal sequence].
[0095] The cytokines IL-4 and IL-13 have been implicated in the pathogenesis of several allergic diseases in humans and animals, including asthma and atopic dermatitis. Because the α-receptor chain of IL-4 is a receptor required for signaling by both of these cytokines, the present invention Petition 870250121500, dated 12 / 30 / 2025, p. 72 / 160 57 / 138 describes the generation and characterization of monoclonal antibodies that block the binding of canine IL-4 and canine IL-13 to IL-4Ra and thus inhibit the signaling of both canine IL-4 and IL-13. These antibodies are therefore useful in the treatment of atopic dermatitis and other diseases in pets, as described herein. Furthermore, a biological function of canine IL-4Ra may be to have, for example, an epitope in the extracellular domain that is specifically bound by an antibody of the present description.
[0096] A particular canine IL-4Ra amino acid sequence will generally be at least 90% identical to the canine IL-4Ra comprising the amino acid sequence of SEQ ID NO: 4. In some cases, a canine IL-4Ra may be at least 95%, or even at least 96%, 97%, 98%, or 99% identical to the canine IL-4Ra comprising the amino acid sequence of SEQ ID NO: 4. In some embodiments, a canine IL-4Ra amino acid sequence will not show differences greater than 10 amino acids from the canine IL-4Ra comprising the amino acid sequence of SEQ ID NO: 4. In some embodiments, the canine IL-4Ra amino acid sequence may not show more than a difference of 5, or even no more than differences of 4, 3, 2, or 1 amino acids from the canine IL-4Ra comprising the amino acid sequence of SEQ ID NO: 4. The percent identity may to be determined as described below.
[0097] The term “immune response” refers to the action of, for example, lymphocytes, antigen-presenting cells, phagocytic cells, granulocytes, and soluble macromolecules produced by the above cells or liver (including antibodies, cytokines, and complement) that results in selective damage to, destruction of, or elimination from the mammalian body (e.g., canine body) of cancerous cells, cells or tissues infected with pathogens, or invading pathogens. Petition 870250121500, dated 12 / 30 / 2025, page 73 / 160 58 / 138 Anti-canine IL-4Ra antibodies
[0098] The present invention provides isolated antibodies (particularly murine anti-canine IL-4Ra antibodies and caninized antibodies thereof) or antigen-binding fragments thereof that bind to canine IL-4Ra and uses of such antibodies or fragments thereof. In specific embodiments, murine anti-canine IL-4Ra CDRs from murine anti-canine IL-4Ra antibodies are provided, which have been shown to bind both to canine IL-4Ra and to block the binding of canine IL-4Ra to one or more of its ligands, canine IL-4 or IL-13. These CDRs can be inserted into a modified canine frame of a canine antibody to generate a caninized murine anti-canine IL-4Ra antibody.
[0099] As used herein, an anti-canine IL-4Ra antibody refers to an antibody that has been created against canine IL-4Ra (e.g., in a mammal such as a mouse or rabbit) and that specifically binds to canine IL-4Ra. An antibody that specifically binds to canine IL-4Ra and in particular to IL-4Ra, or an antibody that specifically binds to a polypeptide comprising the amino acid sequence of IL-4Ra, is an antibody that exhibits preferential binding to canine IL-4Ra as compared to other antigens, but this specificity does not require absolute binding specificity.An IL-4Ra anti-canine antibody is considered specific for IL-4Racanine if its binding is determinative of the presence of IL-4Racanine in a sample, or if it is able to alter the activity of IL-4Racanine without unduly interfering with the activity of other molecules in a canine sample, for example without producing undesirable results such as false positives in a diagnostic context or side effects in a diagnostic context. The degree of specificity required for an IL-4Ra anti-canine antibody may depend on the intended use of the antibody and in any given context. Petition 870250121500, dated 12 / 30 / 2025, pp. 74 / 160 59 / 138 rate is defined by its suitability for use for an intended purpose. The antibody, or binding compound derived from the antigen-binding site of an antibody, of the contemplated method, binds to its antigen, or a variant or mutain thereof, with an affinity that is at least twice as high, preferably at least ten times higher, more preferably at least 20 times higher, and most preferably at least 100 times higher than the affinity for any other antigen.
[00100] As used herein, an antibody is said to bind specifically to a polypeptide comprising a given antigen sequence (in this case, a portion of the amino acid sequence of canine IL-4Ra) if it binds to polypeptides comprising the portion of the amino acid sequence of canine IL-4Ra, but does not bind to other canine proteins lacking this portion of the canine IL-4Ra sequence. For example, an antibody that specifically binds to a polypeptide comprising canine IL-4Ra may bind to a FLAG®-tagged form of canine IL-4Ra, but not bind to another FLAG®-tagged form of canine proteins.An antibody, or binding compound derived from the antigen-binding site of an antibody, binds to its canine antigen, or a variant or mutein thereof, "with specificity" when it has an affinity for that canine antigen or a variant or mutein thereof that is at least ten times greater, more preferably at least 20 times greater, and even more preferably at least 100 times greater than its affinity for any other canine antigen tested.
[00101] As used herein, the term “antibody” refers to any form of antibody that exhibits the desired biological activity. Thus, it is used in its broadest sense and specifically covers, but is not limited to, monoclonal antibodies (including monoclonal antibodies of varying length). Petition 870250121500, dated 12 / 30 / 2025, pp. 75 / 160 60 / 138 complete), polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), canonized antibody, fully canine antibodies, chimeric antibodies, and camelized single-domain antibodies. “Parental antibodies” are antibodies obtained by exposing an immune system to an antigen before modifying the antibodies for an intended use, such as caninizing an antibody for use as a canine therapeutic antibody.
[00102] As used herein, unless otherwise indicated, “antibody fragment” or “antigen-binding fragment” refers to antibody antigen-binding fragments, i.e., antibody fragments that retain the ability to bind specifically to the antigen bound by the full-length antibody, for example, fragments that retain one or more CDR regions. Examples of antibody-binding fragments include, but are not limited to, Fab, Fab', F(ab')2 and Fv fragments, diabodies, linear antibodies, single-chain antibody molecules, for example, scFv and nanobodies, and multi-specific antibodies formed from antibody fragments.
[00103] A “Fab fragment” is composed of a light chain and the Ch1 and variable regions of a heavy chain. The heavy chain of a Fab molecule cannot form a disulfide bond with another heavy chain molecule. A “Fab fragment” can be the product of the cleavage of paperin from an antibody.
[00104] A “crystallizable fragment” (Fc) region contains two heavy chain fragments comprising the CH3 and CH2 domains of an antibody. The two heavy chain fragments are held together by two or more disulfide bonds and by hydrophobic interactions of the Ch3 domains.
[00105] A Fab' fragment contains a light chain and a portion Petition 870250121500, dated 12 / 30 / 2025, pp. 76 / 160 61 / 138 or a fragment of a heavy chain containing the Vh domain and the Ch1 domain and also the region between the Ch1 and Ch2 domains, so that a disulfide bond between the chains can be formed between the two heavy chains of two Fab' fragments to form an F(ab') 2 molecule.
[00106] An “F(ab')2 fragment” contains two light chains and two heavy chains containing a portion of the constant region between the Ch1 and Ch2 domains, such that a disulfide bond is formed between the two heavy chains. An F(ab')2 fragment is thus composed of two Fab' fragments that are held together by a disulfide bond between the two heavy chains. An “F(ab')2 fragment” may be the product of the cleavage of paperin from an antibody.
[00107] The “Fv region” comprises the variable regions of both the heavy and light chains, but lacks the constant regions.
[00108] The term “single-chain Fv” or “scFv” antibody refers to antibody fragments comprising the Vh and Vl domains of an antibody, wherein these domains are present in a single polypeptide chain. Generally, the Fv polypeptide further comprises a polypeptide linker between the Vh and Vl domains that allows the scFv to form the desired structure for antigen binding. [See, Pluckthun, THE PHARMACOLOGY OF MONOCLONAL ANTIBODIES, vol. 113 Rosenburg and Moore eds., Springer-Verlag, New York, pp. 269-315 (1994); WO 88 / 01649; and US 4,946,778 and US 5,260,203.]
[00109] As used herein, the term “canonical structure” refers to the local conformation that can be adopted by each of the hypervariable regions of the heavy and light chains of an antibody within the scaffold in which they reside. For each hypervariable region, there is a small number of canonical structures (usually denoted by unique integers such as 1 or 2, etc.) that can be predicted with high accuracy from the amino acid sequences. Petition 870250121500, dated 12 / 30 / 2025, page 77 / 160 62 / 138 of the corresponding hypervariable region [particularly within the context of an amino acid sequence of its framework, as provided below for the corresponding variable domains of anti-canine IL-4Ra (see Table 3 below)]. These canonical structures can be determinative with respect to whether a modification of the amino acid sequence of a given CDR will result in the retention or loss of the ability to bind to its antigen-binding partner [See, Chothia and Lesk, Canonical Structures for hypervariable regions of immunoglobulins, J. Mol. Biol. 196:901-917(1987); Chothia et al., Conformation of immunoglobulin hypervariable regions, Nature, 34:877-883(1989); and AlLazikani et al., Standard Conformations for the Canonical Structures of Immunoglobulins, J. Mol. Biol. 273:927-948 (1997)].
[00110] A “domain antibody” is an immunologically functional immunoglobulin fragment containing only the variable region of a heavy chain or the variable region of a light chain. In some cases, two or more VH regions are covalently linked with a peptide linker to create a bivalent domain antibody. The two VH regions of a bivalent domain antibody can target or label the same or different antigens.
[00111] A “bivalent antibody” comprises two antigen-binding sites. In some cases, the two binding sites have the same antigen specificities. However, bivalent antibodies can be bispecific (see below).
[00112] In some embodiments, monoclonal antibodies here also include camelized single-domain antibodies. [See, for example, Muyldermans et al., Trends Biochem. Sci. 26:230 (2001); Reichmann et al., J. Immunol. Methods 231:25 (1999); WO 94 / 04678; WO 94 / 25591; US 6,005,079]. In one embodiment, the present invention provides antibodies for Petition 870250121500, dated 12 / 30 / 2025, page 78 / 160 63 / 138 single domain comprising two Vh domains with modifications and the way in which single domain antibodies are formed.
[00113] As used herein, the term diabodies refers to small antibody fragments with two antigen-binding sites, which fragments comprise a variable heavy chain domain (Vh) connected to a variable light chain domain (Vl) on the same polypeptide chain (Vh-Vl or Vl-Vh). Using a linker that is too short to allow pairing between the two domains on the same chain, the domains are forced to pair with complementary domains on another chain and create two antigen-binding sites. [See EP 0404097; WO 93 / 11161; and Holliger et al. Proc. Natl. Acad. Sci. USA 90: 6444-6448 (1993). For a review of engineered antibody variants [generally see Holliger and Hudson Nat. Biotechnol. 23: 1126-1136. (2005)
[00114] Typically, an antibody or antigen-binding fragment of the invention retains at least 10% of its canine IL-4Ra binding activity (when compared to the parental antibody) when this activity is expressed on a molar basis. Preferably, an antibody or antigen-binding fragment of the invention retains at least 20%, 50%, 70%, 80%, 90%, 95% or 100% or more of the canine IL-4Ra binding affinity as the parental antibody. It is also intended that an antibody or antigen-binding fragment of the invention may include conservative or non-conservative amino acid substitutions (referred to as conservative variants or conserved-function variants of the antibody) that do not substantially alter its biological activity.
[00115] Isolated antibodies refers to the state of purification and, in such a context, means that the molecule is substantially free of other biological molecules, such as nucleic acids, proteins, lipids, carbohydrates, Petition 870250121500, dated 12 / 30 / 2025, pp. 79 / 160 64 / 138 or other material such as cell debris and growth media. Generally, the term isolates is not intended to refer to a complete absence of such material or to an absence of water, buffers or salt, unless they are present in quantities that substantially interfere with the experimental or therapeutic use of the binding compound as described herein.
[00116] As used herein, a chimeric antibody is an antibody having the variable domain from a first antibody and the constant domain from a second antibody, wherein the first and second antibodies are from different species. (US 4,816,567; and Morrison et al. Proc Natl Acad Sci USA 81:6851-6855(1984)). Typically, the variable domains are obtained from an antibody from an experimental animal (the parental antibody), such as a rodent, and the constant domain sequences are obtained from antibodies from the individual animal, for example, either human or canine, so that the resulting chimeric antibody will be less likely to elicit an adverse immune response in a canine or human subject respectively than the parental antibody (e.g., from a rodent).
[00117] As used herein, the term caninized antibody refers to antibody forms that contain antibody sequences from both canines and non-canines (e.g., murine). In general, a caninized antibody will comprise substantially all of at least one or more, typically two variable domains in which all or substantially all of the hypervariable loops correspond to those of a non-canine immunoglobulin (e.g., comprising 6 CDRs of murine anti-canine IL-4Ra, as exemplified below) and all or substantially all of the framework regions (FR) (and typically all or substantially all of the remaining frames) are those of a canine immunoglobulin sequence. As exemplified herein, a caninized antibody comprises both three CDRs of Petition 870250121500, dated 12 / 30 / 2025, pp. 80 / 160 65 / 138 heavy chain and the three CDRS light chain of a murine anticanine IL-4Ra antibody together with a canine frame or a modified canine frame. A modified canine frame comprises one or more amino acid changes as exemplified here, which further optimize the efficacy of the caninized antibody, for example, to increase its binding to canine IL4Ra and / or its ability to block the binding of canine IL-4 and / or canine IL13 to type I and / or type II IL-4 receptors.
[00118] The term completely canine antibody refers to an antibody comprising canine immunoglobulin protein sequences only. A completely canine antibody may contain murine carbohydrate chains if produced in a mouse, in a mouse cell, or in a mouse cell-derived hybridoma. Similarly, mouse antibody refers to an antibody comprising mouse immunoglobulin sequences only. Alternatively, a completely canine antibody may contain rat carbohydrate chains if produced in a rat, or in a rat cell, or in a rat cell-derived hybridoma. Similarly, mouse antibody refers to an antibody comprising mouse immunoglobulin sequences only.
[00119] There are four known IgG heavy chain subtypes of pup IgG and they are referred to as IgG-A, IgG-B, IgG-C and IgG-D. The two known light chain subtypes are referred to as lambda and kappa.
[00120] The variable regions of each light / heavy chain pair form the antibody binding site. Thus, in general, an antibody has two binding sites. Except in bifunctional or bispecific antibodies, the two binding sites are generally the same.
[00121] Typically, the variable domains of both chains Petition 870250121500, dated 12 / 30 / 2025, pp. 81 / 160 66 / 138 heavy and light chains comprise three hypervariable regions, also called complementarity-determining regions (CDRs), located within relatively conserved scaffold regions (FRs). The CDRs are generally aligned by the scaffold regions, allowing binding to a specific epitope. In general, from N-terminal to C-terminal, both variable light and heavy chain domains comprise FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4. The amino acid designation of each domain is generally in accordance with the definitions of Sequences of Proteins of Immunological Interest, Kabat, et al.; National Institutes of Health, Bethesda, Md.; 5th ed.; NIH Publ. No. 91-3242 (1991); Kabat, Adv. Prot. Chem. 32:1-75 (1978); Kabat, et al., J. Biol. Chem. 252:6609-6616 (1977); Chothia, et al., J. Mol. Biol. 196:901-917 (1987) or Chothia, et al., Nature 342:878-883 (1989)].
[00122] As used herein, the term “hypervariable region” refers to the amino acid residues of an antibody that are responsible for antigen binding. The hypervariable region comprises amino acid residues of a “complementarity-determining region” or “CDR” (i.e., CDRL1, CDRL2, and CDRL3 in a variable light chain domain and CDRH1, CDRH2, and CDRH3 in a variable heavy chain domain). [See Kabat et al. Sequences of Proteins of Immunological Interest, 5th ed. Public Health Service, National Institutes of Health, Bethesda, Md. (1991), defining antibody CDR regions by sequence; see also Chothia and Lesk, J. Mol. Biol. 196: 901-917 (1987) defining antibody CDR regions by structure]. As used herein, the term “framework” or “FR” residuals refers to variable domain residuals other than hypervariable region residuals defined herein as CDR residuals.
[00123] In addition to binding to and activating canine immune cells, an optimal canine or caninized antibody against ^-4Kα has two attributes: Petition 870250121500, dated 12 / 30 / 2025, page 82 / 160 67 / 138 1. lacking effector function such as antibody-dependent cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), and 2. be readily purified on a large scale using industry-standard technologies such as protein A-based chromatography.
[00124] None of the naturally occurring canine IgG isotypes satisfy both criteria. For example, IgG-B can be purified using protein A, but has a high level of ADCC activity. On the other hand, IgG-A binds weakly to protein A, but exhibits undesirable ADCC activity. Furthermore, neither IgG-C nor IgG-D can be purified on protein A columns, although IgGD does not exhibit any ADCC activity. (IgG-C has considerable ADCC activity). One way in which the present invention overcomes this difficulty is by providing IL-4Ra-specific mutant canine IgG-B antibodies; such antibodies do not possess effector functions such as ADCC and can be easily purified using industry-standard protein A chromatography.
[00125] Homology refers to the similarity of sequences between two polynucleotide sequences or between two polypeptide sequences when they are optimally aligned. When a position in both of the two compared sequences is occupied by the same base or amino acid monomer subunit, for example, if a position in each of the two DNA molecules is occupied by adenine, then the molecules are homologous at that position. The percentage of homology is the number of homologous positions shared by the two sequences, divided by the total number of positions compared x 100. For example, if 6 out of 10 positions in the two sequences are matched or homologous when the sequences are optimally aligned, then the two sequences are 60% homologous. Generally, the Petition 870250121500, dated 12 / 30 / 2025, p. 83 / 160 The 68 / 138 comparison is made when two sequences are aligned to give maximum percent homology.
[00126] “Isolated nucleic acid molecule” means a DNA or RNA of genomic, mRNA, cDNA or synthetic origin or a combination thereof that is not associated with all or a portion of a polynucleotide wherein the isolated polynucleotide is found in nature or is linked to a polynucleotide to which it is not linked in nature. For the purposes of this description, it should be understood that “a nucleic acid molecule comprising” a particular nucleotide sequence does not include intact chromosomes. Isolated nucleic acid molecules “comprising” specific nucleic acid sequences may include, in addition to the specified sequences, coding sequences for up to ten or even up to twenty or more other proteins or portions or fragments thereof, or may include operatively linked regulatory sequences that control the expression of the coding region of the cited nucleic acid sequences, and / or may include vector sequences.
[00127] The phrase “control sequences” refers to sequences of DNA is necessary for the expression of an operatively bound coding sequence in a particular host organism. Control sequences that are suitable for prokaryotes, for example, include a promoter, optionally an operator sequence, and a ribosome binding site. Eukaryotic cells are known to use promoters, polyadenylation signals, and enhancers.
[00128] A nucleic acid is “operatively linked” when it is placed in a functional relationship with another nucleic acid sequence. For example, the DNA for a presequence or secretory leader is operatively linked to the DNA for a polypeptide if it is expressed as a preprotein that Petition 870250121500, dated 12 / 30 / 2025, pp. 84 / 160 69 / 138 participates in polypeptide secretion; a promoter or enhancer is operatively linked to a coding sequence if it affects the transcription of the sequence; or a ribosome-binding site is operatively linked to a coding sequence if it is positioned to facilitate translation. Generally, "operatively linked" means that the DNA sequences being linked are contiguous and, in the case of a secretory leader, contiguous and in the reading frame. However, enhancers do not need to be contiguous. Ligation is achieved by ligation at convenient restriction sites. If these sites do not exist, synthetic oligonucleotide adapters or linkers are used according to conventional practice.
[00129] As used herein, the terms “cell,” “cell line,” and “cell culture” are used interchangeably, and all these designations include the progeny. Thus, the words “transforming cells” and “transformed cells” include the primary individual cell and cultures derived from it, without regard to the number of transfers. It is also understood that not all progeny will have precisely identical DNA content, due to deliberate or inadvertent mutations. Mutant progeny that have the same biological function or activity as screened in the originally transformed cell are included. Where distinct designations are intentional, this will be evident from the context.
[00130] As used herein, “germline sequence” refers to a sequence of unrearranged immunoglobulin DNA sequences. Any appropriate source of unrearranged immunoglobulin sequences may be used. Human germline sequences may be obtained, for example, from JOINSOLVER® lineage databases on the website of the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the United States National Institutes of Health. Petition 870250121500, dated 12 / 30 / 2025, pp. 85 / 160 70 / 138 Health. Mouse germline sequences can be obtained, for example, as described in Giudicelli et al. (2005) Nucleic Acids Res. 33:D256-D261. Properties of murine anti-canine IL-4Ra antibodies and caninized murine anti-canine IL-4Ra antibodies
[00131] The present invention provides isolated murine anti-canine IL-4Ra antibodies and caninized antibodies thereof, methods of using the antibodies or antigen-binding fragments thereof in the treatment of diseases, for example, in the treatment of atopic dermatitis in canines. In canines, there are four IgG heavy chains referred to as A, B, C, and D. These heavy chains represent four different canine IgG subclasses, which are referred to as IgGA, IgGB, IgGC, and IgGD. Each of the two heavy chains consists of a variable domain (VH) and three constant domains referred to as CH-1, CH-2, and CH-3. The CH-1 domain is connected to the CH-2 domain via an amino acid sequence referred to as the hinge or alternatively as the hinge region.
[00132] The amino acid and DNA sequences of these four heavy chains were first identified by Tang et al. [Vet. Immunol. Immunopathol. 80: 259-270 (2001)]. Amino acid and DNA sequences for these heavy chains are also available in GenBank databases. For example, the amino acid sequence of heavy chain IgGA has accession number AAL35301.1, IgGB has accession number AAL35302.1, IgGC has accession number AAL35303.1, and IgGD has accession number AAL35304.1. Canine antibodies also contain two types of light chains, kappa and lambda. The DNA and amino acid sequences of these light chains can be obtained from GenBank databases. For example, the amino acid sequence of kappa light chain has accession number ABY 57289.1 and the lambda light chain has Petition 870250121500, dated 12 / 30 / 2025, pp. 86 / 160 71 / 138 access number ABY 55569.1.
[00133] In the present invention, the amino acid sequence for each of the four canine IgG Fc fragments is based on the identified boundary of CH1 and CH2 domains as determined by Tang et al., supra. Caninized murine anti-canine IL-4Ra antibodies that bind to canine IL-4Ra include, but are limited to: antibodies comprising canine IgG-A, IgG-B, and IgG-D heavy chains and / or canine kappa light chains along with murine anti-canine IL-4Ra CDRs. Consequently, the present invention provides isolated murine anti-canine IL-4Ra antibodies and / or caninized murine anti-canine IL-4Ra or antigen-binding fragments thereof that bind to canine IL-4Ra and block the binding of canine IL-4 and canine IL-13 to type I or type II IL-4 receptors.
[00134] The present invention further provides full-length canine heavy chains that can be matched with corresponding light chains to obtain a caninized antibody. Consequently, the present invention further provides caninized murine anti-canine antigen antibodies (including isolated caninized murine anti-canine IL-4Ra antibodies) and methods of using the antibodies or antigen-binding fragments thereof in the treatment of diseases, for example, the treatment of atopic dermatitis in canines.
[00135] The present invention also provides caninized murine anti-canine IL-4Ra antibodies comprising a canine fragment crystallizable region (cFc region) in which the cFc has been genetically modified to enhance, decrease, or eliminate one or more effector functions. In one aspect of the present invention, the genetically modified cFc decreases or eliminates one or more effector functions. In another aspect of the invention, the genetically modified cFc enhances one or more effector functions. In certain Petition 870250121500, dated 12 / 30 / 2025, page 87 / 160 In 72 / 138 embodiments, the genetically modified cFc region is a genetically modified canine IgGB Fc region. In another such embodiment, the genetically modified cFc region is a genetically modified canine IgGC Fc region. In one particular embodiment, the effector function is antibody-dependent cytotoxicity (ADCC), which is increased, decreased, or eliminated. In another embodiment, the effector function is complement-dependent cytotoxicity (CDC), which is increased, decreased, or eliminated. In yet another embodiment, the cFc region has been genetically modified to increase, decrease, or eliminate both ADCC and CDC.
[00136] In order to generate canine IgG variants lacking effector functions, several mutant canine IgGB heavy chains were generated. These variants may include one or more of the following single or combined substitutions in the Fc portion of the heavy chain amino acid sequence: P4A, D31A, N63A, G64P, T65A, A93G, and P95A. Variant heavy chains (i.e., containing such amino acid substitutions) were cloned into expression plasmids and transfected into HEK 293 cells along with a plasmid containing the gene encoding the light chain. Intact antibodies expressed and purified from HEK 293 cells were evaluated for binding to FcvRI and C1q to assess their potential for mediating immune effector functions. [See provisional patent application U.S. 62 / 030,812, filed July 30, 2014, and provisional patent application U.S. 62 / 092,496, filed December 16, 2014, the contents of both of which are incorporated by reference in their entirety.]
[00137] The present invention also provides modified canine IgGDs that instead of their natural IgGD hinge region, comprise a hinge region of: IgGA: FNECRCTDTPPCPVPEP, SEQ ID NO: 101; Petition 870250121500, dated 12 / 30 / 2025, pp. 88 / 160 73 / 138 IgGB: PKRENGRVPRPPDCPKCPAPEM, SEQ ID NO: 102; or IgGC: AKECECKCNCNNCPCPGCGL, SEQ ID NO: 103.
[00138] Alternatively, the IgGD hinge region can be genetically modified by exchanging a serine residue for a proline residue, i.e., PKESTCKCIPPCPVPES, SEQ ID NO: 104 (with the proline (P) residue underlined and in bold replacing the naturally occurring serine residue). Such modifications can lead to a canine IgGD lacking the fab arm exchange. Modified canine IgGDs can be constructed using standard recombinant DNA technology methods [e.g., Maniatis et al., Molecular Cloning, A Laboratory Manual (1982)]. In order to construct these variants, the nucleic acids encoding the canine IgGD amino acid sequence can be modified to encode the modified IgGDs. The modified nucleic acid sequences are then cloned into expression plasmids for protein expression.
[00139] The antibody or antigen-binding fragment thereof that binds to canine IL-4Ra may comprise one, two, three, four, five, or six complementarity-determining regions (CDRs) of the murine anticanine antibody, as described herein. One, two, three, four, five, or six CDRs may be independently selected from CDR sequences provided below. In another embodiment, the isolated antibodies or antigen-binding fragment thereof that bind to canine IL-4Ra comprise a canine kappa light chain antibody comprising a murine CDR-1, CDR-2, and / or CDR-3 light chain and a canine antibody heavy chain IgG comprising murine CDR-1, CDR-2, and / or CDR-3 heavy chain.
[00140] In other embodiments, the invention provides antibodies or antigen-binding fragments thereof that specifically bind to Petition 870250121500, dated 12 / 30 / 2025, pp. 89 / 160 74 / 138IL-4Ra and canine kappa antibody light chains comprising one to six different CDRs comprising at least 80%, 85%, 90%, 95%, 98%, or 99% sequence identity with the amino acid sequences of SEQ IDs: 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, and / or 73 and canine antibody heavy chain IgG comprising one to six different CDRs comprising at least 80%, 85%, 90%, 95%, 98%, or 99% sequence identity with the amino acid sequences of SEQ IDs Nos: 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, and / or 100, while still exhibiting the desired linking and functional properties.In another embodiment, the antibody or antigen-binding fragment of the present invention comprises a canine frame comprising a combination of IgG heavy chain sequence with a kappa light chain having one or more of the aforementioned CDR amino acid sequences with 0, 1, 2, 3, 4, or 5 conservative or non-conservative amino acid substitutions, while still exhibiting the desired binding and functional properties.
[00141] Sequence identity refers to the degree to which the amino acids of two polypeptides are the same in equivalent positions when the two sequences are optimally aligned. As used herein, an amino acid sequence is 100% identical to a second amino acid sequence when the amino acid residues of both sequences are identical. Consequently, an amino acid sequence is 50% identical to a second amino acid sequence when 50% of the amino acid residues of the two amino acid sequences are identical. Sequence comparison is performed on a contiguous block of amino acid residues constituting a given protein, for example, a protein, or the portion of the polypeptide being compared. In a particular embodiment, deletions or insertions Petition 870250121500, dated 12 / 30 / 2025, pp. 90-160 75 / 138 selected amino acids that could otherwise alter the correspondence between the two amino acid sequences are taken into consideration.
[00142] Sequence similarity includes identical and non-identical residues, biochemically related amino acids. Biochemically related amino acids that share similar properties and may be interchangeable are discussed.
[00143] Conservatively modified variants or conservative substitutions refer to amino acid substitutions in a protein with other amino acids with similar characteristics (e.g., charge, side chain size, hydrophobicity, hydrophilicity, backbone conformation and stiffness, etc.), such that changes can be made frequently without altering the biological activity of the protein. Those skilled in the art recognize that, in general, single amino acid substitutions in non-essential regions of a polypeptide do not substantially alter biological activity (see, for example, Watson et al., Molecular Biology of the Gene, The Benjamin / Cummings Pub. Co., p. 224 (4th ed.; 1987)). Furthermore, substitutions of structurally or functionally similar amino acids are less likely to disrupt biological activity. Exemplary conservative substitutions are specified in Table 1 directly below. TABLE 1 Exemplary conservative amino acid substitutions Original residue Conservative substitution Ala (A) Gly; Ser; Arg (R) Lys; His Asn (N) Gln; His Asp (D) Glu; Asn Cys(C) Ser; Ala Petition 870250121500, dated 12 / 30 / 2025, pp. 91 / 160 76 / 138 Original residue Conservative substitution Gln (Q) Asn Glu (E) Asp; Gln Gly (G) Wing His (H) Asn; Gln Ile (I) Leu; Val Leu (L) Ile; ValLys(K)Arg; His Met (M) Leu; Ile; TyrPhe(F)Tyr; Met; Leu Pro (P) Wing; Gly Ser (S) Thr Thr (T) Ser Trp (W) Tyr; Phe Tyr(Y) Trp; Phe Val (V) Ile; Read
[00144] Conservative variants of the antibodies of the invention are also contemplated by the present invention. “Conservative variants,” as used herein, refers to antibodies or fragments in which one or more amino acid residues have been changed without altering a desired property, such as an affinity and / or specificity for antigen. Such variants include, but are not limited to, the exchange of an amino acid with one having similar properties, such as the conservative amino acid substitutions of Table 1 above. Nucleic acids
[00145] The present invention further comprises nucleic acids encoding the immunoglobulin chains of canine anti-IL-4Ra antibodies. Petition 870250121500, dated 12 / 30 / 2025, pp. 92 / 160 77 / 138 murine and / or canine anti-canine IL-4Ra from caninized murine and antigen-binding fragments thereof described herein (see Examples below).
[00146] Also included in the present invention are nucleic acids encoding immunoglobulin polypeptides comprising amino acid sequences that are at least about 70% identical, preferably at least about 80% identical, more preferably at least about 90% identical, and most preferably at least about 95% identical (e.g., 95%, 96%, 97%, 98%, 99%, 100%) with the amino acid sequences of CDRs and antibodies provided herein when the comparison is performed by a BLAST algorithm in which the algorithm parameters are selected to give the highest match between the respective sequences over the full length of the respective reference sequences.The present invention also provides nucleic acids encoding immunoglobulin polypeptides comprising amino acid sequences that are at least about 70% similar, preferably at least about 80% similar, more preferably at least about 90% similar, and most preferably at least about 95% similar (e.g., 95%, 96%, 97%, 98%, 99%, 100%) to any of the amino acid reference sequences when the comparison is performed with a BLAST algorithm, in which the algorithm parameters are selected to give the highest match between the respective sequences over the full length of the respective reference sequences, are also included in the present invention.
[00147] As used herein, percent identity of nucleotide and amino acid sequences can be determined using C, MacVector (MacVector, Inc. Cary, NC 27519), Vector NTI (Informax, Inc. MD), Oxford Molecular Group PLC (1996), and the Clustal W algorithm with default alignment parameters and default parameters for identity. These Petition 870250121500, dated 12 / 30 / 2025, page 93 / 160 78 / 138 commercially available programs can also be used to determine sequence similarity using the same or analogous default parameters. Alternatively, an Advanced Blast search under default filter conditions can be used, for example, using the GCG pileup program (Genetics Computer Group, Program Manual for the GCG Package, Version 7, Madison, Wisconsin) using the default parameters.
[00148] The following references relate to algorithms BLAST com frequência usados para a análise de sequências: BLAST ALGORITHMS: Altschul, S.F., et al., J. Mol. Biol. 215:403-410 (1990); Gish, W., et al., Nature Genet. 3:266-272 (1993); Madden, T.L., et al., Meth. Enzymol. 266:131-141(1996); Altschul, S.F., et al., Nucleic Acids Res. 25:3389-3402 (1997); Zhang, J., et al., Genome Res. 7:649-656 (1997); Wootton, J.C., et al., Comput. Chem. 17:149-163 (1993); Hancock, J.M. et al., Comput. Appl. Biosci. 10:67-70 (1994); ALIGNMENT SCORING SYSTEMS: Dayhoff, M.O., et al., “A model of evolutionary change in proteins.” em Atlas of Protein Sequence and Structure, vol. 5, suppl. 3. M.O. Dayhoff (ed.), pp. 345-352, (1978); Natl. Biomed. Res. Found., Washington, DC; Schwartz, R.M., et al., Matrices for detecting distant relationships.” em Atlas of Protein Sequence and Structure, vol. 5, suppl. 3.” (1978), M.O. Dayhoff (ed.), pp. 353-358 (1978), Natl. Biomed. Res. Found., Washington, DC; Altschul, S.F., J. Mol. Biol. 219:555-565 (1991); States, D.J., et al., Methods 3:66-70(1991); Henikoff, S., et al., Proc. Natl. Acad. Sci. USA 89:10915-10919 (1992); Altschul, S.F., et al., J. Mol. Evol. 36:290-300 (1993); ALIGNMENT STATISTICS: Karlin, S., et al., Proc. Natl. Acad. Sci. USA 87:2264-2268 (1990); Karlin, S., et al., Proc. Natl. Acad. Sci. USA 90:5873-5877 (1993); Dembo, A., et al., Ann. Prob. 22:2022-2039 (1994); e Altschul, S.F. Evaluating the statistical significance of multiple distinct local alignments.” em Theoretical and Computational Methods in Genome Research (S. Suhai, ed.), pp. Petição 870250121500, de 30 / 12 / 2025, pág. 94 / 160 79 / 138 1-14, Plenum, New York (1997).
[00149] This present invention also provides expression vectors comprising the isolated nucleic acids of the invention, wherein the nucleic acid is operatively linked to control sequences that are recognized by the host cell when the host cell is transfected with the vector. Host cells comprising an expression vector of the present invention and methods for producing the antibody or antigen-binding fragment thereof described herein are also provided, comprising culturing a host cell harboring an expression vector encoding the antibody or antigen-binding fragment in culture medium and isolating the antigen or antigen-binding fragment thereof from the host cell or culture medium. Epitope binding and binding affinity
[00150] The present invention also provides antibodies or antigen-binding fragments thereof that bind to amino acid residues of the same canine IL-4Ra epitope as the murine anti-canine IL-4Ra antibodies described herein. In particular embodiments, the murine anti-canine IL-4Ra antibodies or antigen-binding fragments thereof are also capable of inhibiting / blocking the binding of canine IL-4 and canine IL-13 to type I and / or type II IL-4 receptors.
[00151] The caninized murine canine anti-canine IL-4Ra antibody can be recombinantly produced by methods known in the field. Cell lines available as hosts for expression of the antibodies or fragments described herein are well known in the art and include many immortalized cell lines available from the American Type Culture Collection (ATCC). These include, inter alia, Chinese hamster ovary (CHO) cells, NSO cells, SP2 cells, HeLa cells, baby hamster kidney cells. Petition 870250121500, dated 12 / 30 / 2025, pp. 95 / 160 80 / 138 (BHK), monkey kidney cells (COS), human hepatocellular carcinoma cells (e.g., Hep G2), A549 cells, 3T3 cells, HEK-293 cells, and several other cell lines. Mammalian host cells include cells from humans, mice, rats, dogs, monkeys, pigs, goats, cattle, horses, and hamsters. Cell lines of particular preference are selected by determining which cell lines have high levels of expression. Other cell lines that can be used are insect cell lines such as Sf9 cells, amphibian cells, bacterial cells, plant cells, and fungal cells.When recombinant expression vectors encoding the heavy chain or antigen-binding portion or fragment thereof, the light chain and / or antigen-binding fragment thereof are introduced into mammalian host cells, antibodies are produced by culturing the host cells for a period of time sufficient to permit antibody expression on the host cells or, more preferably, by secretion of the antibody into the culture medium in which the host cells are cultured.
[00152] Antibodies can be recovered from the culture medium using standardized protein purification methods. Furthermore, expression of antibodies of the invention (or other portions thereof) from production cell lines can be improved using various known techniques. For example, the glutamine synthetase gene expression system (the GS system) is a common approach to improve expression under certain conditions. The GS system is discussed in whole or in part in connection with European Patents Nos. 0 216 846, 0 256 055 and 0 323 997 and European Patent Application No. 89303964.4.
[00153] In general, glycoproteins produced in a particular cell line or transgenic animal will have a glycosylation pattern that is Petition 870250121500, dated 12 / 30 / 2025, pp. 96 / 160 81 / 138 characteristic for glycoproteins produced in the transgenic animal or cell line. Thus, the particular glycosylation pattern of an antibody will depend on the particular cell line or transgenic animal used to produce the antibody. However, all antibodies encoded by the nucleic acid molecules provided herein, or comprising the amino acid sequences provided herein, comprise the present invention, regardless of the glycosylation pattern that the antibodies may have. Similarly, in particular embodiments, antibodies with a glycosylation pattern comprising only non-fucosylated N-glycans may be advantageous, because such antibodies have been shown to typically exhibit more potent efficacy than their fucosylated counterparts both in vitro and in vivo [See, for example, Shinkawa et al., J. Biol. Chem. 278: 3466-3473 (2003); US Patents Nos. 6,946,292 and 7,214,775].
[00154] The present invention further includes antibody fragments of the murine anti-canine IL-4Ra antibodies described herein. The antibody fragments include F(ab)2 fragments, which can be produced by enzymatic cleavage of an IgG by, for example, pepsin. Fab fragments can be produced by, for example, reduction of F(ab)2 with dithiothreitol or mercaptoethylamine. A Fab fragment is a Vl-Cl chain attached to a Vh-Ch1 chain by a disulfide bridge. An F(ab)2 fragment is a Fab of two fragments which, in turn, are attached by two disulfide bridges. The Fab portion of an F(ab)2 molecule includes a portion of the Fc region between which disulfide bridges are located. An Fv fragment is a Vl or Vh region.
[00155] In one embodiment, the antibody or antigen-binding fragment comprises a heavy chain constant region, for example, a canine constant region, such as the canine IgG-A, IgG-B, IgG-C, and IgG-D heavy chain constant region, or a variant thereof. In another Petition 870250121500, dated 12 / 30 / 2025, pp. 97 / 160 82 / 138 modality, the antibody or antigen-binding fragment comprises a constant light chain region, for example, a canine constant light chain region, such as a canine lambda or kappa light chain region or a variant thereof. By way of example and not limitation, the canine heavy chain constant region may be IgG-B and the canine light chain constant region may be kappa. Antibody engineering
[00156] Caninized murine anti-canine IL-4Ra antibodies of the present invention can be engineered to include modifications to canine scaffold and / or canine frame residues within the variable domains of a parental (i.e., canine) monoclonal antibody, for example to improve antibody properties. Experimental and diagnostic uses
[00157] Murine anti-canine IL-4Ra antibodies and / or caninized murine anti-canine IL-4Ra antibodies or antigen-binding fragments thereof of the present invention may also be usable in diagnostic tests for canine IL-4Ra protein, for example, by detecting its expression in conjunction with and / or in relation to atopic dermatitis.
[00158] For example, this method comprises the following steps: (a) coating a substrate (e.g., the surface of a well in a microtiter plate, e.g., a plastic plate) with a murine anti-canine IL-4Ra antibody or an antigen-binding fragment thereof; (b) apply the sample to be tested for the presence of canine IL-4Ra to the substrate; (c) wash the plate so that no material is bound to the sample Petition 870250121500, dated 12 / 30 / 2025, pp. 98 / 160 83 / 138 is removed; (d) apply in a detectable manner labeled antibodies (e.g., enzyme-linked antibodies) that are also specific for the IL-4Ra antigen; (e) wash the substrate so that unbound labeled antibodies are removed; (f) if the labeled antibodies are enzyme-bound, apply a chemical that is converted by the enzyme into a fluorescent signal; and (g) detect the presence of the labeled antibody.
[00159] In another embodiment, the labeled antibody is labeled with peroxidase that reacts with ABTS [e.g., 2,2'-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid)] or 3,3,5,5-tetramethylbenzidine to produce a detectable color change. Alternatively, the labeled antibody is labeled with a detectable radioisotope (e.g., 3H) that can be detected by scintillation counter in the presence of a scintillation agent. Anti-canine murine IL-4Ra antibodies of the invention can be used in a Western blot or immunoprotein blot procedure.
[00160] This procedure forms part of the present invention and includes, for example: (i) Contacting a membrane or other solid substrate to be tested for the presence of bound canine IL-4Ra or a fragment thereof with a murine anti-canine IL-4Ra antibody or antigen-binding fragment thereof of the present invention. Such a membrane may be in the form of a nitrocellulose or vinyl-based membrane [e.g., polyvinylidene fluoride (PVDF)] to which the proteins to be tested for the presence of canine IL-4Ra are attached on a non-denaturing PAGE gel (polyacrylamide gel electrophoresis) or SDS-PAGE gel (dodecyl sulfate gel electrophoresis). Petition 870250121500, dated 12 / 30 / 2025, pp. 99 / 160 84 / 138 sodium polyacrylamide) were transferred (e.g., after electrophoretic separation on the gel). Before contact of the membrane with the murine anti-canine IL-4Ra antibody or antigen-binding fragment thereof, the membrane is optionally blocked, for example, with a skimmed milk powder or similar in order to bind to non-specific protein binding sites on the membrane. (ii) wash the membrane one or more times to remove unbound murine anti-canine IL-4Ra antibody or antigen-binding fragment thereof and other unbound substances; and (iii) detect murine anti-canine IL-4Ra antibody or antigen-binding fragment thereof.
[00161] Detection of the bound antibody or antigen-binding fragment can be achieved by binding the antibody or antigen-binding fragment to a secondary antibody (an anti-immunoglobulin antibody) that is labeled in a detectable manner and then detecting the presence of the secondary antibody.
[00162] Murine anti-canine IL-4Ra antibodies and antigen-binding fragments thereof described herein can also be used for immunohistochemistry. Such a method forms part of the present invention and comprises, for example, (1) contacting a cell to be tested for the presence of canine IL-4Ra with a murine anti-canine IL-4Ra antibody or antigen-binding fragment thereof of the present invention; and (2) detecting the antibody or fragment on or in the cell. If the antibody or antigen-binding fragment itself is detectably labeled, it can be detected directly. Alternatively, the antibody or antigen-binding fragment can be bound by a detectably labeled secondary antibody that is detected. Petition 870250121500, dated 12 / 30 / 2025, pp. 100 / 160 85 / 138
[00163] Imaging techniques include SPECT (single-photon emission computed tomography) imaging or PET (positron emission tomography) imaging. Labels include, for example, iodine-123 (123I) and technetium-99m (99mTc), for example, in conjunction with SPECT imaging or 11C, 13N, 15O or 18F, for example, in conjunction with PET imaging or Indium-111 [See, for example, Gordon et al., International Rev. Neurobiol. 67:385-440 (2005). Cross-blocking antibodies
[00164] Furthermore, an anti-canine IL-4Ra antibody or antigen-binding fragment thereof of the present invention includes any antibody or antigen-binding fragment thereof that binds to the same epitope on canine IL-4Ra to which the antibodies and fragments discussed herein bind and any antibody or antigen-binding fragment that cross-blocks (partially or completely) or is cross-blocked (partially or completely) by an antibody or fragment discussed herein for binding to canine IL-4Ra; as well as any variant thereof.
[00165] The cross-blocking antibodies and antigen-binding fragments thereof discussed herein can be identified based on their ability to cross-compete with the antibodies described herein (based on the CDRs as given below in Example 5), i.e., 1A3, 1A9, 1B12, 10C12, 10F2, 10E10, 10G8, and / or 11D3; or more particularly, 11B6 and / or 6C12; and even more particularly 4D8, 4H3, 2E2, and / or 11H2, in standard binding tests (e.g., BIACore®, ELISA, as exemplified below, or flow cytometry). For example, standard ELISA tests can be used in which a recombinant canine IL-4Ra protein is immobilized on the plate, one of the antibodies is fluorescently labeled, and the ability of the unlabeled antibody to compete for binding away from the labeled antibody is evaluated. Petition 870250121500, dated 12 / 30 / 2025, pp. 101 / 160 86 / 138 Additionally or alternatively, BIAcore® analysis can be used to assess the ability of antibodies to cross-compete. The ability of the test antibody to inhibit the binding of, for example, 1A3, 1A9, 1B12, 10C12, 10F2, 10E10, 10G8, and / or 11D3; or more particularly, 11B6 and / or 6C12; and even more particularly 4D8, 4H3, 2E2, and / or 11H2, for canine IL-4Ra demonstrates that the test antibody can compete with 1A3, 1A9, 1B12, 10C12, 10F2, 10E10, 10G8, 11D3, 11B6, 6C12, 4D8, 4H3, 2E2, and / or 11H2 for binding to a canine IL-4Ra and thus, may, in some cases, bind to the same epitope in canine IL-4Ra as 1A3, 1A9, 1B12, 10C12, 10F2, 10E10, 10G8, 11D3, 11B6, 6C12, 4D8, 4H3, 2E2, and / or 11H2. As specified above, antibodies and fragments that bind to the same epitope, such as any of the canine anti-IL-4Ra antibodies or fragments of the present invention, were also part of the present invention. Pharmaceutical compositions and administration
[00166] To prepare pharmaceutical or sterile compositions of a caninized murine anti-canine IL-4Ra antibody or antigen-binding fragment thereof, they may be mixed with a pharmaceutically acceptable carrier or excipient. [see, for example, Remington's Pharmaceutical Sciences and US Pharmacopeia: National Formulary, Mack Publishing Company, Easton, PA (1984)].
[00167] Formulations of therapeutic and diagnostic agents may be prepared by mixing with acceptable vehicles, excipients, or stabilizers in the form of, for example, lyophilized powders, fluid pastes, aqueous solutions, or suspensions [see, for example, Hardman, et al. (2001) The Pharmacological Basis of Therapeutics by Goodman and Gilman, McGraw-Hill, New York, NY; Gennaro (2000) Remington: The Science and Practice of Pharmacy, Lippincott, Williams & Wilkins, New York, NY; Avis, et al. (eds.) (1993) Petition 870250121500, dated 12 / 30 / 2025, pp. 102 / 160 87 / 138 Pharmaceutical Dosage Forms: Parenting Medications, Marcel Dekker, NY; Lieberman, et al. (eds.) (1990) Pharmaceutical Dosage Forms: Tablets, Marcel Dekker, NY; Lieberman, et al. (eds.) (1990) Pharmaceutical Dosage Forms: Dispersed Systems, Marcel Dekker, NY; Weiner and Kotkoskie (2000) Toxicity and Safety of Excipients, Marcel Dekker, Inc., New York, NY]. In one embodiment, anti-IL-4Ra antibodies of the present invention are diluted to an appropriate concentration in a sodium acetate solution at pH 5-6 and NaCl or sucrose is added for tonicity. Additional agents, such as polysorbate 20 or polysorbate 80, may be added to improve stability.
[00168] The toxicity and therapeutic efficacy of antibody compositions, administered alone or in combination with another agent, can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, for example, to determine the LD50 (the lethal dose for 50% of the population) and the ED50 (the therapeutically effective dose in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index (LD50 / ED50). In particular aspects, antibodies exhibiting high therapeutic indices are desirable. Data obtained from these cell culture tests and animal studies can be used in formulating a dosage range for use in canines. The dosage of such compounds is preferably within a range of circulating concentrations that include the ED50 with little or no toxicity. The dosage may vary within this range depending on the dosage form employed and the route of administration.
[00169] The method of administration may vary. Appropriate routes of administration include oral, rectal, transmucosal, intestinal, parenteral; intramuscular, subcutaneous, intradermal, intramedullary, intrathecal, direct intraventricular, intravenous, intraperitoneal, intranasal, intraocular, inhalation, insufflation, topical, cutaneous, transdermal, or intra-arterial. In Petition 870250121500, dated 12 / 30 / 2025, pp. 103 / 160 In particular embodiments, the murine anti-canine IL-4Ra antibody or antigen-binding fragment thereof may be administered by an invasive route such as by injection. In other embodiments of the invention, a murine anti-canine IL-4Ra antibody or antigen-binding fragment thereof, or pharmaceutical composition thereof, is administered intravenously, subcutaneously, intramuscularly, intra-arterially, or by inhalation, aerosol release. Administration by non-invasive routes (e.g., orally; e.g., in a pill, capsule or tablet) is also within the scope of the present invention.
[00170] Compositions can be administered with medical devices known in the art. For example, a pharmaceutical composition of the invention can be administered by injection with a hypodermic needle, including, for example, a pre-filled syringe or auto-injector. The pharmaceutical compositions described herein can also be administered with a needle-free hypodermic injection device; such as the devices described in U.S. Patents Nos.: 6,620,135; 6,096,002; 5,399,163; 5,383,851; 5,312,335; 5,064,413; 4,941,880; 4,790,824 or 4,596,556.
[00171] The pharmaceutical compositions described herein may also be administered by infusion. Examples of well-known implants and modules for the administration of pharmaceutical compositions include: U.S. Patent 4,487,603, which describes an implantable micro-infusion pump for the release of medication at a controlled rate; U.S. Patent 4,447,233, which describes a medication infusion pump for the release of medication at a precise infusion rate; U.S. Patent 4,447,224, which describes an implantable variable-flow infusion apparatus for continuous drug release; U.S. Patent 4,439,196, which describes an osmotic drug delivery system having multiple chamber compartments. Many others of this kind exist. Petition 870250121500, dated 12 / 30 / 2025, pp. 104 / 160 89 / 138 implants, delivery systems and modules are well known to those skilled in the art.
[00172] Alternatively, a murine anti-canine or caninized murine anti-canine IL4Ra antibody can be administered locally rather than systemically, for example, via injection of the antibody directly into an arthritic joint or pathogen-induced lesion distinguished by immunopathology, often in a depot or sustained-release formulation. Additionally, the antibody can be administered in a target-labeled drug delivery system, for example, in a liposome coated with a tissue-specific antibody, targeting, for example, the arthritic joint or pathogen-induced lesion distinguished by immunopathology. Liposomes can be targeted and selectively absorbed by the affected tissue.
[00173] The administration regimen depends on several factors, including the serum or tissue turnover rate of the therapeutic antibody, the level of symptoms, the immunogenicity of the therapeutic antibody, and the accessibility of target cells in the biological matrix. Preferably, the administration regimen delivers sufficient therapeutic antibody to achieve an improvement in the target disease state while simultaneously minimizing undesirable side effects. Therefore, the amount of biological product delivered depends, in part, on the particular therapeutic antibody and the severity of the condition being treated. Guidance on selecting appropriate doses of therapeutic antibodies is available [see, for example, Wawrzynczak Antibody Therapy, Bios Scientific Pub. Ltd, Oxfordshire, UK (1996); Kresina (ed.) Monoclonal Antibodies, Cytokines and Arthritis, Marcel Dekker, New York, NY (1991); Bach (ed.) Monoclonal Antibodies and Peptide Therapy in Autoimmune Diseases, Marcel Dekker, New York, NY (1993); Baert et al. New Engl. J. Med. 348:601-608 (2003); Petition 870250121500, de 30 / 12 / 2025, pág. 105 / 160 90 / 138 Milgrom et al. New Engl. J. Med. 341:1966-1973 (1999); Slamon et al. New Engl. J. Med. 344:783-792 (2001); Beniaminovitz et al. New Engl. J. Med. 342:613-619 (2000); Ghosh et al. New Engl. J. Med. 348:24-32 (2003); Lipsky et al. New Engl. J. Med. 343:1594-1602 (2000)].
[00174] Determining the appropriate dose is done by the veterinarian, for example, using known or suspected parameters or factors in the technique that affect the treatment. Generally, the dose starts with a slightly lower amount than the optimum dose and is increased by small increments thereafter until the desired or optimum effect is achieved in relation to any negative side effects. Important diagnostic measurements include those of symptoms of, for example, inflammation or the level of inflammatory cytokines produced.
[00175] Antibodies or antigen-binding fragments of the same described herein may be delivered by continuous infusion, or by doses administered, for example, daily, 1-7 times a week, weekly, bi-weekly, monthly, bimonthly, quarterly, semi-annually, annually, etc. Doses may be delivered, for example, intravenously, subcutaneously, topically, orally, nasally, rectally, intramuscularly, intracerebrally, intraspinally, or by inhalation. A total weekly dose is generally at least 0.05 μg / kg of body weight, more commonly at least 0.2 μg / kg, 0.5 μg / kg, 1 μg / kg, 10 μg / kg, 100 μg / kg, 0.25 mg / kg, 1.0 mg / kg, 2.0 mg / kg, 5.0 mg / ml, 10 mg / kg, 25 mg / kg, 50 mg / kg or more [see, for example, Yang, et al. New Engl. J. Med. 349:427-434 (2003); Herold, et al. New Engl. J. Med. 346:1692-1698 (2002); Liu, et al. J. Neurol. Neurosurg. Psych. 67:451-456 (1999); Portielji, et al. Cancer Immunol. Immunother. 52:133-144 (2003)].Doses can also be administered to achieve a predetermined target concentration of one. Petition 870250121500, dated 12 / 30 / 2025, pp. 106 / 160 91 / 138 caninized murine anti-canine IL-4Ra antibody in the subject's serum, such as 0.1, 0.3, 1, 3, 10, 30, 100, 300 μg / ml or more. In other embodiments, a caninized murine anti-canine IL-4Ra antibody of the present invention is administered subcutaneously or intravenously, on a weekly, bi-weekly, “every 4 weeks”, monthly, bi-monthly, or quarterly basis at 10, 20, 50, 80, 100, 200, 500, 1000 or 2500 mg / subject.
[00176] Antigenic peptides recognized by canine anti-IL-4Ra mAbs can also be used as vaccines to elicit antibodies that block the binding of canine IL-4 and canine IL-13 to type I and type II IL-4 receptors. Such vaccines may be usable as therapeutic vaccines for diseases such as atopic dermatitis. In order to use these antigenic peptides as vaccines, one or more of these peptides can be chemically coupled or through recombinant DNA technology techniques to another carrier protein in order to improve the immunogenicity of these peptides and elicit peptide-specific antibodies. Techniques for coupling peptides to carrier proteins are known to those skilled in the art. Peptide vaccines can be used to vaccinate animals via IM, S / C, oral, spray, or in ovo routes.Peptide vaccines can be used as subunit proteins expressed from bacterial, viral, yeast, or baculovirus systems. Alternatively, such peptide vaccines can be delivered after administration of various viral or bacterial vectors expressing such peptide vaccines, as can be practiced by methods known to those skilled in the art. Peptide vaccines can be administered in doses of 1-1000 μg and optionally contain an adjuvant and an acceptable pharmaceutical carrier.
[00177] As used herein, “inhibit” or “treat” or “treatment” includes Petition 870250121500, dated 12 / 30 / 2025, pp. 107 / 160 92 / 138 a delay in the development of symptoms associated with a disorder and / or a reduction in the severity of the symptoms of such a disorder. The terms also include improving existing uncontrollable or unwanted symptoms, preventing additional symptoms, and improving or preventing the underlying causes of such symptoms. Thus, the terms denote that a beneficial outcome is conferred on a vertebrate individual with a disorder, disease, or symptom, or with the potential to develop such a disorder, disease, or symptom.
[00178] As used herein, the terms “therapeutically effective amount,” “therapeutically effective dose,” and “effective amount” refer to an amount of a caninized murine anti-canine IL-4Ra antibody or antigen-binding fragment thereof of the present invention that, when administered alone or in combination with an additional therapeutic agent to a cell, tissue, or subject, is effective in causing a measurable improvement in one or more symptoms of a disease or condition or the progression of such disease or condition. A therapeutically effective dose further refers to that amount of the binding compound sufficient to result in at least partial improvement of symptoms, for example, treatment, cure, prevention, or improvement of the relevant medical condition, or an increase in the rate of treatment, cure, prevention, or improvement of such conditions.When applied to an individual active ingredient administered alone, a therapeutically effective dose refers to that ingredient alone. When applied to a combination, a therapeutically effective dose refers to combined amounts of the active ingredients that result in the therapeutic effect, whether administered in combination, serially, or simultaneously. An effective amount of a therapeutic will result in an improvement in a measurement or diagnostic parameter by at least 10%; generally at least 20%; preferably at least about 30%; more preferably at least. Petition 870250121500, dated 12 / 30 / 2025, pp. 108 / 160 93 / 138 40% and more, preferably at least 50%. An effective amount may also result in an improvement in a subjective measurement, in cases where subjective measurements are used to assess disease severity. Other combination therapies
[00179] As previously described, a caninized murine anti-canine IL-4Ra antibody or antigen-binding fragment thereof and / or an antigenic peptide of the present invention may be co-administered with one or more other therapeutic agents (such as an inhibitor, as discussed in the next paragraph) and / or a murine (or caninized murine) anti-canine TSLP antibody [see, US 8,791,242]. The antibody(ies) may be linked to the agent (as an immune complex) and / or may be administered separately from the agent or other antibody. In the latter case (separate administration), the antibodies may be administered before, after, or simultaneously with the agent or may be co-administered with other known therapies. Kits
[00180] Kits comprising one or more components are also provided, including, but not limited to, an antibody or antigen-binding fragment, as discussed herein, that specifically binds to IL-4Ra (e.g., a caninized murine anti-canine IL-4Ra antibody or antigen-binding fragment thereof) in association with one or more additional components including, but not limited to, a pharmaceutically acceptable carrier and / or an inhibitor such as a Janus kinase (JAK) inhibitor, for example, oclacitinib [see, WO 2013 / 040241], a spleen tyrosine kinase (SYK) inhibitor [see, for example, US 8,759,366], or an antagonist for a chemoattractant receptor homolog molecule expressed on TH2 cells [see, for example, WO 2010 / 099039; WO 2010 / 031183; and US$8,546,422]. A Petition 870250121500, dated 12 / 30 / 2025, pp. 109 / 160 94 / 138 The linking composition and / or an inhibitor, as described directly above, may be formulated as a pure composition or in combination with a pharmaceutically acceptable carrier, in a pharmaceutical composition.
[00181] In one embodiment, the kit includes a binding composition of the present invention (e.g., caninized murine anti-canine IL-4Ra or a pharmaceutical composition thereof in one container (e.g., in a sterile glass or plastic bottle) and a pharmaceutical composition thereof and / or an inhibitor, as described above, in another container (e.g., in a sterile glass or plastic bottle).
[00182] If the kit includes a pharmaceutical composition for parenteral administration to an individual, the kit may also include a device for performing such administration. For example, the kit may include one or more hypodermic needles or other injection devices, as discussed above. The kit may also include a package insert containing information regarding the pharmaceutical compositions and dosage forms in the kit. Generally, such information helps pet owners and veterinarians to use the pharmaceutical compositions and dosage forms contained therein effectively and safely.For example, the following information regarding a combination of the invention may be provided by the package insert: pharmacokinetics, pharmacodynamics, clinical studies, efficacy parameters, indications and use, contraindications, warnings, precautions, adverse reactions, overdose, appropriate dosage and administration, how to provide it, appropriate storage conditions, references, manufacturer / distributor information, and patent information.
[00183] For convenience, a specific antibody or binding agent described herein may be supplied in a kit, i.e., a packaged combination of reagents in predetermined quantities with Petition 870250121500, dated 12 / 30 / 2025, pp. 110 / 160 95 / 138 Instructions for performing the diagnostic and detection test. Where the antibody is labeled with an enzyme, the kit will include substrates and cofactors required by the enzyme (e.g., a substrate precursor that provides the detectable chromophore or fluorophore). In addition, other additives may be included, such as stabilizers, buffers (e.g., a blocking buffer or lysis buffer), and the like. The relative amounts of the various reagents may be varied widely to give reagent solution concentrations that substantially optimize the sensitivity of the test. In particular, the reagents may be supplied as dry powders, usually lyophilized, including excipients which, upon dissolution, will give a reagent solution having the appropriate concentration. EXAMPLES EXAMPLE 1 IDENTIFICATION AND CLONING OF CANINE IL-4 RECEPTOR α-CHAIN
[00184] The cDNA encoding a full-length canine IL-4 receptor alpha chain (SEQ ID NO: 1) was identified using a Genbank database search (accession # XM_547077.4; see also, US 7,208,579 B2). This predicted cDNA encodes an 823 amino acid sequence (SEQ ID NO: 2) including a 25 amino acid leader sequence and is identified as accession # XP_547077.3. The predicted mature canine IL-4 receptor α chain protein (SEQ ID NO: 4) shares 65% identity with human IL-4 receptor α chain (accession # NP_000409.1) and 70% identity with porcine IL-4 receptor α chain (accession # NP_999505.1). The mature canine IL-4 receptor α-chain protein is encoded by the nucleotide sequence identified as SEQ ID NO: 3. Comparison of the mature IL-4 receptor α-chain with known α-chain sequences of Petition 870250121500, dated 12 / 30 / 2025, pp. 111 / 160 96 / 138 human IL-4 receptor identified the extracellular domain (ECD) of the mature canine IL-4 receptor α-chain protein and is designated as SEQ ID NO: 6. The DNA sequence encoding the ECD of the mature canine IL-4 receptor α-chain is identified as SEQ ID NO: 5. Canine IL-4 receptor α-strand full-length DNA with signal sequence (SEQ ID NO:1): atgggcagactgtgcagcggcctgaccttccccgtgagctgcctggtgctggtgtgggtggccagcagcggcagcg tgaaggtgctgcacgagcccagctgcttcagcgactacatcagcaccagcgtgtgccagtggaagatggaccacc ccaccaactgcagcgccgagctgagactgagctaccagctggacttcatgggcagcgagaaccacacctgcgtgc ccgagaacagagaggacagcgtgtgcgtgtgcagcatgcccatcgacgacgccgtggaggccgacgtgtaccag ctggacctgtgggccggccagcagctgctgtggagcggcagcttccagcccagcaagcacgtgaagcccagaac ccccggcaacctgaccgtgcaccccaacatcagccacacctggctgctgatgtggaccaacccctaccccaccga gaaccacctgcacagcgagctgacctacatggtgaacgtgagcaacgacaacgaccccgaggacttcaaggtgt acaacgtgacctacatgggccccaccctgagactggccgccagcaccctgaagagcggcgccagctacagcgcc agagtgagagcctgggcccagacctacaacagcacctggagcgactggagccccagcaccacctggctgaacta ctacgagccctgggagcagcacctgcccctgggcgtgagcatcagctgcctggtgatcctggccatctgcctgagc tgctacttcagcatcatcaagatcaagaagggctggtgggaccagatccccaaccccgcccacagccccctggtg gccatcgtgatccaggacagccaggtgagcctgtggggcaagagaagcagaggccaggagcccgccaagtgcc cccactggaagacctgcctgaccaagctgctgccctgcctgctggagcacggcctgggcagagaggaggagagccccaagaccgccaagaacggccccctgcagggccccggcaagcccgcctggtgccccgtggaggtgagcaagac catcctgtggcccgagagcatcagcgtggtgcagtgcgtggagctgagcgaggcccgtggacaacgagg aggaggaggtggaggaggacaagagaagcctgccccagcctggagggcgggcggcgcttccaggagg gcagagagggcatcgtggccagactgaccgagagcctgttcgctgctgggcggcgagaacggcggctct gccccagggcctggaggagagctgcccccccgcggcgtgggccgcccgcctgggccgc cagccccacccagagccccggcgcgcgacaacccgcctacag aagcttcggcgctctcgggccagagcgccggcggc Petition 870250121500, of 30 / 12 / 2025, p. 112 / 160 97 / 138 ccggcgaggccgaccccggcatccccagcgccccccagccccccgagccccccgccgccctgcagcccgagccc gagagctgggagcagatcctgagacagagcgtgctgcagcacagagccgcccccgcccccggccccggccccgg cagcggctacagagagttcacctgcgccgtgaagcagggcagcgcccccgacgccggcggccccggcttcggcc ccagcggcgaggccggctacaaggccttctgcagcctgctgcccggcggcgccacctgccccggcaccagcggcg gcgaggccggcagcggcgagggcggctacaagcccttccagagcctgacccccggctgccccggcgcccccacc cccgtgcccgtgcccctgttcaccttcggcctggacaccgagccccccggcagcccccaggacagcctgggcgccg gcagcagccccgagcacctgggcgtggagcccgccggcaaggaggaggacagcagaaagaccctgctggcccc cgagcaggccaccgaccccctgagagacgacctggccagcagcatcgtgtacagcgccctgacctgccacctgtg cggccacctgaagcagtggcacgaccaggaggagagaggcaaggcccacatcgtgcccagcccctgctgcggct gctgctgcggcgacagaagcagcctgctgctgagccccctgagagcccccaacgtgctgcccggcggcgtgctgc tggaggccagcctgagccccgccagcctggtgcccagcggcgtgagcaaggagggcaagagcagccccttcagc cagcccgccagcagcagcgcccagagcagcagccagacccccaagaagctggccgtgctgagcaccgagccca cct gcatgagcgccagc Full-length α protein of canine IL-4 receptor with signal sequence in bold font (SEQ ID NO: 2). MGRLCSGLTFPVSCLVLVWVASSGSVKVLHEPSCFSDYISTSVCQWKMDHPTNCSA ELRLSYQLDFMGSENHTCVPENREDSVCVCSMPIDDAVEADVYQLDLWAGQQLLWSGSF QPSKHVKPRTPGNLTVHPNISHTWLLMWTNPYPTENHLHSELTYMVNVSNDNDPEDFK VYNVTYMGPTLRLAASTLKSGASYSARVRAWAQTYNSTWSDWSPSTTWLNYYEPWEQH LPLGVSISCLVILAICLSCYFSIIKIKKGWWDQIPNPAHSPLVAIVIQDSQVSLWGKRSRGQEP AKCPHWKTCLTKLLPCLLEHGLGREEESPKTAKNGPLQGPGKPAWCPVEVSKTILWPESIS VVQCVELSEAPVDNEEEEVEEDKRSLCPSLEGSGGSFQEGREGIVARLTESLFLDLLGGEN GGFCPQGLEESCLPPPSGSVGAQMPWAQFPRAGPRAAPEGPEQPRRPESALQASPTQSA GSSAFPEPPPVVTDNPAYRSFGSFLGQSSDPGDGDSDPELADRPGEADPGIPSAPQPPEPP AALQPEPESWEQILRQSVLQHRAAPAPGPGPGSGYREFTCAVKQGSAPDAGGPGFGPSG EAGYKAFCSLLPGATCPGTSGGEAGSGEGGYKPFQSLTPGCPGAPTPVPVPLFTFGLDTE PPGSPQDSLGAGSSPEHLGVEPAGKEEDSRKTLLAPEQATDPLRDDLASSIVYSALTCHLCG Petition 870250121500, dated 12 / 30 / 2025, pp. 113 / 160 98 / 138 HLKQWHDQEERGKAHIVPSPCCGCCCGDRSSLLLSPLRAPNVLPGGVLLEASLSPASLVPS GVSKEGKSSPFSQPASSSAQSSSQTPKKLAVLSTEPTCMSAS Mature full-length protein of canine IL-4 receptor without signal sequence (SEQ ID NO: 4) VKVLHEPSCFSDYISTSVCQWKMDHPTNCSAELRLSYQLDFMGSENHTCVPENREDSVCV CSMPIDDAVEADVYQLDLWAGQQLLWSGSFQPSKHVKPRTPGNLTVHPNISHTWLLM WTNPYPTENHLHSELTYMVNVSNDNDPEDFKVYNVTYMGPTLRLAASTLKSGASYSARV RAWAQTYNSTWSDWSPSTTWLNYYEPWEQHLPLGVSISCLVILAICLSCYFSIIKIKKGWW DQIPNPAHSPLVAIVIQDSQVSLWGKRSRGQEPAKCPHWKTCLTKLLPCLLEHGLGREEES PKTAKNGPLQGPGKPAWCPVEVSKTILWPESISVVQCVELSEAPVDNEEEEEVEEDKRSLC PSLEGSGGSFQEGREGIVARLTESLFLDLLGGENGGFCPQGLEESCLPPPSGSVGAQMPW AQFPRAGPRAAPEGPEQPRRPESALQASPTQSAGSSAFPEPPPVVTDNPAYRSFGSFLGQS SDPGDGDSDPELADRPGEADPGIPSAPQPPEPPAALQPEPESWEQILRQSVLQHRAAPAP GPGPGSGYREFTCAVKQGSAPDAGGPGFGPSGEAGYKAFCSLLPGGATCPGTSGGEAGS GEGGYKPFQSLTPGCPGAPTPVPVPLFTFGLDTEPPGSPQDSLGAGSSPEHLGVEPAGKEE DSRKTLLAPEQATDPLRDDLASSIVYSALTCHLCGHLKQWHDQEERGKAHIVPSPCCGCCC GDRSSLLLSPLRAPNVLPGGVLLEASLSPASLVPSGVSKEGKSSPFSQPASSSAQSSSQTPKKL AVLSTEPTCMSAS Mature full-length DNA of canine IL-4 receptor without signal sequence (SEQ ID NO: 3) gtgaaggtgctgcacgagcccagctgcttcagcgactacatcagcaccagcgtgtgccagtggaagatgg accaccccaccaactgcagcgccgagctgagactgagctaccagctggacttcatgggcagcgagaaccacacct gcgtgccccgagaacagagaggacagcgtgtgcgtgtgcagcatgcccatcgacgacgccgtggaggccgacgtg taccagctggacctgtgggccggccagcagctgctgtggagcggcagcttccagcccagcaagcacgtgaagccc agaacccccggcaacctgaccgtgcaccccaacatcagccacacctggctgctgatgtggaccaacccctacccc accgagaaccacctgcacagcgagctgacctacatggtgaacgtgagcaacgacaacgaccccgaggacttcaa ggtgtacaacgtgacctacatgggccccaccctgagactggccgccagcaccctgaagagcggcgccagctaca Petition 870250121500, dated 12 / 30 / 2025, pp. 114 / 160 99 / 138 gcgccagagtgagagcctgggcccagacctacaacagcacctggagcgactggagccccagcaccacctggctg aactactacgagccctgggagcagcacctgcccctgggcgtgagcatcagctgcctggtgatcctggccatctgcc tgagctgctacttcagcatcatcaagatcaagaagggctggtgggaccagatccccaaccccgcccacagccccc tggtggccatcgtgatccaggacagccaggtgagcctgtggggcaagagaagcagaggccaggagcccgccaa gtgcccccactggaagacctgcctgaccaagctgctgccctgcctgctggagcacggcctgggcagagaggagga gagccccaagaccgccaagaacggccccctgcagggccccggcaagcccgcctggtgccccgtggaggtgagca agaccatcctgtggcccgagagcatcagcgtggtgcagtgcgtggagctgagcgaggcccccgtggacaacgag gaggaggaggaggtggaggaggacaagagaagcctgtgccccagcctggagggcagcggcggcagcttccag gagggcagagagggcatcgtggccagactgaccgagagcctgttcctggacctgctgggcggcgagaacggcgg cttctgcccccagggcctggaggagagctgcctgcccccccccagcggcagcgtgggcgcccagatgccctgggc ccagttccccagagccggccccagagccgcccccgagggccccgagcagcccagaagacccgagagcgccctgc aggccagccccacccagagcgccggcagcagcgccttccccgagcccccccccgtggtgaccgacaaccccgcct acagaagcttcggcagcttcctgggccagagcagcgaccccggcgacggcgacagcgaccccgagctggccgacagacccggcgaggccgaccccggcatccccagcgccccccagccccccgagccccccgccgccctgcagcccga gcccgagagctgggagcagatcctgagacagagcgtgctgcagcacagagccgcccccgcccccggccccggcc ccggcagcggctacagagagttcacctgcgccgtgaagcagggcagcgcccccgacgccggcggccccggcttc ggccccagcggcgaggccggctacaaggccttctgcagcctgctgcccggcggcgccacctgccccggcaccagc ggcggcgaggccggcagcggcgagggcggctacaagcccttccagagcctgacccccggctgccccggcgcccc cacccccgtgcccgtgcccctgttcaccttcggcctggacaccgagccccccggcagcccccaggacagcctgggc gccggcagcagccccgagcacctgggcgtggagcccgccggcaaggaggaggacagcagaaagaccctgctgg cccccgagcaggccaccgaccccctgagagacgacctggccagcagcatcgtgtacagcgccctgacctgccacc tgtgcggccacctgaagcagtggcacgaccaggaggagagaggcaaggcccacatcgtgcccagcccctgctgc ggctgctgctgcggcgacagaagcagcctgctgctgagccccctgagagcccccaacgtgctgcccggcggcgtg ctgctggaggccagcctgagccccgccagcctggtgcccagcggcgtgagcaaggagggcaagagcagcccctt cagccagcccgccagcagcagcgcccagagcagcagccagacccccaagaagctggccgtgctgagcaccgag cccacctgcatgagcgccagc Canine IL-4 receptor α-chain extracellular protein domain Petition 870250121500, dated 12 / 30 / 2025, pp. 115 / 160 100 / 138 without the signal sequence (SEQ ID NO: 6): VKVLHEPSCFSDYISTSVCQWKMDHPTNCSAELRLSYQLDFMGSENHTCVPENRED SVCVCSMPIDDAVEADVYQLDLWAGQQLLWSGSFQPSKHVKPRTPGNLTVHPNISHTWL LMWTNPYPTENHLHSELTYMVNVSNDNDPEDFKVYNVTYMGPTLRLAASTLKSGASYSA RVRAWAQTYNSTWSDWSPSTTWLNYYEPWEQHLP Canine IL-4 receptor α-strand extracellular DNA domain without signal sequence (SEQ ID NO: 5): gtgaaggtgctgcacgagcccagctgcttcagcgactacatcagcaccagcgtgtgccagtggaagatgg accaccccaccaactgcagcgccgagctgagactgagctaccagctggacttcatgggcagcgagaaccacacct gcgtgcccgagaacagagaggacagcgtgtgcgtgtgcagcatgcccatcgacgacgccgtggaggccgacgtg taccagctggacctgtgggccggccagcagctgctgtggagcggcagcttccagcccagcaagcacgtgaagccc agaacccccggcaacctgaccgtgcaccccaacatcagccacacctggctgctgatgtggaccaacccctacccc accgagaaccacctgcacagcgagctgacctacatggtgaacgtgagcaacgacaacgaccccgaggacttcaa ggtgtacaacgtgacctacatgggccccaccctgagactggccgccagcaccctgaagagcggcgccagctaca gcgccagagtgagagcctgggcccagacctacaacagcacctggagcgactggagccccagca ccacctggctgaactactacgagccctgggagcagcacctgccc Domínio extracelular de cadeia α de receptor de IL-4 canino com um cterminal 8 HIS Tag (SEQ ID NO: 8): VKVLHEPSCFSDYISTSVCQWKMDHPTNCSAELRLSYQLDFMGSENHTCVPENRED SVCVCSMPIDDAVEADVYQLDLWAGQQLLWSGSFQPSKHVKPRTPGNLTVHPNISHTWL LMWTNPYPTENHLHSELTYMVNVSNDNDPEDFKVYNVTYMGPTLRLAASTLKSGASYSA RVRAWAQTYNSTWSDWSPSTTWLNYYEPWEQHLPHHHHHHHH Canine IL-4 receptor α-chain extracellular DNA domain with a c-terminal 8 HIS Tag (SEQ ID NO: 7): gtgaaggtgctgcacgagcccgcttcagcgactacatcagcaccacgtgtgccagtggaagatgg accaccccaccaactgcagcgccgagctgagactgagctaccagctggacttcatgggcagcgagaaccacacct gcgtgcccgagaacagagaggacggtgtgcgtgtgcagcatgcccatcgacgacgcgtggaggcgacgtg Petition 870250121500, of 30 / 12 / 2025, p. 116 / 160 101 / 138 taccagctgacctgtgggccggccagcagctgtggcggcgcttccagcccagcagcacgtgaagccc agaacccccggcaacctgaccgtgcaccccaacatcagccacacctgctgctgatgtggaccaaccctacc accgagaaccacctgcacagcgacctgacctacatggtgaacgtgagcaacgaacgacccgagacttcaa ggtgtacaacgtgacctacatgggccccaccctgagactggccgccagcaccctgaagagcggcgcctaca gcgccagagtgagagcctgggcccagacctacaacagcacctggagcgactggagccccagcaccacctgg aactactacgagccctgggagcagcacctgccccaccaccaccaccaccaccaccac Canine IL-4 plus human IgG1 Fc receptor α-chain extracellular domain (SEQ ID NO: 10): VKVLHEPSCFSDYISTSVCQWKMDHPTNCSAELRLSYQLDFMGSENHTCVPENRED SVCVCSMPIDDAVEADVYQLDLWAGQQLLWSGSFQPSKHVKPRTPGNLTVHPNISHTWL LMWTNPYPTENHLHSELTYMVNVSNDNDPEDFKVYNVTYMGPTLRLAASTLKSGASYSA RVRAWAQTYNSTWSDWSPSTTWLNYYEPWEQHLEPKSCDKTHTCPPCPAPELLGGPSVF LFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYR VVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQ VSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNV FSCSVMHEALHNHYTQKSLSLSPG K Canine IL-4 receptor extracellular α-chain DNA domain plus human IgG1 Fc (SEQ ID NO: 9): gtgaaggtgctgcacgagcccagctgcttcagcgactacatcagcaccagcgtgtgccagtggaagatgg accaccccaccaactgcagcgccgagctgagactgagctaccagctggacttcatgggcagcgagaaccacacct gcgtgcccgagaacagagaggacagcgtgtgcgtgtgcagcatgcccatcgacgacgccgtggaggccgacgtg taccagctggacctgtgggccggccagcagctgctgtggagcggcagcttccagcccagcaagcacgtgaagccc agaacccccggcaacctgaccgtgcaccccaacatcagccacacctggctgctgatgtggaccaacccctacccc accgagaaccacctgcacagcgagctgacctacatggtgaacgtgagcaacgacaacgaccccgaggacttcaa ggtgtacaacgtgacctacatgggccccaccctgagactggccgccagcaccctgaagagcggcgccagctaca gcgccagagtgagagcctgggcccagacctacaacagcacctggagcgactggagccccagcaccacctggctg aactactacgagccctgggagcagcacctggagcccaagagctgcgacaagacccacacctgccccccctgcccc Petition 870250121500, dated 12 / 30 / 2025, pp. 117 / 160 102 / 138 gccccgagctgggcggccccagcgtgttcctgttccccccaagcccaaggacaccctgatgatcagcagaa ccccgaggtgacctgcgtggtggtggacgtgagcca gcgtggaggtgcaacgccaagaccaagcccagagaggcagtacaacagcacctacagagtggtgagcgt gctgaccgtgctgcaccaggactggctgaacggcaaggagtacaagtgcaaggtgagcaacaaggccctgcg cccccatcgagagaccatcagcaagccaagggccagcccagagagccccaggtgtacaccctgcccccgc agagacgagctgaccaagaaccaggtgagcctgcctggtgaagggcttctaccccagcgacatcgcgtg gagtgggagagcaacggccagcccgaacaactacaagaccaccccccgtgctggacagcgacggcgct tcttcctgtacagcaagctgaccgtggacaagacagatggcagggcaacgtgttcagctgcagcgtgatgc acgaggccctgcacaacc EXAMPLE 2 MURINE ANTI-CANINE IL-4 RECEPTION ALPHA CHAIN ANBODIES Generation of antiCanine IL-4 receptor alpha chain antibodies
[00185] A total of three Balb / c mice were immunized multiple times (with 10 μg each time) over a period of 17 days. The immunizing antigen was the extracellular domain of canine IL-4 R-chain alpha (ECD) and human Fc fusion protein. After immunization, serum was collected from each mouse and tested for reactivity with the HIS-tagged protein of canine IL-4 receptor ECD alpha chain. Mouse spleen cells with the highest titer of anti-IL-4 receptor ECD alpha chain in serum were fused into the P3X63Ag8.653 myeloma cell line. Approximately 2 weeks after fusion, supernatant from putative hybridoma cells was tested by ELISA for its reactivity to the HIS-tagged protein of IL-4 receptor ECD alpha chain. Hybridomas producing strong positive signals in ELISA were subcloned by limiting dilution and retested for reactivity to the HIS-tagged protein of the ECD receptor alpha chain. Petition 870250121500, dated 12 / 30 / 2025, pp. 118 / 160 103 / 138 IL-4 canine. Confirmation of reactivity of monoclonal antibodies against the α chain of the canine IL-4 receptor.
[00186] The reactivity of antibodies secreted by hybridomas to ECD of canine IL-4 receptor alpha chain was confirmed by ELISA. Hybridoma cells were cultured using CELLine bioreactors (Integrabiosciences) for 10–30 days. Cells were initially maintained in DMEM supplemented with 4 mM L-glutamine and fetal bovine serum at 10% Ultra Low IgG (FBS) from Gibco. Hybridoma cells were seeded in CELLine bioreactor cell chambers at a cell density of approximately 2 x 10⁶ cells / mL in 15 mL of the same medium with the FBS concentration increased to 20%. The outer chamber was filled with 1 L of nutrient medium (DMEM with 4 mM L-glutamine and 2% standard FBS). Hybridoma cells in the cell chamber were expanded to approximately 2.5 x 10⁷ cells / mL in 3–7 days. Then, 10 mL of the cell suspension were collected from the cell chamber and exchanged for fresh medium to allow for cell re-expansion and subsequent harvesting.These procedures were repeated as needed to obtain appropriate amounts of mAb from each hybridoma clone. Collected cell suspensions were centrifuged and the supernatants were filtered through 0.2 µm filter membranes. For antibody purification, each clone supernatant was purified using a 5 mL Protein G Sepharose 4 (GE Healthcare) fast-flow column by gravity flow. After washing with Tris-EDTA (TE) buffer pH 8.0, bound antibodies were eluted using 0.1 M glycine buffer, pH 2.7, followed by pH neutralization using 1 M Tris, pH 8.0. Antibodies were concentrated and buffer exchanged in phosphate-buffered saline (PBS) using Centriprep YM-10 kDa NMWL centrifugal filter units (Millipore). Antibody concentrations were quantified using... Petition 870250121500, dated 12 / 30 / 2025, pp. 119 / 160 104 / 138 spectrophotometry. Canine anti-IL-4 receptor α chain mAbs were tested for reactivity with the HIS-tagged ECD domain of canine IL-4 receptor alpha chain by ELISA as follows: HIS-tagged canine IL-4 receptor alpha chain protein is diluted to 10 pg / mL in coating buffer (Carbonate / Bicarbonate pH 9.0) and distributed 100 µl / well in 96-well flat-bottom ELISA plates (NUNC). The plates are incubated at 4°C overnight. The plates are then washed three times with phosphate-buffered saline containing 0.05% Tween-20 (PBST). Next, 200 µl of blocking buffer (5% skim milk PBST) is added to each well and the plates are incubated at 37°C for 60 minutes. The plates are then washed three times with PBST. Next, 100 pl of mAbs test diluted in blocking buffer is added to the first cavities of the appropriate columns.The test mAbs are then diluted three times to the appropriate plate position. After incubating the plates at 37°C for 60 minutes, the plates are washed three times with PBST. Next, 100 µl per well of a 1:2000 dilution of a horseradish peroxidase-conjugated goat anti-mouse IgG (KPL) are added to the plates, which are then incubated at 37°C for 60 minutes. Then, the plates are washed three times with PBST and 100 µl / well of 3,3,5,5-tetramethylbenzidine (TMB) substrate (of KPL) is added to the plates. The color reaction is allowed to develop for 5–20 minutes at 37°C before absorbance measurement at 650 nm.
[00187] Several mouse ^-48α anti-canine monoclonal antibodies (mAbs) were tested by ELISA for their ability to bind to the extracellular domain of canine ^-48α. As shown in Figure 1, most of these mAbs exhibited a positive dose-dependent binding. EXAMPLE 3 Petition 870250121500, dated 12 / 30 / 2025, pp. 120 / 160 105 / 138 IDENTIFICATION OF THE PREDICTED DNA AND PROTEIN SEQUENCES OF THE VARIABLE DOMAINS OF HEAVY AND LIGHT CHAINS OF ANTI-CANINE IL-4 RECEPTOR ALPHA CHAIN MONOCLONAL ANTIBODIES
[00188] Mouse VH and VL DNA sequences are identified after mRNA isolation from each hybridoma using standard molecular biology methods. As SEQ ID NOs., the predicted VH and VL DNA and amino acid sequences of these hybridomas are listed below. The DNA encoding the signal sequence and the amino acids corresponding to the predicted signal sequence are underlined, those corresponding to the CDRs are in bold, and FRs are neither underlined nor in bold (i.e., signal sequence-FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4). mAb 1A3 Heavy chain: DNA sequence (SEQ ID NO: 11): ATGGACTCCAGGCTCAATTTAGTTTTCCTTGTCCTTATTTTAAAAGGTGTCCGGTG TGAGGTGCAGCTGGTGGAGTCTGGGGAGACTTAGTGAAGCCTGGAGGGTCCCTGAA ACTCTCCTGTGCAGCCTCTGGATTCACTTTCAGTGACTTTGGAATGCACTGGGTTCGTC AGGCTCCAGAGAAGGGGCTGGGGTGGGTTGCATACATTAGTAGTGGCAGTGGTACC ATCTACTATGCAGACAGTGAGGGGCCGATTCACCATCCAGAGACAATGTCAAG AACACCCTGTTCCTGCAAATGACCAGTCTGAGGTCTGAGGACACGGCCATGTTACT GTGTAAGGGGGGACCTTTACTACGGTTAGTTTCGATGCTTATTGGGGCCGAGGGA CTCTGGTCACTGTCTCTGCA Heavy chain: Amino acid sequence (SEQ ID NO: 12): MDSRLNLVFLVLILKGVRCEVQLVESGGDLVKPGGSLKLSCAASGFFSDFGMHWV RQAPEKGLGWVAYISSGSGTIYADTVRGRFTISRDNVKNTLFLQMTSLRSEDTAMYYCV RGDLYYGSSFDAYWGRGTLVTVSA Light Chain: DNA Sequence (SEQ ID NO: 13): ATGGATTTTCAAGTGCAGATTTTCAGCTTCCTGCTAATCAGTGCTTCAGTCATAAT Petition 870250121500, of 30 / 12 / 2025, p. 121 / 160 106 / 138 GTCCAGAGGACAAATTGTTCTCTCCCAGTCTCCAGCAATCCTGTCTGCATCTCCAGGGG AGAAGGTCACAATGACTTGCAGGGCCAGCTCAAGTGTAAGTTTCATGTTCTGGTACCA GCAGAAGCCAGGATCCTCCCCCAAACCCTGGATTTATGACACATCCAACCTGGCTTCT GGAGTCCCTGCTCGCTTCAGTGGCAGTGGGTCTGGGACCTCTTACTCTCTCACAATCAG CAGAGTGGAGGCTGAAGATGCTGCCACTTATTACTGCCAGCAGTGGAGTAGTAACCC ACTCAC GTTCGGTGCTGGGACCAAGCTGGAGCTGAAA Light chain: Amino acid sequence (SEQ ID NO: 14): MDFQVQIFSFLLISASVIMSRGQIVLSQSPAILSASPGEKVTMTCRASSSVSFMFWYQ QKPGSSPKPWIYDTSNLASGVPARFSGSGSGTSYSLTISRVEAEDAATYYCQQWSSNPLTF GAGTKLELK mAb 1A9 Heavy Chain: DNA Sequence (SEQ ID NO: 15): ATGGAATGGCCTTGTATCTTTCTCTTCCCCTGTCAGTAACTGAAGGTGTCCACTC CCAGGTTCCGCTGCAGCAGTCTGGACCTGAGCTGGTGAAGCCTGGGGCCTCAGTGAA GATTTCCTGCAAGGCTTCTGGCTACGCATTCAGTAGCTCCTGGATGACTGGGTGAAG CAGAGGCCTGGAAAGGGTCTTGAGTGGATTGGACGGATTTATCCTGGAGATGGAGAT ACTAAGTACAATGGGAAGTTCAAGGGCAAGGCCACACTGACTGCAGACAAATCCTCC AGCACAGCCTACATGCAACTCAGCAGCCTGACATCGGAGGACTCTGCGGTTTACTTCTCT GTGCAAGAGATGATTACGACGAGGCTTCCTGGGGCCAAGGGACTCTGGTCACTGTCT CTGCA Heavy chain: Amino acid sequence (SEQ ID NO: 16): MEWPCIFFLLSSVTEGVHSQVPLQQSG PE LVKPGASVKISC KASGYAFSSSWM N WV KQRPGKGLEWIGRIYPGDGDTKYNGKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYFCA RDDYDEASWGQGTLVTVSA Light Chain: DNA Sequence (SEQ ID NO: 17): ATGGGCATCAAGATGGAGTTTCAGACCAGGTCTTTGTATTCGTGTTGCTCTGGT TGTCTGGTGTTGATGGAGACATTGTGATGACCCAGTCTCAAAATTCATGTCCACATCA Petition 870250121500, of 30 / 12 / 2025, p. 122 / 160 107 / 138 GTAGGAGACAGGGTCAGCATCACCTGCAAGGCCAGTCAGAATGTTCGTTCTGCTGTA GCCTGGTATCAACAGAAACCAGGGCAGTCTCCTAAATCACTGATTTACTGGCATCCAA CCGGCACACTG GAGTCCCTGATCG CTTCACAGGCAGTG GATCTGGGACAGATTTCACT CTCACCATTAGCAATGTGCAATCTGAAGACCTGGCAGATTATTTCTGTCTGCAATCTTG GAATTATCCATTCACGTTCGGCTCGGGACAAAGTTGGAAATAAAA Light chain: Amino acid sequence (SEQ ID NO: 18): MGICMEFQTQVFVFVLLWLSGVDGDIVMTQSQKFMSTSVGDRVSITCCASQNVRS AVAWYQQKPGQSPKSLIYLASNRHTGVPDRFTGSGTDFTLTISNVQSEDLADYFCLQH WNYPFTFGSGTKLEIK mAb 1B12 Heavy Chain: DNA Sequence (SEQ ID NO: 19): ATGGGATGGAGCTGGATCTTTCTCTTTCTCCTGTCAGGAACTGCAGGTGTCCTCT CTGAGGTCCAGCTGCAACAATCTGGACCTGAGCTGGTGAAGCCTGGGGCTTCAGTGA AGATATCCTGTAAGGCTTCTGGATACACGTTCACTGACTATTACATGAACTGGGTGAACT GCAGAGCCATGGAAAGAGCCTTGAGTGGATTGGAGACATTATTCCTAGCAATGGTGG TACTAGCTACAACCAGAAGTTCAAGGGCAAGGCCACATTGACTGTAGACAAGTCCTCC AGCGCAGCCTACATGGAGCTCCGCAGCCTGACATCTGAGGACTCTGCAGTCTATTACT GTGCAAGAGGGATCAGCTACTATGGTAACCGATATTACTTTACTATGGACTATTGGG GTCAAGGAACCTCAGTCACC GTCTCCTCA Heavy chain: Amino acid sequence (SEQ ID NO: 20): MGWSWIFLFLLSGTAGVLSEVQLQQSG PE LVKPGASVKISC KASGYTFTDYYM NW VKQSHGKSLEWIGDIIPSNGGTSYNQKFKGKATLTVDKSSSAAYMELRSLTSEDSAVYYCA RGISYYG N RYYFTM DYWGQGTSVTVSS Light chain: DNA sequence (SEQ ID NO: 21): ATGAGGTGCCTAGCTGAGTTCCTGGGGCTGCTTGTGCTCTGGATCCCTGGAGCC ATTGGGGATATTGTGATGACTCAGGCTGCACCCTCTGTACCTGTCACTCCTGGAGAGTC AGTATCCATCTCCTGCAGGTCTAGTAAGAGTCTCCTGCATAGTAATGGCAACACTTAC Petition 870250121500, dated 12 / 30 / 2025, pp. 123 / 160 108 / 138 TTGTTTTGGTTCGTGCAGAGGCCAGGCCAGTCTCCTCAGCTCCTGATATATCGGATGTC CAACCTTGCCTCAGGAGTCCCAGACAGGTTCAGTGGCAGTGGGTCAGGAACTGCTTTC ACACTGAGAATCAGTAGAGTGGAGGCTGAGGATGTGGGTGTTTATTACTGTATGCAA CATCTAGA ATATCCATTCACGTTCGGCTCGGGGACAAAGTTGGACATAAAA Light chain: Amino acid sequence (SEQ ID NO: 22): MRCLAEFLGLLVLWIPGAIGDIVMTQAAPSVPVTPGESVSISCRSSKSLLHSNGNTYL FWFVQRPGQSPQLLIYRMSNLASGVPDRFSGSGSGTAFTLRISRVEAEDVGVYYCMQHLE YPFTFGSGTKLDIK mAb 10C12 Heavy Chain: DNA Sequence (SEQ ID NO: 23): ATGGAATGGAGCTGGATCTTTCTCTTCCTCCTGTCAGTAACTGCAGGTGTTCCAAT CCCAGGTTCAACTGCAGCAGTCTGGGGCTGAGCTGGTGAGGCCTGGGGCTTCAGTGA AGCTGTCCTGCAAGGCTTCGGGCTACACATTTACTGACTATGAAATGCACTGTGTGTGAA GCAGACACCTGTGCACGGCCTGGAATGGATTGGAGCTATTGATCCTGAAACTTGTGG TACTGCCTACAATCAGAAGTTCAAGGGCAAGGCCACACTGACTGCAGAAATCCTCC AGCACAGCCTACATGGAGCTCCGCAGCCTGACATCTGAGGACTCTGCCGTCTATTACT GTACAAGATCGAAACTGGGACGAGGGTGGTACTTCGATGTCTGGGGCACAGGGACC ACGGTCACCGTCTCCTCCA Heavy chain: Amino acid sequence (SEQ ID NO: 24): MEWSWIFLFLLSVTAGVQSQVQLQQSGAELVRPGASVKLSCCASGYTFTDYEMHC VKQTPVHGLEWIGAIDPETCGTAYNQKFKGKATLTADKSSSTAYMELRSLTSEDSAVYCT RSKLGRGWYFDVWGTGTGTTVTVSS Light Chain: DNA Sequence (SEQ ID NO: 25): ATGGAATCACAGACCAGGTCCTCATGTTTCTTCTGCTCTGGGTATCTGGTGCCT GTGCAGACATTGTGACAGTCTCCATCCCTCCCTGGCTATGTCAGTAGGACAGAA GGTCACTATGAGCTGCAAGTCCAGTCAGCCTTTAATAGTAGCAATCAATCAAAAGAA CTATTTGGCCTGGTACCAGCAGAAACCAGGACAGTCTCCTAAACTTCTGGTATACTTTG Petition 870250121500, of 30 / 12 / 2025, p. 124 / 160 109 / 138 CATCCACTAGGGAATCTGGGGTCCCTGATCGCTTCATAGGCAGTGGATCTGGGACAG ATTTCACTCTTACCATCAGCAGTGCAGGCTGAAGACCTGGCAGATTACTCTCTGTCAG CAACATT ATAGCACTCCGTACACGTTCG GAGGGGG GACCAAG CTGGAAATAAAAAA Light chain: Amino acid sequence (SEQ ID NO: 26): MESQTQVLMFLLLWVSGACADIVMTQSPSSLAMSVGQKVTMSCKSSQSLLNSSN QKNYLAWYQQKPGQSPKLLVYFASTRESGVPDRFIGSGSGTDFTLTISSVQAEDLADYFCQ QHYSTPYTFGGGTKLEIK mAb 10F2 Heavy Chain: DNA Sequence (SEQ ID NO: 27): ATGGCTGTCCTGGCACTGCTCCTCTGCCTGGTGACATTCCCAAACTGTGTCCTGTC CCAG GTG CACCTGAAG GAGTCAG GACCTGGCCTG GTGGCGCCCTCACAGAGCCTGTC CATCACATGCACTGTCTCAGGGTTCTCTTTAACCAGCTATGGTGTAAGCTGGGTTCGCC AGCCTCCAGGAGAGGGTCTGGAGTGGCTGGGAGTAATATGGGGTGACGGGAGCACA TATTTTCATTCAGCTCTTCATATCCAGACTGAGCATCAAGCAAGGATGACTCCAAGAGCCA AGTTTTCTTAAAATTGAACAGTCTACAAACTGATGACAGCCACGTACTACTGTGCCA AACAAGGGACGATCTATGATGGTTACTACAACTATGCTATGGACTACTGGGGTCAAG GAACCTCAGTCACCGTCTC CTCA Heavy chain: Amino acid sequence (SEQ ID NO: 28): MAVLALLLCLVTFPNCVLSQVH LKESG PG LVAPSQSLSITCTVSG FSLTSYGVSWVRQ PPGEGLEWLGVIWGDGSTYFHSALISRLSISKDDSKSQVFLKNSLQTDDTATYYCAKQGTI YDGYYNYAMDYWGQGTSVTVSS Light Chain: DNA Sequence (SEQ ID NO: 29): ATGGATTCACAGGCCCAGGTTCTTATGTTACTGCTGCTATGGGTATCTGGTACCT GTGGGGACATTGTGATGTCACAGTCTCCATCCTCCCTAACTGTGTCAGTTGGAGAGAA GGTTACTATGAGCTGCAAGTCCAGTCAGAACCTTTTATGGTGGCAATCAATCAAAAGAA CTACTTGGCCTGGTACCAGCAGAAACCAGGGCAGTCTCCTAAACTGCTGATTTACTGG GCATCCACTAGGGAATCTGGGGTCCCTGATCGCTTCACAGGCAGTGGATCTGGGACA Petition 870250121500, of 30 / 12 / 2025, p. 125 / 160 110 / 138 GATTTCACTCTCACCATCAGCAGTGTGAGGGCTGAAGACCTGGCAGTTTATTACTGTCA GCAATATTA TGACTATCCGTACACGTTCGGAGGGGGGACCAAGCTGGAAATAAAA Light chain: Amino acid sequence (SEQ ID NO: 30): MDSQAQVLMLLLLWVSGTCCGDIVMSQSPSSLTVSVGEKVTMSCKSSQNLLYGGNQ KNYLAWYQQKPGQSPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVRAEDLAVYYCQ QYYDYPYTFGGGTKLEIK mAb 10E10 Heavy Chain: DNA Sequence (SEQ ID NO: 31): ATGGGATGGAGCTGGATCTTTCTCTTCCTCCTGTCAGGAACTGCAGGTGTTCCACT CCCAGGTTCAGCTGCAGCAGTCTGGACCTGAGCTGGTGAAGCCTGGGGCTTCAGTGA AGTTGTCCTGCAAGGCTTCTGGCTACACCTTCACAACCTACGATACACTGGGTGACACT GCAGAGGCCTGGGCAGGGCCTTGAGTGGATTGGATGGATTTATCCTAGAGATGGTCG TACTACTTACAATGAGAAGTTCAAGGCCAAGGCCACATTGACTGTAGACACATCCTCC ACCACAGCGTACATGGAGCTCCACAGCCTGACCTGAGGACTCTGCGGTCTGATTG TGCGATTGATTG AGTAGCCCCTTTGGCTACTGGGGCCAAGGCACCACTCTCACAGTCTCCTCA Heavy chain: Amino acid sequence (SEQ ID NO: 32): MGWSWIFLLSGTAGVHSQVQLQQSGPELVKPGASVKLSCCASGYTFTTTYDIHWV KQRPGQGLEWIGWIYPRDGRTTYNEKFKAKATLTVDTSSTTAYMELHSLTSEDSAVYFCA RSSPFGYWGQGTTLTVSS Light Chain: DNA Sequence (SEQ ID NO: 33): ATGAAGTTTCCTTCTCCAACTTCTGCTCTTCCTGCTGTTCAGAATCACAGGCATAAT ATGTGACATCCAGATGACAATCTTCATCCTACTGTCTGTATCTCTAGGAGGCAGAG TCACCATTACTTGCAAGGCAAGTGACCACATTAAATTGGTTAGCCTGGTATCAGCA GAAACCAGGAAATGCTCCTAGGCTCTTAATATCTGGTGCAACCAGTTTGGAAACTGGG GTTCCTTCAAGATTCAGTGGCAGTGGATCTGGAAAGGATTACTCTCAGCATTACCA GTCTTCAGACTGAAGATGCTGCTACTTATCACTGTCACCAGTATTGGAGTAGTATTTCCAGTTCC CGGAGGGGGACCAAGGTGGAAATAAAA Petition 870250121500, of 30 / 12 / 2025, p. 126 / 160 111 / 138 Light chain: Amino acid sequence (SEQ ID NO: 34): MKFPSQLLLFLLFRITGIICDIQMTQSSSYLSVSLGGRVTITCKASDHINNWLAWYQQ KPGNAPRLLISGATSLETGVPSRFSGSGSGKDYTLSITSLQTEDAATYHCHQYWSIPYTFGG GTKVEIK mAb 10G8 Heavy Chain: DNA Sequence (SEQ ID NO: 35): ATGGAATGGAGCTGGGTCTTTCTCTTCCTCCCTGTCAGTAATTGCAGGTGTCCAAT CCCAGGTTCAACTGCAGCAGTCTGGGGCTGAGCTGGTGGGGCCTGGGGCTTCAGTGA CGCTGTCCTGCAAGGCTTCGGGCTACACATTTACTGACTATGAAATGGCACTGGGTGACTGGAGCTGGTGGGGCCTGGGGCTTCAGTGA GCAGACACCTGTGCATGGCCTGGAATGCATTGGAGCTATTGATCCTGAAACTGGTGG TACTGCCTACAATCAGAAGTTCAAGGGCAAGGCCATACTGACTGCAGACAAATCCTCT AGCACAGCCTACATGGAGCTCCGCAGCCTGACATCTGAGGACTCTGCCGTCTTACTG GGTTTGACTACTGGGGCCAAGGCACCACTCTCACAGTCTCCTCA Heavy chain: Amino acid sequence (SEQ ID NO: 36): MEWSWVFLFLLSVIAGVQSQVQLQQSGAELVGPGASVTLSCKASGYTFTDYEMH WVKQTPVHGLECIGAIDPETGGTAYNQKFKGKAILTADKSSSTAYMELRSLTSEDSAVYYC LTGFDYWGQGTTLTVSS Light Chain: DNA Sequence (SEQ ID NO: 37): ATGGATTTTCAGGTGCAGATTTTCAGCTTCCTGCTAATCAGTGTCTCAGTCATAAT GTCCAGAGGACAAATTGTTCTCACCCAGTCTCCAG CAATCATGTCTG CATCTCCTGGGG AGAAGGTCACCTTGACCTGCAGTGCCAGCTCAAGTGAATTCCAGCTACTTGTACTG GTACCAGCAGAAGCCAGGATCCTCCCCCAAACTCTGGATTTATAGCACATCCAACCTG GCTTCTGGAGTCCCTGCTCGCTTCAGTGGCAGTGGGTCTGGGACCTTACTCTCAC AATCAGCAGCATGGAGGCTGAAGATGCTGCCTCTTATTTCTGCCATCAGTTAGGAGGTACGTACG TACACGTTCGGAGGGGGACCAAGCTGGAAATAAAA Light chain: Amino acid sequence (SEQ ID NO: 38): MDFQVQIFSFLLISVSVIMSRGQIVLTQSPAIMSASPGEKVTLTCSASSSVNSSYLYWY Petition 870250121500, of 30 / 12 / 2025, p. 127 / 160 112 / 138 QQKPGSSPKLWIYSTSNLASGVPARFSGSGSGTSYSLTISSMEAEDAASYFCHQWSSYPYT FGGGTKLEIK mAb 11B6 Heavy Chain: DNA Sequence (SEQ ID NO: 39): ATGATGGTGTTAAGTCTTCTGTACCTGTTGACAGCCCTTCCGGGTATCCTGTCAG AGGTGCAGCTTCAGGAGTCAGGACCTGGCCTGGCAAAACCTTCTCAGACTCTGTCCCT CACCTGTTCTGTCACTGGCTACTCCATCACCAGTGATTACTGGAACTGGATCCGGAAT TCCCAGGGAATAAACTTGAATACATGGGGTACATAAACTACAGTGGTAACACTTACTA CAATCCATCTCTCAAAAGTCGAATCTCCATAACTCGAGACATCCAAACCAGTATT ACCTGCAATTGAATCTGTGACTACTGAGGACACAGCCACGTTACTGTGCAAGATAT GGGGGATTACGACAGGGTTCCTGGCACTTCGATGTCTGGGGCCCAGGGACCACGGTC ACCGTCTCCTCA Heavy chain: Amino acid sequence (SEQ ID NO: 40): MMVLSLLYLLTALPGILSEVQLQESGPGLAKPSQTLSLTCSVTGYSITSDYWNWIRKF PGNKLEYMGYINYSGNTYYNPSLKSRISITRDTSKNQYYLQLNSVTTEDTATYYCARYGGLR QGSWHFDVWGPGTTVTVSS Light Chain: DNA Sequence (SEQ ID NO: 41): ATGGATTTTCAGGTGCAGATTTTCAGCTTCCTGCTAATCAGTGCCTCAGTCATAAT GTCCAGAGGACAAATTGTTCCACCAGTCTCCAGCAATCATGCATCTCCAGGGG AGAAGGTCACCATATCCTGCAGTGCCAGCTCAAGTGTAAGTTACATGTACTGGTACCA GCAGAAGCCAGGATCCTCCCCCAAACCCTGGATTTATCGCACATCCAACCTGGCTTCTG GAGTCCCTGCGCGCTTCAGTGGCAGTGGGTCTGGGACCTCTTACTCTCTCAATCAGC AGCATGGAGGCTGAAGATGCTGCCACTTTACTGCCAGCAGTATCATAGTTACCTACCAGTACCATCAGC GTTCGGTGGAGGCACCAAGCTGGAAATCAAA Light chain: Amino acid sequence (SEQ ID NO: 42): MDFQVQIFSFLLISASVIMSRGQIVLTQSPAIMSASPGEKVTISCSASSSVSYMYWYQ QKPGSSPKPWIYRTSNLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCQQYHSYPATF Petition 870250121500, of 30 / 12 / 2025, p. 128 / 160 113 / 138 GGGTKLEIK mAb 11D3 Heavy Chain: DNA Sequence (SEQ ID NO: 43): ATGGGTTGGCTGTGGAACTTGCTATTCCTGATGGCAGCTGCCCAAAGTGCCCAA GCACAGATCCAGTTGGTACAGTCTGGACCTGAGCTGAAGAAGCCTGGAGAGACAGTC AAGATCTCCTGCAAGGCTTCTGGGTATATCTTCACAACCTATGGAATGTACTGGGTGA AACAGGCTCCAGGAAAGGGTTTAAAGTGGATGGGCTGGATAAACACCTACTCTGGAG TGCCAACATATGTTGATGACTTCAAGGGACGGTTTGCCTTCTCTTTGGAAACATCTGCC AGCACTGCCTATTTGCAGATCAACTCTCAAATGAGGACACGGCTACATTAGTTTTTTTT GCCGGGTGGTTTGCTTACTGGGGCCAAGGGACTCTGGTCACTGTCTCTGCA Heavy chain: Amino acid sequence (SEQ ID NO: 44): MGWLWNLLFLMAAAQSAQQIQLVQSGPELKKPGETVKISCKASGYIFTTYGMYW VKQAPG KG LKWMG WINTYSGVPTYVDDFKG RFAFSLETSASTAYLQIN N LKNEDTATYF CVVAGWFAYWGQGTLVTVSA Light Chain: DNA Sequence (SEQ ID NO: 45): ATGGACATGAGGACCCCCTGCTCAGTTTCTTGGAATCTTGTTGCTCTGGTTTCCAG GTATCAAATGTGACATCAAGATGACCCAGTCTCCATCTTTCCATGCATCTCTAGGA GAGAGAGTCACTATCACTTGCAAGGCGAGTCAGGACATTAAGAGCTATTTAAGCTGG TTCCAGCAGAAACCAGGGAAATCTCCTAAGACCCTGATCTATCGTGCAAATATTGA TAGATGGGGTCCCATCAAGGTTCAGTGGCAGTGGATCTGGGCAAGATTATTCTCTCAC CATCAGCAGCCTGGAGTATGAAGATATGGGAATTTTATTGTCTACAATATGATTCCGCAG GTTCGCAG GTTGCAG CTG GAAATAAAA Light chain: Amino acid sequence (SEQ ID NO: 46): MDMRTPAQFLGILLLWFPGIKCDIKMTQSPSSMYASLGERVTITCKASQDIKSYLSW FQQKPGKSPKTLIRANILIDGVPRSRFSGSGQDYSLTISSLEYEDMGIYYCLQYDEFPYTF GGGTKLEIK mAb 11H2 Petition 870250121500, of 30 / 12 / 2025, p. 129 / 160 114 / 138 Heavy Chain: DNA Sequence (SEQ ID NO: 105) ATGAACTTGGGGCTCAGCTTGATTTTCCTTGTCCTTGTTTTAAAAGGTGTCCAGTG TGACGTGAAGCTGGTGGAGTCTGGGGGAGGCTTAGTGCAGCCTGGAGGGTCCCTGAA ACTCTCCTGTGCAGCCTCTGGATTCACTTTCAGTGACTATTACATGTATTGGGTTCGCC AGACTCCAGAGAAGAGACTGGAGTGGGTCGCATATGTTAGTAGTGGTGGTGGTAGT ATCTATTATCCAGACACTGTAAAGGGCCGATTCACCATCTCCAGAGACAATGCCAAGA ACACCCTGTATTTGCAAATGAGCCGTCTGAAGTCTGAGGACACAGCCATGTATTACTGT GCAAGGCATGGGTCCCCCTTCGGTAGTAGCCGAGGGGCCTGGTTTGCTTACTGGGGC CAGGGGACTCTGGTCACTGTCTCTGCA Cadeia pesada: Sequência de aminoácido (SEQ ID NO: 106) MNLGLSLIFLVLVLKGVQCDVKLVESGGGLVQPGGSLKLSCAASGFTFSDYYMYWV RQTPEKRLEWVAYVSSGGGSIYYPDTVKGRFTISRDNAKNTLYLQMSRLKSEDTAMYYCA RHGSPFGSSRGAWFAYWGQGTLVTVSA Cadeia leve: Sequência de DNA (SEQ ID NO: 107) ATGAGTGTG CCCACTCAG GTCCTG GGGTTG CTG CTG CTGTG G CTTACAG GTGCC AGATGTGACATCCAGATGACTCAGTCTCCAGCCCTCCCTGTCTGCATCTGTGGGAGAAA CTGTCACCATCACATGTCGAGCAAGTGAGAATATTTACAGTTATTCAGGGTTATTTA GCAGAAACAGGGAAAATCTCCTCAGCTCCTGGTCTATAATGCAAAAACCTTAGCAGA GGGTGTGCCATCAAGGTTCAGTGGCAGTGGATCAGGCACACAGTTCTCTGAAGATC AACAGCCCTGCAGCCTGAAGATTTTGGGAATTACTGTCAACATGATGGTTTTCC GTTCACGTTCGGTGGTGGGACCAAGCTGGAGCTGAAA Light chain: Amino acid sequence (SEQ ID NO: 108) MSVPTQVLG LLLLWLTGARCDIQMTQS PASLSASVG ETVTITCRASENIYSYLAWYQ QKQGKSPQLLVYNAKTLAEGVPSRFSGSGSGTQFSLKINSLQPEDFGNYYCQHYDGFPFTF GGGTKLELK mAb 6C12 Heavy Chain: DNA Sequence (SEQ ID NO: 109) Petition 870250121500, of 30 / 12 / 2025, p. 130 / 160 115 / 138 ATGGGTTGGCTGTGGAACTTGCTATTCCTGATGGCAGCTGCCCAAAGTGCCCAA GCACAGATCCAGTTGATACAGTCTG GACCTGAGCTGAAGAAG CCTG GAGAGACAGTC AAGATCTCCTGCAAGGCTTCTGGGTATACCTTCACAACCTTTGGAATGAGCTGGGTGA AACAGGCTCCAGGAAAGGGTTTAAAGTGGATGGGCTGGATAAGCACCTACTCTGGAG TGCCAACATATGCTGATGACTTCAAGGGACGGTTTGCCTTCTCTTTGGAAACCTCTGCC AGCACTGCCTATTTGCAGATCAACAACCTCAAAAATGAGGACACGGCTTCATATTTCTG TGCAAGACACACCTTCCAAAGTCGCGGGTTGGCTTACTGGGGCCAAGGGACTCTGGT CACTGTCTCTGCA Cadeia pesada: Sequência de aminoácido (SEQ ID NO: 110) MGWLWNLLFLMAAAQSAQAQIQLIQSG PELKKPGETVKISC KASGYTFTTFGMSW VKQAPG KG LKWMG WISTYSGVPTYADDFKG RFAFSLETSASTAYLQIN N LKNEDTASYFC ARHTFQSRGLAYWGQGTLVTVSA Cadeia leve: Sequência de DNA (SEQ ID NO: 111) ATGGGCATCAAAATGGAGTCACAGATTCAGGTCTTTGTATTCGTGTTTCTCTGGT TGTCTGGTGTTGACGGAGACATTGTGATGACCCAGTCTCACAAATTCATGTCCACATCA GTAGGAGACAGGGTCAGCATCACCTGCAAGGCCAGTCAGGATGTGATTACTACTGTA GCCTGGTATCAACAGAAACCAGGACAATCTCCTAAACTACTGATTTACTCGGCATCCTA CCGGTACACTGGAGTCCCTGATCGCTTCACTGGCAGTGGATCTGGGACGGATTTCACT TTCACCATCACCAGTGTGCAGACTGAAGACCTGGCAGTTTATTACTGTCAGCAACATTA TAGTAC TCCGTGGACGTTCGGTGGAGGCACCAAGCTGGAAATCAAA Light chain: Amino acid sequence (SEQ ID NO: 112) MGIKMESQIQVFVFVFLWLSGVDG DIVMTQSHKFMSTSVGDRVSITCCASQDVITT VAWYQQKPGQSPKLLIYSASYTGVPDRFTGSGSGTDFTFTITSVQTEDLAVYYCQQHYS TPWTFGGGTKLEIK mAb 4H3 Heavy Chain: DNA Sequence (SEQ ID NO: 113) ATGGGATGGAGCTGTATCATGCTCTTCTTGGCAGCAACAGCTACAGGTGTCCACT Petition 870250121500, of 30 / 12 / 2025, p. 131 / 160 116 / 138 CCCAGGTCCAACTGCAGCAGCCTGGGGCTGAGCTTGTGAAGCCCTGGGGCTTCAGTGA AGCTGTCCTGCAAGGCTTCTGGCTACACCTTCACCAACTACTGGATACACTGGATGAA G CAGAG GCCTGGACGAGG CCTTGAGTG GATTG GAAGGATTGATCCGGTGTAGTA GTACTAAGTACAATGAGAAGTTCAAGAGCAAGGCCACACTGACTGTCGACAAACCCT CCATCACAGCCTACATGCAGCTCAGCAGCTGACATCTGAGGACTCTGCGGTCTATTAT TGTGCAGCATTCGGTAGTACCTACGGGTTTGCTTACTGGGGCCAAGGGACTCTGGTCTCA CTGCTCA Heavy chain: Amino acid sequence (SEQ ID NO: 114) MGWSCIMLFLAATATGVHSQVQLQQPGAELVKPGASVKLSCCASGYTFTNYWIH WMKQRPGRGLEWIGRIDPNSGGTKYNEKFKSKATLTVDKPSITAYMQLSSLTSEDSAVYY CAAFGSTYGFAYWGQGTLVTVSA Light chain: DNA sequence (SEQ ID NO: 115) ATGGATTCACAGGCCCAGGTTCTTATATTGCTGCTGCTATGGGTATCTGGTACCT GTGGGGACATTGTGATGTCACAGTCTCCATCCCTCCCTGGCTGTCAGCAGGAGAGAA GGTCACTATGAGTTGCAAATCCAGTCAGCTGCTCAACAGTAGAACCCGAAAGAA CTACTTGGCTTGGTACCAGCAGAAACCAGGGCAGTCTCCTAAACTGCTGATCTACTGG GCATCCACTAGGGAATCTGGGGTCCCTGATCGCTTCACAGGCAGTGGATCTGGGACA GATTTCACTCTCACCATCAGCAGTGCAGGCTGAAGACCTGGCAGTTTTAGCCATTAGCTTAGCTATTAGCTATTAGGGCTGATCGGACA GAGGGGGGACCAAG CTG GAAATAAAA Light chain: Amino acid sequence (SEQ ID NO: 116) MDSQAQVLILLWVSGTCCGDIVMSQSPSSLAVSAGEKVTMSCKSSQSLLNSRTRC NYLAWYQQKPGQSPKLLIYWASTRESGVPDRFTGSGTDFTLTISSVQAEDLAVYYCKQS YNLYTFGGGTKLEIK mAb 4D8 Heavy Chain: DNA Sequence (SEQ ID NO: 117) ATGAACTTGGGGCTCAGCTTGATTTTCCTTGTCCTTGTTTTAAAAGGTGTCCAGTG TGAAGTGACGCTGGTGGAGTCTGGGGGAGGCTTAGTGCAGCCTGGAGGGTCCCTGAA Petition 870250121500, of 30 / 12 / 2025, p. 132 / 160 117 / 138 ACTCTCCTGTGCAGCCTCTGGATTCACTTTCAGTGACTATTACATGTATTGGGTTCGCC AGACTCCAGAGAAGAGGCTGGAGTGGGTCGCATACATTAGTCCTGGTGGTGGTAGCA CCTATTATCCGGACACTATAAAGGGCCGATTCACCATCCAGAGACAATGCCAAGAA CACCCTGTACCTGCAAATGAGCCGTCTGAAGTCTGAGGACACAGCCATGTATTACTGTA CAAGACATGGGTCCCCCTACGGTAGTAGTCGAGGGCCTGGTTTGCTTACTGGGGCC AAGGGACTCTGGTCACT GTCTCTGCA Heavy chain: Amino acid sequence (SEQ ID NO: 118) MNLGLSLIFLVLVLKGVQCEVTLVESGGGLVQPGGSLKLSCAASGFTFSDYYMYWVR qtpekrlewwayispgggstyypdtikgrftisrdnakntlylqmsrlksedtamyyctrh GSPYGSSRGAWFAYWGQGTLVTVSA Light chain: DNA sequence (SEQ ID NO: 119 ) ATGAGTGTG CCCACTCAG GTCCTG GGGTTG CTG CTG CTGTG G CTTACAG GTGCC AGATGTGACATCCAGATGACTCAGTCTCCAGCCTCCCTATCTGCATCTGTGGGAGAAAC TGTCACCATCACATGTCGAGCAAGTGAGAATATTTACAGTTATTTAGCATGGTATCAG CAGAAACAGGGAAAATCTCCTCAGCTCCTGGTCTATAATGGAAAAACCTTAGCAGAA GGTGTGCCAGCAAGGTTCAGTGGCAGTGGATCAGGCACACAGTTTTCCTGAAGATCA ACAGCCTACAGCCTGAAGATTTTGGGAGTTATTACTGTCAACATCATGATGGTATTCC GGTCACGT TCGGTGCTGGACCAAGCTGGAGCTGAAA Light chain: Amino acid sequence (SEQ ID NO: 120) mAb 2E2 Heavy chain: DNA sequence (SEQ ID NO: 121) ATGAACTTGGGGCTCAGCTTGATTTTCCTTGTCCTTGTTTTAAAAGGTGTCCAGTG TGAAGTGAAGCTGGTGGAGTCGGGGGGAGGCTTAGTGCAGCCTGGAGGGTCCCTGA AACTCTCCTGTGTAGCCTCTGGATTCACTTTCAGTGACTATCACATGCATTGGGTTCGC Petition 870250121500, dated 12 / 30 / 2025, pp. 133 / 160 118 / 138 CAGACTCCAGAGAAGAGGCTGGAGTGGGTCGCATACATTAGTAAAGGTGGTGGTAG CACCTATTATCCAGACACTGAAAAGGGCCGATTCACCATCTCCAGAGACAATGCCAAG AATACCCTGTACCTGCAAATGAGCCGTCTGAAGTCTGAGGACACAGCCATGTATTACT GTG CAAGATCCCCCGGCCCTAGTAGCTTCTACTGGTACTTCGATGTCTGGGGCACAG G G ACCACGGTCACCGTCTCCTCA Cadeia pesada: Sequência de aminoácido (SEQ ID NO: 122) MNLGLSLIFLVLVLKGVQCEVKLVESGGGLVQPGGSLKLSCVASGFTFSDYHMHWV RQTPEKRLEWVAYISKGGGSTYYPDTEKGRFTISRDNAKNTLYLQMSRLKSEDTAMYYCA RSPGPSSFYWYFDVWGTGTTVTVSS Cadeia leve: Sequência de DNA (SEQ ID NO: 123) ATGAGTGTG CCCACTCAG GTCCTG GGGTTG CTG CTG CTGTG G CTTACAG GTGCC AGATGTGACATCCAGATGACTCAGTCTCCAGCCTCCCTATCTGCATCTGTGGGAGAAAC TGTCACCATCACATGTCGAGCAAGTGAGAATATTTACAGTTATTTAGCATGGTATCAG CAGAAACAGGGAAAATCTCCTCAGCTCCTGGTCTATAATGCAAAAACCTTAGCAGAA GGTGTGCCATCAAGGTTCAGTGGCAGTGGATCAGGCACACAGTTTTCTCTGAAGATCA ACAGCCTGCAGCCTGAAGATTTTGGGAGTTATTACTGTCAACATCATTATGGTATTCCG GTCACGGTCGGTGTAGGGACCAAGCTGGAGCTGAAA Light chain: Amino acid sequence (SEQ ID NO: 124) MSVPTQVLG LLLLWLTGARCDIQMTQS PASLSASVG ETVTITCRASENIYSYLAWYQ QKQGKSPQLLVYNAKTLAEGVPSRFSGSGSGTQFSLKINSLQPEDFGSYYCQHHYGIPVTV GVGTKLELK EXAMPLE 4 CONSTRUCTION OF A CHO CELL LINE EXPRESSING CANINE IL-4 RECEPTOR ALPHA CHAIN AND USE IN LIGAND BLOCKADE ASSAYS
[00189] The gene encoding the alpha chain of the full-length canine IL-4 receptor (cIL-4Ra; SEQ ID NO: 4) was synthesized and subcloned in Petition 870250121500, dated 12 / 30 / 2025, pp. 134 / 160 119 / 138 mammalian expression vectors. The resulting plasmid was transfected into CHO DG44 cells. 48 hours post-transfection, the cells were diluted in 96-well plates to generate single-cell clones. Approximately 130 clones were obtained after 4 weeks of incubation. All clones were screened for cIL-4Ra expression by FACS using the anti-cIL-4Ra monoclonal antibody 6B2. Three clones were selected for stability assessment. Stability was monitored for 20 passages by FACS.
[00190] In order to evaluate the ability of canine IL-4 alpha receptor-specific monoclonal antibodies to block the binding of canine IL-4 alpha receptor to canine IL-4 expressed on the surface of CHO cells, a ligand-blocking assay was established as follows: Reagents and equipment: • Cell growth medium: CD OptiCHO medium + 8mM L-Glutamine + 0.018% F-68 • FACS Buffer: BD Pharmingen staining buffer (BD cat#: 554657) • Streptavidin conjugated to R-phycoerythrin (Life Technologies: SB66) • Canine IL-4 (R&D System, cat #754-CL / CF) • Lightning-Link Biotin Type A Conjugation Kit (Novus: 704-0010) used to biotillate canine IL-4 according to the manufacturer's recommendations • Flow cytometry: BD Accuri-C6 Procedure: 1. CHO-DH44-canIL-4Ra cells cultured at 2-4 x 10⁶ cells / mL with over 96% viability. 2. The cells were rotated, the supernatant discarded, and the Petition 870250121500, dated 12 / 30 / 2025, pp. 135 / 160 120 / 138 cells were suspended in FACS buffer at 2 x 107 cells / mL. 3. The cells were distributed in a 96-well U-shaped plate, 50 pl per well. 4. The anti-canine IL-4Ra mAbs in FACS buffer was triple-diluted in a 96-well plate from top to bottom of the well, starting at 50 pg / mL. 5. 50 pl of each diluted Ab was transferred to the cell plate and then incubated on ice for 30 min. 6. The cells were washed twice with FACS buffer. 7. The cells were resuspended in 100 pg canine IL-4 debiotinylated at 0.32 pg / mL in FACS buffer and incubated on ice for 30 min. 8. The cells were washed twice with FACS buffer. 9. The cells were placed in 100 µl of streptavidin conjugated to R-phycoerythrin (1:1000 dilution) in FACS buffer and incubated on ice for 30 min. 10. The cells were washed twice with FACS buffer. 11. The cells were brought to 300 µl in FACS buffer. 12. 10,000 cells were ligated for each sample by BD. Accuri-C6. 13. The resulting reading was analyzed by FlowJo to obtain the mean fluorescent intensity (MFI).
[00191] The dose-response curve for canine IL-4 binding to canine IL4Ra expressed on the surface of CHO cells was obtained using a cell-based CHO-cIL-4Rα binding assay (see Figure 2A). A half-maximum effective concentration (EC50) of 25 nM was determined from this curve. The following are dose-response curves for CHO-cIL-4Rα binding by Petition 870250121500, dated 12 / 30 / 2025, pp. 136 / 160 121 / 138 mouse canine IL-4Ra monoclonal antibodies (mAbs): 11B6, 4D8, 4H3, 2E2, 11H2, and 6C12 were obtained (see Figure 2B). The half-maximal effective concentrations (EC50) for each of the antibodies are given in Table 2 below. TABLE 2 Connecting / blocking multiple mABS mABs EC50 (nM) IC50 (nM) 11B6 7.5 53.2 4D8 1.1 4.2 4H3 1.6 3.9 2E2 1.2 2.1 11H2 1.2 1.7 / 1.0* 6C12 8.6 19.3 *Determinations based on two separate studies
[00192] Mouse anti-canine IL-4Ra monoclonal antibodies (mAbs) were then tested for their ability to block canine IL-4 binding based on CHO-cIL-4R α cells. As shown in Figure 3A, the five mAbs, 11B6, 4D8, 4H3, 2E2, and 11H2, showed a significant blocking capacity. In a complementary study, a sixth mAbs was tested (6C12) and compared with one of the five mAbs tested (11H2) in Figure 3A. As evident from Figure 3B and Table 2, 6C12 mAbs has a significantly higher half-maximum inhibitory concentration (IC50) than 11H2 mAbs. Four of the anti-cIL monoclonal antibodies, 4Ra, 4D8, 2E2, 4D8, and 11H2, showed superior blocking capacity, as can be seen in Figures 3A and 3B, as well as in Table 2. EXAMPLE 5 AMINO ACID SEQUENCES OF MICE CDRS Petition 870250121500, dated 12 / 30 / 2025, pp. 137 / 160 122 / 138
[00193] CDRs of receptor α-chain monoclonal antibodies Mouse anti-canine IL-4: VL CDR-1 SEQ ID NO: 1A3Arg Ala Ser Ser Ser Val Ser Phe Met Phe47 1A9Lys Ala Ser Gln Asn Val Arg Ser Ala Val Ala48 1B12Arg Ser Ser Lys Ser Leu Leu His Ser Asn Gly Asn Thr Tyr Leu Phe49 10C12Lys Ser Ser Gln Ser Leu Leu Asn Ser Ser Asn Gln Lys Asn Tyr Leu Ala50 10F2Lys Ser Ser Gln Asn Leu Leu Tyr Gly Gly Asn Gln Lys Asn Tyr Leu Ala51 10E10Lys Ala Ser Asp His Ile Asn Asn Trp Leu Ala52 10G8Ser Ala Ser Ser Ser Val Asn Ser Ser Tyr Leu Tyr53 11B6Ser Ala Ser Ser Ser Val Ser Tyr Met Tyr54 11D3Lys Ala Ser Gln Asp Ile Lys Ser Tyr Leu Ser55 11H2 Arg Ala Ser Glu Asn Ile Tyr Ser Tyr Leu Ala129 6C12 Lys Ala Ser Gln Asp Val Ile Thr Thr Val Ala130 4D8 Arg Ala Ser Glu Asn Ile Tyr Ser Tyr Leu Ala129 4H3 Lys Ser Ser Gln Ser Leu Leu Asn Ser Arg Thr Arg Lys Asn Tyr Leu Ala131 2E2 Arg Ala Ser Glu Asn Ile Tyr Ser Tyr Leu Ala129 V L CDR-2 SEQ ID NO: 1A3Asp Thr Ser Asn Leu Ala Ser56 1A9Leu Ala Ser Asn Arg His Thr57 1B12Arg Met Ser Asn Leu Ala Ser58 10C12Phe Ala Ser Thr Arg Glu Ser59 10F2Trp Ala Ser Thr Arg Glu Ser60 10E10Gly Ala Thr Ser Leu Glu Thr61 10G8Ser Thr Ser Asn Leu Ala Ser62 11B6Arg Thr Ser Asn Leu Ala Ser63 11D3Arg Ala Asn Ile Leu Ile Asp64 11H2 Asn Ala Lys Thr Leu Ala Glu132 6C12 Ser Ala Ser Tyr Arg Tyr Thr133 4D8 Asn Gly Lys Thr Leu Ala Glu134 4H3 Trp Ala Ser Thr Arg Glu Ser60 2E2 Asn Ala Lys Thr Leu Ala Glu132 V L CDR-3 SEQ ID NO: 1A3Gln Gln Trp Ser Ser Asn Pro Leu Thr65 1A9Leu Gln His Trp Asn Tyr Pro Phe Thr66 1B12Met Gln His Leu Glu Tyr Pro Phe Thr67 10C12Gln Gln His Tyr Ser Thr Pro Tyr Thr68 10F2Gln Gln Tyr Tyr Asp Tyr Pro Tyr Thr69 10E10His Gln Tyr Trp Ser Ile Pro Tyr Thr70 10G8His Gln Trp Ser Ser Tyr Pro Tyr Thr71 11B6Gln Gln Tyr His Ser Tyr Pro Ala Thr72 11D3Leu Gln Tyr Asp Glu Phe Pro Tyr Thr73 11H2 Gln His Tyr Asp Gly Phe Pro Phe Thr135 6C12 Gln Gln His Tyr Ser Thr Pro Trp Thr136 Petição 870250121500, de 30 / 12 / 2025, pág. 138 / 160 123 / 138 4D8 Gln His His Asp Gly Ile Pro Val Thr137 4H3 Lys Gln Ser Tyr Asn Leu Tyr Thr138 2E2 Gln His His Tyr Gly Ile Pro Val Thr139 VH CDR-1 SEQ ID NO: 1A3Asp Phe Gly Met His74 1A9Ser Ser Trp Met Asn75 1B12Asp Tyr Tyr Met Asn76 10C12Asp Tyr Glu Met His77 10F2Ser Tyr Gly Val Ser78 10E10Thr Tyr Asp Ile His79 10G8Asp Tyr Glu Met His80 11B6Ser Asp Tyr Trp Asn81 11D3Thr Tyr Gly Met Tyr82 11H2 Asp Tyr Tyr Met Tyr140 6C12 Thr Phe Gly Met Ser141 4D8 Asp Tyr Tyr Met Tyr140 4H3 Asn Tyr Trp Ile His142 2E2 Asp Tyr His Met His143 VH CDR-2 SEQ ID NO: 1A3 Tyr Ile Ser Ser Gly Ser Gly Thr Ile Tyr Tyr Ala Asp Thr Val Arg Gly83 1A9 Arg Ile Tyr Pro Gly Asp Gly Asp Thr Lys Tyr Asn Gly Lys Phe Lys Gly84 1B12 Asp Ile Ile Pro Ser Asn Gly Gly Thr Ser Tyr Asn Gln Lys Phe Lys Gly85 10C12 Ala Ile Asp Pro Glu Thr Cys Gly Thr Ala Tyr Asn Gln Lys Phe Lys Gly86 10F2 Val Ile Trp Gly Asp Gly Ser Thr Tyr Phe His Ser Ala Leu Ile Ser87 10E10 Trp Ile Tyr Pro Arg Asp Gly Arg Thr Thr Tyr Asn Glu Lys Phe Lys Ala88 10G8 Ala Ile Asp Pro Glu Thr Gly Gly Thr Ala Tyr Asn Gln Lys Phe Lys Gly89 11B6 Tyr Ile Asn Tyr Ser Gly Asn Thr Tyr Tyr Asn Pro Ser Leu Lys Ser90 11D3 Trp Ile Asn Thr Tyr Ser Gly Val Pro Thr Tyr Val Asp Asp Phe Lys Gly91 11H2 Tyr Val Ser Ser Gly Gly Gly Ser Ile Tyr Tyr Pro Asp Thr Val Lys Gly144 6C12 Trp Ile Ser Thr Tyr Ser Gly Val Pro Thr Tyr Ala Asp Asp Phe Lys Gly145 4D8 Tyr Ile Ser Pro Gly Gly Gly Ser Thr Tyr Tyr Pro Asp Thr Ile Lys Gly146 4H3 Arg Ile Asp Pro Asn Ser Gly Gly Thr Lys Tyr Asn Glu Lys Phe Lys Ser147 2E2 Tyr Ile Ser Lys Gly Gly Gly Ser Thr Tyr Tyr Pro Asp Thr Glu Lys Gly148 VH CDR-3 SEQ ID NO: 1A3Gly Asp Leu Tyr Tyr Gly Ser Ser Phe Asp Ala Tyr92 1A9Asp Asp Tyr Asp Trp Ala Ser93 1B12Gly Ile Ser Tyr Tyr Gly Asn Arg Tyr Tyr Phe Thr Met Asp Tyr94 10C12Ser Lys Leu Gly Arg Gly Trp Tyr Phe Asp Val95 10F2Gln Gly Thr Ile Tyr Asp Gly Tyr Tyr Asn Tyr Ala Met Asp Tyr96 10E10Ser Ser Pro Phe Gly Tyr97 10G8Gly Phe Asp Tyr98 11B6Tyr Gly Gly Leu Arg Gln Gly Ser Trp His Phe Asp Val99 11D3 Ala Gly Trp Phe Ala Tyr100 11H2 His Gly Ser Pro Phe Gly Ser Ser Arg Gly Ala Trp Phe Ala Tyr149 Petition 870250121500, dated 12 / 30 / 2025, pp. 139 / 160 124 / 138 6C12 His Thr Phe Gln Ser Arg Gly Leu Ala Tyr 150 4D8 His Gly Ser Pro Tyr Gly Ser Ser Arg Gly Ala Trp Phe Ala Tyr 151 4H3 Phe Gly Ser Thr Tyr Gly Phe Ala Tyr 152 2E2 Ser Pro Gly Pro Ser Ser Phe Tyr Trp Tyr Phe Asp Val 153 TABLE 3 CANONICAL STRUCTURES L1 L2 L3 H1 H2 H3 1A3 L1-1 L2-1 L3-1 H1-1 H2-3A H3-12 1A9 L1-2A L2-1 L3-1 H1-1 H2-2A H3-7 1B12 L1-4 L2-1 L3-1 H1-1 H2-2B H3-15 10C12 L1-3 L2-1 L3-1 H1-1 * H3-11 10F2 L1-3 L2-1 L3-1 H1-1 H2-1 H3-15 10E10 L1-2A L2-1 L3-1 H1-1 H2-2B H3-6 10G8 L1-6 L2-1 L3-1 H1-1 H2-2B H3-4 11B6 L1-1 L2-1 L3-1 H1-1 H2-1 H3-13 11D3 L1-2A L2-1 L3-1 H1-1 H2-2A** H3-6 11H2 L1-6 L2-1 L3-1 H1-1 H2-3A H3-15 6C12 L1-6 L2-1 L3-1 H1-1 H2-2A H3-10 4D8 L1-6 L2-1 L3-1 H1-1 H2-3A H3-15 4H3 L1-3 L2-1 L3-3 H1-1 H2-3A H3-9 2E2 L1-6 L2-1 L3-1 H1-1 H2-3A H3-13 * Cisteína em uma CDR **A Melhor atribuição que pode ser feita em vista dorão particular. EXEMPLO 6 MAPEAMENTO OF ANTICORPOS OF RECEPTOR ALFA OF IL4 ANTI-CANINO OF MURINO
[00194] An anti-corpuscle interface with cognath-protein antigens mediates the content of specific amino acids from the anti-corpuscle (paratopus) with specific antigen (epitopos) amino acids. Petition 870250121500, dated 12 / 30 / 2025, pages 140 / 160 125 / 138 targets. An epitope is an antigenic determinant that causes a specific reaction by an immunoglobulin. An epitope consists of a group of amino acids on the surface of the antigen. The protein of interest may contain several epitopes that are recognized by different antibodies. The epitopes recognized by antibodies are classified as linear or conformational epitopes. Linear epitopes are formed by a continuous sequence of amino acids in a protein, while conformational epitopes are composed of amino acids that are discontinuous (i.e., spaced apart) in the primary amino acid sequence but are brought together in a three-dimensional protein duplication.
[00195] Epitope mapping refers to the process of identifying amino acid sequences (i.e., epitopes) that are recognized by antibodies on their target antigens. Identifying epitopes recognized by monoclonal antibodies (mAbs) on target antigens has important applications. For example, it can aid in the development of new therapeutics, diagnostics, and vaccines. Epitope mapping can also help in the selection of optimized therapeutic mAbs and help elucidate their mechanisms of action. Epitope information on IL-4 alpha receptors can also elucidate specific epitopes and define their protective and pathogenic effects on vaccines. Epitope identification can also lead to the development of subunit vaccines based on chemical or genetic coupling of the identified peptide epitope to a carrier protein or other immunostimulatory agents.
[00196] Epitope mapping can be performed using polyclonal or monoclonal antibodies, and various methods are employed for epitope identification depending on the suspected nature of the epitope (i.e., linear versus conformational). Mapping linear epitopes is more Petition 870250121500, dated 12 / 30 / 2025, pp. 141 / 160 126 / 138 direct and relatively easier to perform. For this purpose, commercial services for mapping linear epitopes frequently employ peptide scanning. In this case, a set of overlapping short peptide sequences of the target protein is chemically synthesized and tested for its ability to bind antibodies of interest. The strategy is fast, high-throughput, and relatively inexpensive to perform. On the other hand, mapping a discontinuous epitope is more challenging from a technical point of view and requires more specialized techniques, such as X-ray co-crystallography of a monoclonal antibody along with its target protein, Hydrogen-Deuterium (H / D) exchange, mass spectrometry coupled with enzymatic digestion, as well as several other methods known to those skilled in the art. Mapping canine IL-4 receptor alpha epitopes using mass spectrometry:
[00197] A method based on chemical crosslinking and mass spectrometry detection was employed to identify epitopes recognized by canine anti-IL-4 receptor alpha mAbs [CovalX Instrument Incorporated]. The application of this technology to mapping canine IL-4 receptor alpha chain epitopes resulted in the identification of mAb-recognized epitopes listed in Table 4.
[00198] The results of mapping canine IL-4 receptor alpha epitopes with the six antibodies included in Table 4 indicate that the mAbs recognize specific peptide epitopes that are present within the extracellular domain of the canine IL-4 receptor alpha. Notably, two to three epitopes were identified for each of the six monoclonal antibodies (mAbs) tested. Interestingly, one of the epitopes identified for mAbs 2E2 was found to have the exact same amino acid sequence as for mAbs 11B6 (i.e., SEQ ID NO: 158). Petition 870250121500, dated 12 / 30 / 2025, pp. 142 / 160 127 / 138 As shown in Table 4 below, mAbs: 4D8, 11H2, and 11B6 all recognize an epitope labeled with a 1 that is a portion of the same linear amino acid sequence; mAbs: 11H2, 4H3, and 2E2 all recognize an epitope labeled with a 2 that is a portion of another linear amino acid sequence; and mAbs 4H3 and 2H2 recognize an epitope labeled with a 3 that is a portion of the third linear amino acid sequence. This relative consistency in identifying the relevant epitopes indicates that these six monoclonal antibodies recognize a limited number of portions of the canine IL-4 alpha receptor within its extracellular domain. TABLE 4 IL-4 alpha receptor epitopes recognized by antibodies MONOCLONAL IL-4 ALPHA RECEPTOR ANTI-CANINE ANTIBODY SEQ ID NO: SEQUENCE EPIIOPO 4D8 125 126 SAELRLSYQLD FQPSKHVKPRT1 11H2 12 / 128 AGQQLLWSGSFQPSKHVKPR11 TLKSGASYS2 154 EDSVCVCSMPI3 4H3 155 156 MWTNPYPTENHL ASTLKSG2 11B6 15 / 158 WSGSFQPSKHVKPR1 VYNVTYMGPTLR 159 VLHEPSCFSDYISTSVCQ 2E2 160 161 ENREDSVCVCSMPI3 KSGASYSARVRAW2 6C12 158 162 VYNVIYMGPILR YYEPWEQHLP 1'2,3 identify three individual groups of epitopes arising from the three portions of the antigen.
[00199] Along with the CDRs given in Example 5 for the six antibodies listed in Table 4 above, a one-to-one relationship is defined between each set of CDRs and their corresponding epitopes in Table 4. This relationship allows a defined link between the set of 6 CDRs in Example 5 for each of the six antibodies in Table 4 and the corresponding epitopes. Petition 870250121500, dated 12 / 30 / 2025, pp. 143 / 160 128 / 138 that they bind. Consequently, antibodies (e.g., caninized antibodies) with the defined set of 6 CDRs given in Example 5 that bind to corresponding epitopes in Table 4 are also part of the present invention. EXAMPLE 7 CONSTRUCTION OF MONOCLONAL ANTIBODIES OF IL4 ALPHA RECEPTOR ANTI-CANINE CANINIZED
[00200] In order to perform the caninization process, the sequence of DNA encoding canine IgG heavy and light chains has been determined. The DNA and protein sequences of canine heavy and light chains are known in the art and can be obtained by searching the NCBI gene and protein databases. As indicated above, for canine antibodies there are four known IgG subtypes: IgG-A, IgG-B, IgG-C, and IgG-D, and two types of light chains, namely kappa and lambda. Without being tied to any specific approach, the general process of producing caninized heavy and light chains that can be mixed in different combinations to produce caninized anti-canine IL-4 alpha receptor mAbs involves the following scheme: i) Identify the DNA sequence of VH and VL domains comprising the desired CDRs of anti-IL-4 alpha receptor mAbs ii) Identify the CDRs of the desired H and L chains of anti-IL-4 receptor mAbs iii) Identify an appropriate sequence for the H and L chains of Canine IgG iv) Identify the DNA sequence encoding the endogenous CDRs of the H and L chains of canine IgG from the sequence above. (v) Replace the DNA sequence encoding strand CDRs Endogenous canine H and L cells with DNA sequences encoding receptor CDRs. Petition 870250121500, dated 12 / 30 / 2025, pp. 144 / 160 129 / 138 alpha anti-IL-4. Additionally, optionally replace some canine scaffold residues with selected residues from anti-IL-4 receptor mAb scaffold regions. vi) Synthesize the DNA from step (v), clone it into an appropriate expression plasmid and transfect the plasmids containing the desired caninized H and L strands into HEK 293 cells. vii) Purify caninized antibody expressed from HEK 293 supernatant. viii) Test the purified caninized antibody for binding to the alpha chain of a canine IL-4 receptor.
[00201] Applying the steps specified above resulted in a set of caninized H and L chain sequences for which SEQ ID NOs. are listed in Table 5 below. TABLE 5 CANINIZED FULL-LENGTH HEAVY AND LIGHT CHAIN SEQUENCES H chain or L chain Nucleic acid Amino acid vH1 SEQ ID NO: 163 SEQ ID NO: 164 vH2 SEQ ID NO: 165 SEQ ID NO: 166 vH3 SEQ ID NO: 167 SEQ ID NO: 168 vL1 SEQ ID NO: 169 SEQ ID NO: 170 vL2 SEQ ID NO: 171 SEQ ID NO: 172 vL3 SEQ ID NO: 173 SEQ ID NO: 174
[00202] The present invention provides caninized antibodies formed by combining various caninized heavy and light chains listed in Table Petition 870250121500, dated 12 / 30 / 2025, pp. 145 / 160 130 / 138 above; such antibodies have a particularly strong binding to the canine IL-4 alpha receptor. In one particular embodiment, the heavy chain comprises the amino acid sequence SEQ ID NO: 164 and the light chain comprises the amino acid sequence SEQ ID NO: 170. In a more particular embodiment of this type, the heavy chain is encoded by the nucleotide sequence SEQ ID NO: 163 and the light chain is encoded by the nucleotide sequence SEQ ID NO: 169. In another embodiment, the heavy chain comprises the amino acid sequence SEQ ID NO: 166 and the light chain comprises the amino acid sequence SEQ ID NO: 172. In a more particular embodiment of this type, the heavy chain is encoded by the nucleotide sequence SEQ ID NO: 165 and the light chain is encoded by the nucleotide sequence SEQ ID NO: 171.In yet another embodiment, the heavy chain comprises the amino acid sequence SEQ ID NO: 168 and the light chain comprises the amino acid sequence SEQ ID NO: 174. In a more particular embodiment of this type, the heavy chain is encoded by the nucleotide sequence SEQ ID NO: 167 and the light chain is encoded by the nucleotide sequence SEQ ID NO: 173. Binding studies for the IL-4 alpha receptor by these caninized antibodies are shown in Figure 4, as described in Example 8 below.
[00203] As indicated above, the Fc portion of caninized antibodies is based on modified canine IgG-B sequences in order to remove ADCC and CDC effector functions. The Fc regions of these antibodies can be exchanged with a modified Fc from other canine IgG isotypes and / or can be combined with surrogate hinge regions, as discussed above and exemplified and described in U.S. Provisional Application 62 / 030,812, filed July 30, 2014; U.S. Provisional Application 62 / 057,541, filed September 30, 2014; U.S. Provisional Application 62 / 092,496 Petition 870250121500, dated 12 / 30 / 2025, pages 146 / 160 131 / 138 filed on December 16, 2014; US Interim Application 62 / 172,511 filed on June 8, 2015; and WO 2015 / 091910, the contents of which are all incorporated herein by reference in their entirety. 4H3 caninized (vH1) SEQ ID NO: 163 GAGGTGCAGCTGGTGGAGAGCGGAGGCGACCTGGTGAAACCCGGAGGCAGCC TGAGACTGAG CTGTGTGGCCAG CGGCTACACCTTCACCAACTACTG GATTCATTGGGT GAGGCAGGCTCCCGGCAAAGGACTGCAGTGGGTGGCCAGGATTGATCCCAACAGCG GCGGCACCAAGTACAACGAGAAGTTCAAGAGCAGGTTCACCATCAGCAGGGACAACG CCAAGAACACCCTCTACCTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTA CTACTGCACCAGGTTCGGCAGCACCTACGGCTTCGCCTACTGGGGCCAAGGCACCCTG GTGACCGTGAGCAGCGCTTCCACAACCGCGCCATCAGTCTTTCCGTTGGCCCCATCATG CGGGTCGACGAGCGGATCGACTGTGGCCCTGGCGTGCTTGGTGTCGGGATACTTTCCC GAACCCGTCACGGTCAGCTGGAACTCCGGATCGCTTACGAGCGGTGTGCATACGTTCC CCTCGGTCTTGCAATCATCAGGGCTCTACTCGCTGTCGAGCATGGTAACGGTGCCCTCA TCGAGGTGGCCCTCCGAAACGTTCACATGTAACGTAGCACATCCAGCCTCCAAAACCA AGGTGGATAAACCCGTGCCGAAAAGAGAGAATGGGCGGGTGCCTCGACCCCCTGATT GCCCCAAGTGTCCGGCTCCGGAAATGCTCGGTGGACCCTCAGTGTTTATCTTCCCTCCG AAGCCCAAGGACACTCTGCTGATCGCGCGCACTCCAGAAGTAACATGTGTAGTGGTGG CACTTGATCCCGAGGACCCCGAAGTCCAGATCTCCTGGTTTGTAGATGGGAAACAGAT GCAGACCGCAAAAACTCAACCCAGAGAGGAGCAGTTCGCAGGAACATACCGAGTGGT ATCCGTCCTTCCGATTGGCCACCAGGACTGGTTGAAAGGGAAGCAGTTTACGTGTAAAGTCAACAATAAGGCGTTGCCTAGCCCTATTGAGCGGACGATTTCGAAAGCTAGGGGAC AGGCCCACCAGCCATCGGTCTATGTCCTTCCGCCTCCGCGAGGAGCTCTCGAAGAAT ACAGTGAGCCTTACATGCCTCATTAAGGATTTCTTCCCGCCTGATATCGACGTAGAGTG GCAATCAAACGGTCAACAGGAGCCGGAATCCAAGTATAGAACCACTCCGCCCCAGCTT GACAGGACGGATCATACTTTTTGTATTCAAAACTGTCGGTGGATAAGAGCCGGTGGC Petition 870250121500, of 30 / 12 / 2025, p. 147 / 160 132 / 138 AGAGAGGTGACACCTTCATCTGTGCGGTGATGCACGAAGCACTCCATAATCACTACAC CCAAGAGAGCCT CTCGCATTCCCCCGGAAAG SEQ ID NO: 164 EVQLVESGGDLVKPGGSLRLSCVASGYTFTNYWIHWVRQAPGKGLQWVARIDPNS GGTKYNEKFKSRFTISRDNAKNTLYLQMNSLRAEDTAVYYCTRFGSTYGFAYWGQGTLVT VSSASTTAPSVFPLAPSCGSTSGSTVALACLVSGFPEVGSWSVLTVSVLTV GLYSLSSSMVTVPSSRWPSETFTCNVAHPASKTKVDKPVPKRENGGRVPPPPDCPPKCPAPEM LGGPSVFIFPPKPKDTLLIARTPEVTCVVVALDPEDPEVQISWFVDGKQMQTACTQPREEQ FAGTYRVVVVLPPIGHQDWLKGKQFTQFTVPSKPPIQPQPQPQVQREGV ELSKNTVSLTCLIKDFFPPDIDVEWQSNGQQEPESKYRTTPPQLDEDGSYFLYSKLSVDKSR WQRGDTFICAVMHEALHNHYTQESLSHSPGK 4H3 Caninizado (vH2) SEQ ID NO: 165 AGGTGCAGCTGGTGGAGAGCGGCGGAGATCTGGTGAAGCCCGGCGGAAGCCT GAGACTGAGCTGTGTGGCCAGCGGCTACACCTTCACCAACTACTGGATTCATTGGGTG AGACAGGCCCCTGGCAAGGGCCTGCAGTGGATCGGCAGGATCGACCCCAACAGCGGC GGCACCAAGTACAACGAGAAGTTCAAGAGCAAGGCCACCCTGAGCGTGGACAAGGCC AAGAACACCCTGTACCTGCAGATGAACTCCCTGAGGGCCGAGGACACCGCCGTGTACT ACTGCGCCGCCTTTGGCAGCACCTACGGCTTCGCCTACTGGGGCCAGGGAACCCTGGT GACCGTGAGCAGCGCTTCCACAACCGCGCCATCAGTCTTTCCGTTGGCCCCATCATGCG GGTCGACGAGCGGATCGACTGTGGCCCTGGCGTGCTTGGTGTCGGGATACTTTCCCGA ACCCGTCACGGTCAGCTGGAACTCCGGATCGCTTACGAGCGGTGTGCATACGTTCCCC TCGGTCTTGCAATCATCAGGGCTCTACTCGCTGTCGAGCATGGTAACGGTGCCCTCATC GAGGTGGCCCTCCGAAACGTTCACATGTAACGTAGCACATCCAGCCTCCAAAACCAAG GTGGATAAACCCGTGCCGAAAAGAGAGAATGGGCGGGTGCCTCGACCCCCTGATTGC CCCAAGTGTCCGGCTCCGGAAATGCTCGGTGGACCCTCAGTGTTTATCTTCCCTCCGAA GCCCAAGGACACTCTGCTGATCGCGCGCACTCCAGAAGTAACATGTGTAGTGGTGGCA Petição 870250121500, de 30 / 12 / 2025, pág. 148 / 160 133 / 138 CTTGATCCGAGGACCCGAAGTCCAGATCTCCTGGTTGTTAGATGGGAAAACAGATGC AGACCGCAAAACTCAACCCAGAGAGGAGCAGTTCCGAGGAACATACCGAGTGGAT CCGTCCTTCCGATTGGGCCACAGGACTGGTTGAAAGGGAAGCAGTTTACGTGAAAGT CAACAATAAGGCGTTGCCTAGCCCTATTGAGCGGACGATTTCGAAAGCTAGGGGACA GGCCCACAGCCATCGGTCTTATGTCCTTCGCCCTTCCGCGAGAGACTCTCGAAGAATA CAGTGAGCCTTACATGCCTCATTAAGGATTTCTCCCGCCTGATATCGACGTAGAGTGG CAATCAAACGGTCAACAGAGCCGGAATCCAAGTATAGAACCACTCCGCCCAGCTTAG ACGAGGACGGATCATACTTTTTGTATTCAAAACTGTCGGTGGATAAGAGCCGGTGCA GAGAGGTGCACCTTCATCTGTGCGGTGATGCACGAAGCACTCCATAATCACTACAC CAGAGAGCCTCT CGCATTCCCCCGGAAAG SEQ ID NO: 166 EVQLVESGGDLVKPGGSLRLSCVASGYTFTNYWIHWVRQAPGKGLQWIGRIDPNS GGTKYNEKFKSKATLSVDKAKNTLYLQMNSLRAEDTAVYYCAAFGSTYGFAYWGQGTLVT VSSASTTAPSVFPLAPSCGSTCGSTVALAPVCGSTVGSCGSTVLSCGSTVLTV GLYSLSSSMVTVPSSRWPSETFTCNVAHPASKTKVDKPVPKRENGGRVPPPPDCPPKCPAPEM LGGPSVFIFPPKPKDTLLIARTPEVTCVVVALDPEDPEVQISWFVDGKQMQTACTQPREEQ FAGTYRVVVVLPPIGHQDWLKGKQFTQFTVPSKPPIQPQPQPQVQREGV ELSKNTVSLTCLIKDFFPPDIDVEWQSNGQQEPESKYRTTPPQLDEDGSYFLYSKLSVDKSR WQRGDTFICAVMHEALHNHYTQESLSHSPGK 4H3 CANINIZED (VH3): SEQ ID NO: 167 GAGGTGCAGCTGGTGGAGAGCGGCGGCGATCTGGTGAAGCCCTGGCGGAAGCCT GAGACTGAGCTGCGTGGCCAGCGGCTACACCTTCACCAACTACTGGATTCATTGGATG AGGCAGGCCCCTGGCAAGGGACTGCAGTGGATCGGCAGAATCGACCCCAAGCCAGGCCAGC GGCACCAAGTACAACGAGAAGTTCAAGAGCAAGGCCACCCTGAGCGTGGACAAGGCC AAGAACACCGCCTACATGCAGCTGAACAGCCCTGAGGGCCGAGGACACCGCCGTGTAC TACTGCGCCGCCTTTGGCAGCACCTACGGCTTCGCCTATTGGGGCCAGGGCACCCTGG TGACCGTGAGCAGCGCTTCCACAACCGCGCCATCAGTCTTTCCGTTGGCCCCATCATGC Petition 870250121500, of 30 / 12 / 2025, p. 149 / 160 134 / 138 GGGTCGACGAGCGGATCGACTGTGGCCCTGGCGTGCTTGGTGTCGGGATACTTTCCCG AACCCGTCACGGTCAGCTGGAACTCCGGATCGCTTACGAGCGGTGTGCATACGTTCCC CTCGGTCTTGCAATCATCAGGGCTCTCACTGCTGTCGAGCATGGTAACGGTGCCCTCAT CGAGGTGGCCTCCGAAACGTTCACATGTAACGTAGCACATCCAGCCTCCAAAAACCAA GGTGGATAACCCGTGCGAAAGAGAGAATGGCGGGTGCCTCGACCCCCTGATT CCCCAAGTGTCCGGCTCCGGAATGCTCGGTGGACCCTCAGTGTTTATCTTCCCTCCGA AGCCCAAGGACACTCTGCTGATCGCGCGCACTCCCAGAAGTAACATGTGTAGTGGTGGC ACTTGATCCCGAGGACCCCCGAAGTCCAGATCTCCTGGTTTGTAGATGGGAAACAGATG CAGACCGCAAAAACTCAACCCAGAGAGGAGCAGTTCGCAGGAACATACCGAGTGGTA TCCGTCCTTCCGATTGGCCACCAGGACTGGTTGAAAGGGAAGCTTCGTGTAAAG TCAACAATAAGGCGTTGCCTAGCCCTATTGAGCGGACGATTTCGAAAGCTAGGGGACA GGCCCACCAGCCATCGGTCTATGTCCCTCCGCCTTCCCGCGAGGAGCTCTCGAAGAATA CAGTGAGCCTTACATGCCTCATTAAGGATTTCTTCCCGCCTGATATCGACGTAGAGTGG CAATCAAACGGTCAACAGAGCCGGAATCCAAGTATAGAACCACTCCGCCCAGCTTTG ACGAGGACGGATCATACTTTTTGTATTCAAAACTGTCGGTGGATAAGACCCGGTGGA GAGAGGTGCACACCTTCATCTGTGCGGTGATGCACGAAGCACTCCATAATCACTACAC CAAGAGAGCCT CTCGCATTCCCCCGGAAAG SEQ ID NO: 168 EVQLVESGGDLVKPGGSLRLSCVASGYTFTNYWIHWMRQAPGKGLQWIGRIDPNS GGTKYNEKFKSKATLSVDKAKNTAYMQLNSLRAEDTAVYCAAFGSTYGFAYWGQGTLVT VSSASTTAPSVFPLAPSCGSTCGSTVALACLVSGFPVGSVPSVLSVLTV GLYSLSSSMVTVPSSRWPSETFTCNVAHPASKTKVDKPVPKRENGGRVPPPPDCPPKCPAPEM LGGPSVFIFPPKPKDTLLIARTPEVTCVVVALDPEDPEVQISWFVDGKQMQTACTQPREEQ FAGTYRVVVVLPPIGHQDWLKGKQFTQFTVPSKPPIQPQPQPQVQREGV ELSKNTVSLTCLIKDFFPPDIDVEWQSNGQQEPESKYRTTPPQLDEDGSYFLYSKLSVDKSR WQRGDTFICAVMHEALHNHYTQESLSHSPGK Caninized 4H3 (vL1) Petition 870250121500, of 30 / 12 / 2025, p. 150 / 160 135 / 138 SEQ ID NO: 169 GACATCGTGATGACCCAGACCCCCTCTGAGCCTGTCCGTGAGCCCTGGCGAACCT GCCAGCATCAG CTG CAAGAG CAG CCAGAG CCTG CTGAACAGCAG GACCAGGAAGAAC TACCTGGCCTGGTTCAGACAGAAGCCCGGCCAGAGCCCCCAGAGACTGATCTACTGGG CCAGCACCAGAGAGAGCGGCGTGCCTGACAGATTTAGCGGCAGCGGCAGCGGCACA GACTTCACCCTGAGGATCAGCAGAGTGGAGGCCGACGATGCCGGCGTGTACTACTGC AAGCAGAGCTACAACCTGTACACCTTCGGCCAGGGCACCAAGGTGGAGATCAAGAGG AACGACGCTCAGCCAGCCGTGTACCTCTTCCAGCCTTCGCCGGACCAGCTTCATACGG GGTCAGCGTCGGTGGTGTGCCTGTTGAACTCGTTTTACCCCAAGGACATTAACGTGAA GTGGAAGGTAGACGGGGTAATTCAAGACACTGGCATTCAAGAGTCCGTCACGGAACA AGACTCAAAAGACTCAACGTATTCACTGTCGTCAACCTTGACGATGTCAAGCACCGAGT ATCTTAGCCATGAGCTGTATTCGTGCGAGATCACCCACAAGTCCCTCCCCTCCACTCTTA TCAAATCCTTTCAGCGGTCGGAATGTCAGCGGGTCGA T SEQ ID NO: 170 DIVMTQTPLSLSVSPGEPASISCKSSQSLLNSRTRKNYLAWFRQKPGQSPQRLIYWAS TRESGVPDRFSGSGSGTDFTLRISRVEADDAGVYYCKQSYN LYTFGQGTKVEIKRN DAQPA VYLFQPSPDQLHTGSASVVCLLNSFYPKDINVKWKVDGVIQDTGIQESVTEQDSKDSTYSLS STLTMSSTEYLSHELYSCEITHKSLPSTLIKSFQ RSECQRVD 4H3 caninizado (vL2) SEQ ID NO: 171 GACATCGTGATGACCCAGACCCCTCTGAGCCTGAGCGTGAGCCCTGGAGAGCCTGCCA GCATCAGCTGCAAGAGCAGCCAGAGCCTGCTGAACAGCAGGACCAGGAAGAACTACC TGGCCTGGTACAGGCAGAAGCCTGGCCAGAGCCCCCAGCTGCTGATCTACTGGGCCA GCACCAGAGAGAGCGGAGTGCCTGACAGGTTCAGCGGAAGCGGCAGCGGCACCGAC TTCACCCTGAGGATCAGCAGAGTGGAGGCCGATGACGCCGGCGTGTACTACTGCAAG CAGAGCTACAACCTGTACACCTTCGGCCAGGGCACCAAGGTGGAGATCAAGAGGAAC GACGCTCAGCCAGCCGTGTACCTCTTCCAGCCTTCGCCGGACCAGCTTCATACGGGGTC Petição 870250121500, de 30 / 12 / 2025, pág. 151 / 160 136 / 138 AGCGTCGGTGGTGTGCCTGTTGAACTCGTTTTACCCCAAGGACATTAACGTGAAGTGG AAGGTAGACGGGGTAATTCAAGACACTGGCATTCAAGAGTCCGTCACGGAACAAGAC TCAAAAGACTCAACGTATTCACTGTCGTCAACCTTGACGATGTCAAGCACCGAGTATCT TAGCCATGAGCTGTATTCGTGCGAGATCACCCACAAGTCCCTCCCCTCCACTCTTATCAA ATCCTTTCAGCGGTCGGAATGTCAGCGGGTCGA T SEQ ID NO: 172 DIVMTQTPLSLSVSPGEPASISCKSSQSLLNSRTRKNYLAWYRQKPGQSPQLLIYWASTRES GVPDRFSGSGSGTDFTLRISRVEADDAGVYYCKQSYNLYTFGQGTKVEIKRNDAQPAVYLF QPSPDQLHTGSASVVCLLNSFYPKDINVKWKVDGVIQDTGIQESVTEQDSKDSTYSLSSTLT MSSTEYLSHELYSCEITHKSLPSTLIKSF QRSECQRVD 4H3 caninizado (vL3) SEQ ID NO: 173 GACATCGTGATGACCCAGACCCCTCTGAGCCTGAGCGTGAGCCCTGGAGAGCCT GCCAGCATCAGCTGCAAGAGCAGCCAGAGCCTGCTGAACAGCAGGACCAGGAAGAAC TACCTGGCCTGGTACCAGCAGAAGCCTGGCCAGAGCCCCCAGCTGCTGATCTACTGGG CCAGCACCAGAGAGAGCGGAGTGCCTGACAGGTTCAGCGGAAGCGGCAGCGGCACC GACTTCACCCTGAGGATCAGCAGAGTGGAGGCCGATGACGCCGGCGTGTACTACTGC AAGCAGAGCTACAACCTGTACACCTTCGGCCAGGGCACCAAGGTGGAGATCAAGAGG AACGACGCTCAGCCAGCCGTGTACCTCTTCCAGCCTTCGCCGGACCAGCTTCATACGG GGTCAGCGTCGGTGGTGTGCCTGTTGAACTCGTTTTACCCCAAGGACATTAACGTGAA GTGGAAGGTAGACGGGGTAATTCAAGACACTGGCATTCAAGAGTCCGTCACGGAACA AGACTCAAAAGACTCAACGTATTCACTGTCGTCAACCTTGACGATGTCAAGCACCGAGT ATCTTAGCCATGAGCTGTATTCGTGCGAGATCACCCACAAGTCCCTCCCCTCCACTCTTA TCAAATCCTTTCAGCGGTCGGAATGTCAGCGGGTCGAT SEQ ID NO: 174 DIVMTQTPLSLSVSPGEPASISCKSSQSLLNSRTRKNYLAWYQQKPGQSPQLLIYWAS TRESGVPDRFSGSGSGTDFTLRISRVEADDAGVYYCKQSYNLYTFGQGTKVEIKRNDAQPA Petition 870250121500, dated 12 / 30 / 2025, pages 152 / 160 137 / 138 VYLFQPSPDQLHTGSASVVCLLNSFYPKDINVKWKVDGVIQDTGIQESVTEQDSKDSTYSLS STLTMSSTEYLSHELYSCEITHKSLPSTLIKSFQ RSECQRVD EXAMPLE 8 Reactivity of caninized antibodies against canine IL-4 alpha receptor
[00204] Caninized antibodies were tested for reactivity with canine IL-4 alpha receptor as follows: 1. Coat 200 ng / well of IL-4 alpha receptor onto an immunoplate and incubate the plate at 40°C overnight. 2. Wash the plate 3 times with phosphate-buffered saline (PBS) containing 0.05% Tween 20 (PBST). 3. Block the plate with 0.5% bovine serum albumin (BSA) in PBS for 45-60 min at room temperature. 4. Wash the plate 3 times with PBST. 5. Dilute the caninized antibody three times in each column or row of dilution plates starting at 0.3 pg / mL. 6. Transfer the diluted caninized antibody into each column or row of the immunoplate and incubate the plate for 45-60 minutes at room temperature. 7. Wash the plate 3 times with PBST. 8. Add IgG Fc anti-canine labeled with horseradish peroxidase diluted 1:4000 to each well of the plate and then incubate the plate for 45-60 min at room temperature. 9. Wash the plate 3 times with PBST. 10. Add 3,3,5,5-tetramethylbenzidine (TMB) substrate to each well of the plate and incubate the plate for 10 to 15 min at room temperature to reveal the color. Petition 870250121500, dated 12 / 30 / 2025, pages 153 / 160 138 / 138 11. Add 100 µL of 1.5 M phosphoric acid to each well to stop the reaction. Read the plate at 450 nm with a reference wavelength of 540 nm.
[00205] As shown in Figure 4, the binding of five (5) antibodies to the IL-4 alpha receptor was studied: 4H3 MC, c4H3 H1-L1, c4H3 H2-L2, c4H3 H3-L3 and 2G9 MC. 2G9 MC was used as a negative control antibody. 4H3 MC is a chimeric antibody consisting of the variable mouse heavy regions of the 4H3 antibody now described along with canine constant regions and the light chain of the mouse 4H3 antibody. c4H3 H1-L1, c4H3 H2L2, c4H3 H3-L3 are three caninized variants of the mouse 4H3 antibody and include specific heavy and light chains, as shown in Table 5 above. 2G9 MC is a chimeric antibody consisting of the variable heavy regions of a mouse antibody for an antigen that is completely unrelated to the IL-4 alpha receptor along with canine constant regions and the light chain of the mouse antibody for the unrelated antigen.Consistently, 2G9 MC does not bind to the IL-4 alpha receptor, while the four remaining antibodies studied, namely 4H3 MC, c4H3 H1-L1, c4H3 H2-L2 and c4H3 H3-L3, all bind relatively firmly (see Figure 4). Petition 870250121500, dated 12 / 30 / 2025, pp. 154 / 160
Claims
1 / 4 CLAIMS 1. Isolated mammalian antibody or antigen-binding fragment thereof, characterized in that it binds to canine interleukin-4 α receptor (IL-4Ra) with specificity comprising three complementarity-determining regions (CDRs) of the light chain: a CDR light 1 (CDRL1), a CDR light 2 (CDRL2) and a CDR light 3 (CDRL3); and three CDRs of the heavy chain: a CDR heavy 1 (CDRH1), a CDR heavy 2 (CDRH2) and a CDR heavy 3 (CDRH3); (a) wherein CDRL1 comprises an amino acid sequence of SEQ ID NO: 129; (b) wherein CDRL2 comprises an amino acid sequence of SEQ ID NO: 134; (c) wherein CDRL3 comprises an amino acid sequence of SEQ ID NO: 137; (d) where CDRH1 comprises an amino acid sequence with SEQ ID NO: 140; (e) where CDRH2 comprises an amino acid sequence with SEQ ID NO: 146; (f) where CDRH3 comprises an amino acid sequence with SEQ ID NO: 151;where the antibody and its antigen-binding fragment bind to canine IL-4Ra and block the binding of canine IL-4Ra to canine interleukin 4.
2. Isolated mammalian antibody or antigen-binding fragment thereof according to claim 1, characterized in that it is a caninized antibody or a caninized antigen-binding fragment thereof. Petition 870250121500, dated 12 / 30 / 2025, pp. 155 / 160 2 / 4 3. Isolated mammalian antibody or antigen-binding fragment thereof according to claim 1 or 2, characterized in that it comprises a variable heavy chain region comprising amino acid residues 20 to 143 of SEQ ID NO: 118, and a variable light chain region comprising amino acid residues 21 to 127 of SEQ ID NO:
120.
4. Isolated mammalian antibody or antigen-binding fragment thereof according to claim 1 or 2, characterized in that it comprises a variable heavy chain region comprising the amino acid sequence of SEQ ID NO: 118, and a variable light chain region comprising the amino acid sequence of SEQ ID NO:
120.
5. Isolated mammalian antibody or antigen-binding fragment thereof according to any one of claims 1 to 4, characterized in that it comprises a hinge region comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 103 and SEQ ID NO:
104.
6. Isolated mammalian antibody or antigen-binding fragment thereof according to any one of claims 1 to 5, characterized in that, when bound to canine IL-4Ra, said antibody or antigen-binding fragment thereof binds to at least one amino acid residue within the amino acid sequence of SEQ ID NO: 125 or SEQ ID NO: 126, or both SEQ ID NO: 125 and SEQ ID NO:
126.
7. Isolated nucleic acid, characterized in that it encodes the variable light chain region or the variable heavy chain region, or Petition 870250121500, dated 12 / 30 / 2025, page 156 / 160 3 / 4 both the variable light chain region and the variable heavy chain region of a mammalian antibody or antigen-binding fragment thereof that binds to canine IL-4Ra, wherein the nucleic acid comprises: (a) a first nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO: 117; (b) a second nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO: 119, or (c) both the first nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO: 117 and the second nucleic acid sequence comprising the nucleotide sequence of SEQ ID NO:
119.
8. Expression vector, characterized in that it comprises the isolated nucleic acid defined in claim 7.
9. Host cell, characterized in that it comprises the expression vector defined in claim 8, wherein the host cell is a transgenic bacterial or fungal cell.
10. Pharmaceutical composition, characterized in that it comprises the isolated mammalian antibody or antigen-binding fragment thereof defined in any one of claims 1 to 6, or the nucleic acid defined in claim 7, the expression vector defined in claim 8, or any combination thereof and a pharmaceutically acceptable carrier or diluent.
11. Use of the pharmaceutical composition defined in claim 10, characterized by being for preparing a medicament for: (i) the treatment of atopic dermatitis; or (ii) the treatment of asthma; or Petition 870250121500, dated 12 / 30 / 2025, pp. 157 / 160 4 / 4 (iii) the treatment of atopic dermatitis and asthma. Petition 870250121500, dated 12 / 30 / 2025, pp. 158 / 160
